OVERVIEW OF Western herbal medicines for preventing and treating health conditions

Evidence evaluation report

prepared by

**HT**ANALYSTS

for

National Health and Medical Research Council

NHMRC | Natural Therapies Working Committee

Canberra ACT 2601

September 2024

**Copyright**

© Commonwealth of Australia 2024

All material presented in this publication is provided under a Creative Commons Attribution 4.0 International licence (www.creativecommons.org.au), with the exception of the Commonwealth Coat of Arms, NHMRC logo and content identified as being owned by third parties.

The details of the relevant licence conditions are available on the Creative Commons website (www.creativecommons.org.au), as is the full legal code for the CC BY 4.0 International licence.

**Attribution**

Creative Commons Attribution 4.0 International Licence is a standard form license agreement that allows you to copy, distribute, transmit and adapt this publication provided that you attribute the work. NHMRC’s preference is that you attribute this publication (and any material sourced from it) using the following wording:

Source: National Health and Medical Research Council.

**Use of images**

Unless otherwise stated, all images (including background images, icons and illustrations) are copyrighted by their original owners.

**Contact**

To obtain information regarding NHMRC publications or submit a copyright request, contact:

communications@nhmrc.gov.au

Reportinformation

Authors

Jorgensen MA1, Ryder I1, Rutherford L1, Antony T1

1 **HT**ANALYSTS, Level 8, 46 Kippax Street, Surry Hills NSW 2010 Australia

Dates

This evidence evaluation report and accompanying technical reports received approval from the National Health and Medical Research Council (NHMRC) Natural Therapies Working Committee (NTWC) on 20 November 2024.

The protocol for the evidence evaluation received approval from the NHMRC NTWC on 11 March 2021 (PROSPERO: CRD42021243337).

History

NHMRC has been engaged by the Department of Health and Aged Care (the Department) to update the evidence underpinning the 2015 Review of the Australian Government Rebate on Natural Therapies for Private Health Insurance (2015 Review) ([1](#_ENREF_1)). The natural therapies to be reviewed are Alexander technique, aromatherapy, Bowen therapy, Buteyko, Feldenkrais, homeopathy, iridology, kinesiology, naturopathy, Pilates, reflexology, Rolfing, shiatsu, tai chi, western herbal medicine and yoga. These therapies are among those excluded from the private health insurance rebate as of 1 April 2019.

To support NHMRC in their evidence review, Health Technology Analysts (**HT**ANALYSTS) was engaged to conduct an overview of the evidence of clinical effectiveness of western herbal medicine. Eligible studies received from the Department’s public call for evidence, the Natural Therapies Review Expert Advisory Panel (NTREAP) and the NTWC were included in the evidence evaluation.

This evidence evaluation report has been developed by **HT**ANALYSTS in conjunction with NHMRC, NTWC, and NTREAP. It describes the main body of evidence related to the effect of western herbal medicines for preventing and treating health conditions. Supplementary data are provided in Appendices A to H. All associated materials have been developed in a robust and transparent manner in accordance with relevant best practice standards ([2-5](#_ENREF_2)).

Funding

This work is paid for by the Australian Government Department of Health and Aged Care (via NHMRC) under Official Order 2019-20P026.

Acknowledgements

Thanks to the members of the Department’s NTREAP and NHMRC’s NTWC for their advice and comments throughout the creation of this document. PRACI data was provided by Dr Amie Steel at UTS. Membership and other details of the Panel and Committee can be found at:

<https://www.health.gov.au/committees-and-groups/natural-therapies-review-expert-advisory-panel>

<https://www.nhmrc.gov.au/about-us/leadership-and-governance/committees/natural-therapies-working-committee>

Contents

[Report information iii](#_Toc183697465)

[List of tables viii](#_Toc183697466)

[List of figures ix](#_Toc183697467)

[List of appendices xi](#_Toc183697468)

[List of abbreviations xii](#_Toc183697469)

[Plain language summary 1](#_Toc183697470)

[Executive summary 5](#_Toc183697471)

[1 Background 11](#_Toc183697472)

[1.1 Description of the condition 11](#_Toc183697473)

[1.2 Description of the intervention 11](#_Toc183697474)

[1.3 How the intervention might work 12](#_Toc183697475)

[1.4 Why it is important to do this review 12](#_Toc183697476)

[2 Objectives 13](#_Toc183697477)

[3 Methods 14](#_Toc183697478)

[4 Results 15](#_Toc183697479)

[4.1 Description of studies 15](#_Toc183697480)

[4.1.1 Flow of studies 15](#_Toc183697481)

[4.1.2 Excluded studies 15](#_Toc183697482)

[4.1.3 Studies awaiting classification 15](#_Toc183697483)

[4.1.4 Ongoing studies 15](#_Toc183697484)

[4.1.5 Included studies 16](#_Toc183697485)

[4.2 Inflammatory bowel disease 23](#_Toc183697486)

[4.2.1 Description of the condition 23](#_Toc183697487)

[4.2.2 Description of reviews 23](#_Toc183697488)

[4.2.3 Description of studies 24](#_Toc183697489)

[4.2.4 Risk of bias 24](#_Toc183697490)

[4.2.5 Summary of findings and evidence statement 27](#_Toc183697491)

[4.2.6 Forest plots 30](#_Toc183697492)

[4.3 Irritable bowel syndrome 34](#_Toc183697493)

[4.3.1 Description of the condition 34](#_Toc183697494)

[4.3.2 Description of reviews 34](#_Toc183697495)

[4.3.3 Description of studies 34](#_Toc183697496)

[4.3.4 Risk of bias 35](#_Toc183697497)

[4.3.5 Summary of findings and evidence statement 39](#_Toc183697498)

[4.3.6 Forest plots 41](#_Toc183697499)

[4.4 Gastro-oesophageal reflux disease 44](#_Toc183697500)

[4.4.1 Description of the condition 44](#_Toc183697501)

[4.4.2 Description of reviews 44](#_Toc183697502)

[4.4.3 Description of studies 44](#_Toc183697503)

[4.4.4 Risk of bias 44](#_Toc183697504)

[4.4.5 Summary of findings and evidence statement 45](#_Toc183697505)

[4.5 Menstrual conditions 46](#_Toc183697506)

[4.5.1 Description of the condition 46](#_Toc183697507)

[4.5.2 Description of reviews 46](#_Toc183697508)

[4.5.3 Description of studies 47](#_Toc183697509)

[4.5.4 Risk of bias 47](#_Toc183697510)

[4.5.5 Summary of findings and evidence statements 49](#_Toc183697511)

[4.5.6 Forest plots 52](#_Toc183697512)

[4.6 Premenstrual disturbances 55](#_Toc183697513)

[4.6.1 Description of the condition 55](#_Toc183697514)

[4.6.2 Description of reviews 55](#_Toc183697515)

[4.6.3 Description of studies 56](#_Toc183697516)

[4.6.4 Risk of bias 56](#_Toc183697517)

[4.6.5 Summary of findings and evidence statements 58](#_Toc183697518)

[4.6.6 Forest plots 60](#_Toc183697519)

[4.7 Symptoms of menopause 63](#_Toc183697520)

[4.7.1 Description of the condition 63](#_Toc183697521)

[4.7.2 Description of reviews 63](#_Toc183697522)

[4.7.3 Description of studies 64](#_Toc183697523)

[4.7.4 Risk of bias 67](#_Toc183697524)

[4.7.5 Summary of findings and evidence statements 67](#_Toc183697525)

[4.7.6 Forest plots 70](#_Toc183697526)

[4.8 Anxiety 75](#_Toc183697527)

[4.8.1 Description of the condition 75](#_Toc183697528)

[4.8.2 Description of reviews 75](#_Toc183697529)

[4.8.3 Description of studies 76](#_Toc183697530)

[4.8.4 Risk of bias 76](#_Toc183697531)

[4.8.5 Summary of findings and evidence statements 79](#_Toc183697532)

[4.8.6 Forest plots 81](#_Toc183697533)

[4.9 Depression 84](#_Toc183697534)

[4.9.1 Description of the condition 84](#_Toc183697535)

[4.9.2 Description of reviews 84](#_Toc183697536)

[4.9.3 Description of studies 85](#_Toc183697537)

[4.9.4 Risk of bias 88](#_Toc183697538)

[4.9.5 Summary of findings and evidence statements 88](#_Toc183697539)

[4.9.6 Forest plots 92](#_Toc183697540)

[4.10 Insomnia 98](#_Toc183697541)

[4.10.1 Description of the condition 98](#_Toc183697542)

[4.10.2 Description of reviews 98](#_Toc183697543)

[4.10.3 Description of studies 99](#_Toc183697544)

[4.10.4 Risk of bias 100](#_Toc183697545)

[4.10.5 Summary of findings and evidence statements 100](#_Toc183697546)

[4.10.6 Forest plots 102](#_Toc183697547)

[4.11 Diabetes and Impaired glucose tolerance 104](#_Toc183697548)

[4.11.1 Description of the condition 104](#_Toc183697549)

[4.11.2 Description of reviews 104](#_Toc183697550)

[4.12 Metabolic syndrome 106](#_Toc183697551)

[4.12.1 Description of the condition 106](#_Toc183697552)

[4.12.2 Description of reviews 106](#_Toc183697553)

[4.13 Fatigue conditions (postviral fatigue, ME/CFS etc.) 107](#_Toc183697554)

[4.13.1 Description of the condition 107](#_Toc183697555)

[4.13.2 Description of reviews 107](#_Toc183697556)

[4.13.3 Description of studies 107](#_Toc183697557)

[4.13.4 Risk of bias 108](#_Toc183697558)

[4.13.5 Summary of findings and evidence statements 109](#_Toc183697559)

[4.13.6 Forest plots 110](#_Toc183697560)

[4.14 Upper respiratory tract infection 112](#_Toc183697561)

[4.14.1 Description of the condition 112](#_Toc183697562)

[4.14.2 Description of studies 112](#_Toc183697563)

[4.15 Dermatitis and eczema 113](#_Toc183697564)

[4.15.1 Description of the condition 113](#_Toc183697565)

[4.15.2 Description of studies 113](#_Toc183697566)

[4.16 Acne 114](#_Toc183697567)

[4.16.1 Description of the condition 114](#_Toc183697568)

[4.16.2 Description of reviews 114](#_Toc183697569)

[4.16.3 Description of studies 114](#_Toc183697570)

[4.16.4 Risk of bias 115](#_Toc183697571)

[4.16.5 Summary of findings and evidence statements 116](#_Toc183697572)

[4.16.6 Forest plots 118](#_Toc183697573)

[5 Discussion 119](#_Toc183697574)

[5.1 Summary of main results 119](#_Toc183697575)

[5.2 Overall completeness and applicability of evidence 121](#_Toc183697576)

[5.3 Certainty of the evidence 122](#_Toc183697577)

[5.4 Potential biases in the review process 123](#_Toc183697578)

[5.5 Limitations 123](#_Toc183697579)

[5.5.1 At review level 123](#_Toc183697580)

[6 Authors' conclusions 125](#_Toc183697581)

[6.1 Implications for health policy 125](#_Toc183697582)

[6.2 Implications for research 125](#_Toc183697583)

[References 126](#_Toc183697584)

List of tables

[Table 1 List of populations (conditions) identified and considered in this review 18](#_Toc177486176)

[Table 2 List of included systematic reviews and overlap with eligible RCTs (per outcome): Inflammatory bowel disease 25](#_Toc177486177)

[Table 3 List of included systematic reviews and overlap with eligible RCTs (per outcome): Irritable bowel syndrome (peppermint oil) 36](#_Toc177486178)

[Table 4 List of included systematic reviews and overlap with eligible RCTs (per outcome): Irritable bowel syndrome (WHM other than peppermint oil) 37](#_Toc177486179)

[Table 5 List of included systematic reviews and overlap with eligible RCTs (per outcome): Gastro-oesophageal reflux disease 45](#_Toc177486180)

[Table 6 List of included systematic reviews and overlap with eligible RCTs (per outcome): Menstrual conditions 48](#_Toc177486181)

[Table 7 List of included systematic reviews and overlap with eligible RCTs (per outcome): Premenstrual disturbances 57](#_Toc177486182)

[Table 8 List of included systematic reviews and overlap with eligible RCTs (per outcome): Symptoms of menopause 65](#_Toc177486183)

[Table 9 List of included systematic reviews and overlap with eligible RCTs (per outcome): Anxiety 77](#_Toc177486184)

[Table 10 List of included systematic reviews and overlap with eligible RCTs (per outcome): Depression 86](#_Toc177486185)

[Table 11 List of included systematic reviews and overlap with eligible RCTs (per outcome): Insomnia 99](#_Toc177486186)

[Table 12 List of included systematic reviews and overlap with eligible RCTs (per outcome): Fatigue conditions 108](#_Toc177486187)

[Table 13 List of included systematic reviews and overlap with eligible RCTs (per outcome): Acne 115](#_Toc177486188)

List of figures

[Figure 1 Literature screening results: Western herbal medicines, systematic reviews 17](#_Toc177486189)

[Figure 2 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – disease activity index 31](#_Toc177486190)

[Figure 3 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – Clinical response in disease activity (response rate) 32](#_Toc177486191)

[Figure 4 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – Clinical remission (remission rate) 33](#_Toc177486192)

[Figure 5 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Symptom severity 41](#_Toc177486193)

[Figure 6 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Global improvement in IBS symptoms (response rate\*) 42](#_Toc177486194)

[Figure 7 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Abdominal pain (response rate\*) 43](#_Toc177486195)

[Figure 8 Forest plot of comparison: WHM vs placebo or control: Menstrual conditions - pain intensity (VAS) 53](#_Toc177486196)

[Figure 9 Forest plot of comparison: WHM vs placebo: Menstrual conditions – menstrual blood loss (Higham score) 54](#_Toc177486197)

[Figure 10 Forest plot of comparison: WHM vs placebo: Premenstrual disturbances - PMS symptoms, anxiety, depression 61](#_Toc177486198)

[Figure 11 Forest plot of comparison: WHM vs placebo: Premenstrual disturbances – patient reported improvement 62](#_Toc177486199)

[Figure 12 Forest plot of comparison: WHM vs placebo: Symptoms of menopause - improvement in KMI, MRS or GCS total symptoms scores 71](#_Toc177486200)

[Figure 13 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – hot flash, daily frequency 72](#_Toc177486201)

[Figure 14 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – sexual functioning 73](#_Toc177486202)

[Figure 15 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – emotional functioning, anxiety, depression 74](#_Toc177486203)

[Figure 16 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – anxiety 82](#_Toc177486204)

[Figure 17 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – depression 83](#_Toc177486205)

[Figure 18 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – Global improvement 83](#_Toc177486206)

[Figure 19 Forest plot of comparison: WHM vs placebo: Depression – depressive symptoms 93](#_Toc177486207)

[Figure 20 Forest plot of comparison: St John’s wort vs placebo: Depression – depressive symptoms 94](#_Toc177486208)

[Figure 21 Forest plot of comparison: WHM vs placebo: Depression – anxiety, stress, and global improvement 95](#_Toc177486209)

[Figure 22 Forest plot of comparison: WHM vs active intervention: Depression – depressive symptoms 96](#_Toc177486210)

[Figure 23 Forest plot of comparison: St John’s wort vs active intervention: Depression – depressive symptoms 97](#_Toc177486211)

[Figure 24 Forest plot of comparison: WHM vs placebo: Insomnia – sleep quality 102](#_Toc177486212)

[Figure 25 Forest plot of comparison: WHM vs placebo: Insomnia – anxiety 103](#_Toc177486213)

[Figure 26 Forest plot of comparison: WHM vs placebo: Fatigue conditions – fatigue severity 111](#_Toc177486214)

[Figure 27 Forest plot of comparison: WHM vs placebo: Acne vulgaris - Global improvement (patient reported) 118](#_Toc177486215)

[Figure 28 Forest plot of comparison: WHM vs placebo: Acne vulgaris - Disease severity (acne lesion count) 118](#_Toc177486216)

List of appendices

Appendix A – Searching, selection criteria and screening

Appendix B – Methods of data appraisal, extraction, analysis and reporting for included studies

Appendix C – Citation details of studies assessed at full text but not included

Appendix D – Details of Included studies

Appendix E – Detailed risk of bias forms

Appendix F – Detailed study descriptions and outcomes

Appendix G – Differences between protocol and review

Appendix H – Response to methodological review

List of abbreviations

BRISA Regional Base of Health Technology Assessment Reports of the Americas

CINAHL Cumulative Index to Nursing and Allied Health Literature

COMET Core Outcome Measures in Effectiveness Trials

GRADE Grading of Recommendations Assessment, Development and Evaluation

ITT Intent-to-treat

MCID minimal clinically important differences

MD mean difference

MID minimal important difference

NHMRC National Health and Medical Research Council

NRSI Nonrandomised study of an intervention

NTREAP Natural Therapies Review Expert Advisory Panel

NTWC Natural Therapies Working Committee

OR Odds ratios

PAHO Pan American Health Organization

PICO Population, Intervention, Comparator, Outcome

PP Per protocol

PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RCT Randomised controlled trial

RoB Risk of bias

RoM Ratio of means

RR Risk ratios

SD Standard deviation

SMD standardised mean difference

SR Systematic review

TIDIER Template for Intervention Description and Replication

Plain language summary

What was the aim of this review?

The aim of this overview was to identify eligible studies and assess whether they demonstrate that Western herbal medicines (WHMs) are effective in preventing and/or treating certain injuries, diseases, medical conditions, or pre-clinical conditions relevant to the Australian population. Western herbalism is the practice of plant-based medicine, originating from Europe, the United Kingdom and North America. Herbalists use plants and unrefined plant extracts to create medicines that target individual body systems, with the aim of treating the underlying cause of disease.

This review is targeted for the Australian Government Department of Health and Aged Care (formerly Department of Health) to assist in their Natural Therapies Review, which is designed to determine whether certain natural therapies, including Western herbalism, have enough evidence of effectiveness to be considered re-eligible for private health insurance rebates. This review is not designed to be a complete review of all studies published for WHMs, nor is it intended to inform decisions about whether an individual or practitioner should use Western herbalism, individual herbs, extracts of herbs or combinations of herbs.

Key messages

For the populations (or conditions) assessed, individual WHMs probably provide people who use them with some benefit for some outcomes, when compared with people given a placebo (i.e. something that looks identical to the intervention but is designed to have no therapeutic effect). In general, the evidence assessed in this review was rated moderate or low certainty. Very few results were found comparing the use of WHM to an inactive control (e.g. waitlist), and those that were found were of very low certainty.

What was studied in the review?

This overview identified reviews using a planned literature search, with no limit on publication date. To make the overview more manageable, the overview only assessed studies for certain conditions or groups of people. These priority conditions and groups were decided based on Australian survey information and from seeking expert advice about the reasons why people in Australia commonly seek to use WHMs and the types of conditions seen by Western herbalists. To be included in the overview, herbs had to be on the list of core herbal medicines used by the Naturopaths & Herbalists Association of Australia, but eligibility was not based on specific pairings of herbs and conditions. Included studies needed to compare the results of people who use WHMs to a group of people who did not. Assessment of cost effectiveness, safety and studies of healthy populations was not included in this overview.

Studies published in languages other than English were listed in an evidence inventory, but not included in the assessment. Studies that compared WHMs with another intervention (active comparator) were also listed but were mostly not included in the main analysis because different studies used different comparators and outcome measures, which did not meet the criteria planned in the protocol. Results comparing the effects of WHM to an evidence-based treatment for depression were included as there were several studies evaluating the same evidence-based treatment in that population (a pre-specified criterion for presenting results).

Studies were assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. GRADE is a method to assess how confident (or certain) systematic review authors can be that the results reported (estimates of effect) in studies are correct. The assessment made by the reviewer is then described as either:

* high certainty – meaning the authors have a lot of confidence that the true effect is similar to the estimated effect
* moderate certainty – meaning that the true effect is probably close to the estimated effect
* low certainty – meaning the true effect might be markedly different from the estimated effect

very low certainty – meaning the true effect is probably markedly different from the estimated effect. Reviewers’ confidence in the result was so limited that interpretation was not provided.

What studies did we identify in this review?

Using a planned approach, 8761 citations from 9 databases were collected and examined, including 658 publications submitted by the public via the Department’s public call for evidence.

Out of 8761 citations screened, 402 reviews covering 16 prioritised conditions, were assessed in the evidence evaluation. A further 199 reviews were awaiting classification and 39 reviews had been registered but were not completed at the time the search was conducted for this review. Evidence from 270 RCTs, covering 11 conditions, were extracted from the reviews and are included in the results. Although prioritisation focused on conditions seen and herbs used by Western herbalists in Australia, we did not evaluate if the herbal preparation (e.g. liquid extracts, herbs, tablet or capsule) or dose prescribed in eligible studies correlated with that typically prescribed by Western herbalists in Australia for that condition. The treatment provider was often not specified. Few studies continued for more than 6-months.

What were the main results of the review?

The evidence provides moderate to low certainty that using WHMs is more effective than not using WHMs for most of the conditions and outcomes assessed in this review. There were 3 conditions for which the evidence also provides moderate to very low certainty that using WHMs has little (to no) benefit for some outcomes assessed in this review. There were 2 conditions assessed in this review where the effect of using WHMs is unknown (reflux and dermatitis/eczema). Because of the overall large volume of evidence, it was not feasible to critically appraise and synthesise data for 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome and upper respiratory tract infections). The Natural Therapies Working Committee (NTWC) was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information). Compared with placebo:

The evidence provides moderate certainty that WHM probably:

* reduces pain intensity in people with menstrual conditions (dysmenorrhoea etc.) (7 RCTs, 601 participants) [WHM included ginger, cinnamon, valerian root or fenugreek]
* increases global improvement in people with premenstrual disturbances (6 RCTs, 839 participants) [WHM included chaste tree berry]
* increases clinical remission in people with inflammatory bowel disease (14 RCTs, 974 participants) [WHM included green tea extract, curcumin, Boswellia, aloe vera gel, Wormwood, St Mary’s thistle or Andrographis]
* increases the proportion of people who achieve global improvement of symptoms in people with irritable bowel syndrome (19 RCTs, 1279 participants) [WHM included peppermint oil, curcumin + fennel, Carmint + Psyllium, anise oil, aloe vera juice, ginger or St Jonh’s wort]
* improves symptom severity in people with symptoms of menopause (16 RCTs, 1680 participants) [WHM included black cohosh extract, alone or in combination with St John’s wort or red clover]
* reduces depressive symptoms in people with depression (33 RCTs, 3910 participants) [WHM included curcumin, saffron or St John’s wort]

reduces anxiety in people with anxiety (20 RCTs, 2087 participants) [WHM included valerian root, kava, Passiflora, saffron, chamomile, ginkgo biloba or lavender].

The evidence provides low certainty evidence that WHM may:

* reduce overall symptoms (8 RCTs, 1133 participants), depressive symptoms (5 RCTs 613 participants) and anxiety (2 RCTs, 208 participants) in people with premenstrual disturbances [WHM included chaste tree]
* reduce anxiety and improve emotional functioning in people with depression (5 RCTs, 397 participants) [WHM included curcumin or saffron]
* reduce disease severity (3 RCTs, 183 participants) and increase patient-reported improvement (1 RCT, 70 participants) in people with acne [WHM included green tea-oral, green tea-topical]
* increase the proportion with clinical improvement (8 RCTs, 403 participants) in people with inflammatory bowel disease [WHM included green tea extract or curcumin]
* reduce pain (7 RCTs, 606 participants) and increase clinical improvement of symptoms (3 RCTs, 236 participants) in people with irritable bowel syndrome [WHM included peppermint oil or aloe vera juice]
* reduce depressive symptoms (2 RCTs, 129 participants), and improve overall symptoms (3 RCTs, 670 participants) and emotional functioning (2 RCTs, 508 participants) in people with anxiety [WHM included lavender, saffron, or chamomile]
* improve physical functioning (2 RCTs 508 participants) and sleep quality (2 RCTs, 382 participants) in people with anxiety [WHM included lavender]
* reduce symptoms of fatigue (3 RCTs, 185 participants) in people with chronic fatigue conditions [WHM included Siberian ginseng or panax ginseng]

reduce hot flush frequency (14 RCTs, 1355 participants) in people with symptoms of menopause [WHM included black cohosh, red clover, valerian, valerian root, St John’s wort or St John’s wort + chaste tree].

The evidence provides moderate certainty that WHM probably has little (to no) effect on:

* sexual functioning in people with symptoms of menopause (7 RCTs, 887 participants) [WHM included ginseng, withania (ashwagandha), red clover or ginseng]

sleep quality in people with insomnia (5 RCTs, 946 participants) [WHM included chamomile, valerian or kava].

The evidence provides low certainty that WHM may result in little (to no) change in:

* disease activity in people with inflammatory bowel disease (2 RCTs, 151 participants) [WHM included curcumin]

symptoms of anxiety in people with insomnia (2 RCTs, 425 participants) [WHM included kava, valerian or chamomile].

Results compared to inactive control (e.g. waitlist) were also examined, but for the majority of conditions there were no results found. For 2 populations (inflammatory bowel disease, menstrual conditions) the evidence was very uncertain.

Results compared to active control were examined for one condition. Here, the evidence provides moderate certainty that WHM (St John’s wort) is probably comparable to antidepressants for improving symptoms of depression in people with depression.

Implications for health policy and research

This review assesses the evidence for certain conditions and groups of people to inform the Australian Government about health policy decisions for private health insurance rebates. The review does not cover all the reasons that people use WHMs, or the reasons practitioners prescribe WHMs and is not intended to inform individual choices about using Western herbalism, individual herbs, extracts of herb or combinations of herbs.

The results of this review indicate that WHMs may be useful for some conditions and outcomes and not useful for others. Whether the individual herbs used in the primary studies for a condition correlate with those typically prescribed by Western herbalists in Australia is not known. A number of studies focussed on the effect of WHMs in people who received treatment for 12 weeks or less, so it is difficult to conclude the possible benefits of WHMs in people who continue to use WHMs for more than 12 weeks. It is unknown whether the effects of WHMs continue once people stop using WHMs. This review listed but did not assess WHMs versus other interventions for most conditions, so no comment can be made on whether WHMs are better or worse than other interventions.

Future research could be improved by studies of WHMs versus placebo or inactive control including outcomes that are considered critical or important for decision-making. Importantly, clinical trials that focus on the broader research question about the effectiveness of Western herbalism as a health service are needed.

How up to date is this review?

Searches were conducted from the earliest date included in the databases until 22 April 2021. Systematic reviews published after this date are not included in this review.

Executive summary

Background

Western herbalism is the practice of plant-based medicine, originating from Europe, the United Kingdom and North America. Herbalists use plants and unrefined plant extracts to create medicines that target individual body systems, with the aim of treating the underlying cause of disease.

In 2015, an overview of systematic reviews conducted for the Australian Government identified no systematic reviews containing evidence evaluating Western herbalism as a health service. The review noted that while there is a large body of research on the effects of individual herbal agents and remedies, the study of the real-life practice and outcomes of herbalism as a health service is a relatively new area of research that has yet to be addressed in systematic reviews. The current overview assesses the effectiveness of individual Western herbal medicines (WHMs), aiming to focus on WHMs prescribed by Western herbalists in Australia and conditions treated by Western herbalists in Australia.

Objectives

The objective of this overview is to evaluate the effectiveness of Western herbal medicines in individuals with a described injury, or to treat or prevent disease, medical condition or preclinical condition, including primary prevention in at-risk individuals, on outcomes that align with the reasons why consumers seek to use WHMs in Australia. This information will be used by the Australian Government in deciding whether to reinclude Western herbalism as eligible for private health insurance rebates, after Western herbalism was excluded in 2019. This overview is not designed to assess all the reasons that people use WHMs, or the reasons herbalists prescribe WHMs and is not intended to inform individual choices about using Western herbalism, individual herbs, extracts of herb or combinations of herbs.

Search methods

Literature searches were conducted in EMBASE, MEDLINE, EMCARE, PsycINFO, AMED, CINAHL, EMB reviews, PAHO, and PUBMED to identify relevant systematic reviews published from database inception to 22 April 2021. The public was also invited by the Department of Health and Aged Care (formerly Department of Health) to submit references of published research evidence. There were no limits on language of publication or date of publication in the search.

Selection criteria

Systematic reviews of randomised controlled trials (RCTs), quasi-RCTs and non-randomised studies that examined the effectiveness of WHMs compared to control (or another intervention, where applicable) were eligible for inclusion. Systematic reviews that included a single RCT or that included both RCTs and NRSIs were eligible; however, only evidence from the RCTs (and quasi-RCTs) were considered. Systematic reviews that did not report study eligibility criteria or did not conduct a comprehensive search of the literature (i.e. searched less than 2 databases) were not included. There were no limits on the type of herbal preparation (i.e. capsule, tablet, liquid extract, tea etc.), however, the herbal preparation (individual herb or combination product) must be used by Western herbalists in Australia and be administered orally, sublingually or be topically applied. Eligibility was not based on specific pairings of herbs and conditions.

RCTs (and quasi-RCTs) in people of any age with any injury, disease, medical condition or preclinical condition were eligible for inclusion. Studies examining WHMs in individuals at-risk, but not studies assessing at-risk populations in general, were also eligible for inclusion. The search was not restricted by comparators, however the 2 main comparators of interest for this review were WHMs versus placebo and WHMs versus control (including no intervention, waitlist, or usual care, if considered inactive). The tertiary comparator of interest was WHMs versus other interventions (inclusive of non-WHMs (i.e. Chinese and Ayurvedic formulations) and usual care if considered active). The search did not use outcomes to screen reviews for eligibility. Reviews were not excluded based on country of origin, however reviews published in a language other than English were not translated and were not included in the synthesis but were listed in an inventory for completeness.

Data collection and analysis

To ensure the overview was most relevant to the Australian population, populations were prioritised without knowledge of potential studies to ensure unbiased prioritisation. In determining the priority conditions for inclusion in the analysis and synthesis of the review, the National Health and Medical Research Council (NHMRC) Natural Therapies Working Committee (NTWC) were guided by relevant patient or practitioner reported Australian survey data (where available) and expert advice from The Department’s Natural Therapies Review Expert Advisory Panel (NTREAP). Prioritisation was conducted after initial searching and screening process, but before data extraction.

After population prioritisation, a blinded outcome prioritisation process was undertaken by NTWC (with input from NTREAP). The outcome prioritisation process was developed based on published core outcome sets and systematic reviews in the priority populations, after the included studies were identified. As part of the process, NTWC (with advice from NTREAP) were asked to specify up to 7 ‘critical’ or ‘important’ outcomes for inclusion in the analysis and synthesis of the overview. Where a study did not report a prioritised outcome for that population or condition, this was noted as an evidence gap in the overview. For outcome domains, NTWC were guided by GRADE methodology, scoring outcome domains on a scale of 0 (of limited importance for decision making) to 9 (critical for decision making). Harms and cost effectiveness measures were out of scope.

Data collection was performed by 2 researchers, the first collected data using data extraction forms and the second checked the forms for completeness and accuracy. Critical appraisal of the eligible reviews was conducted using A MeaSurement Tool to Assess systematic Reviews (AMSTAR-2).

In the data analysis and synthesis for each prioritised population, the overall certainty of evidence for a maximum of 7 critical or important outcomes were reported in GRADE summary of findings tables, with corresponding evidence statements assigned to each outcome. Data were assessed for reported outcomes at ‘end of treatment’ and reported minimal clinically important differences (MCID) or minimal important difference (MID) (where available). In instances where MCID were unavailable, effect estimates were assessed using a threshold of (1) small (mean difference [MD] <10% of the scale) (2) moderate (MD between 10% to 20% of the scale), or (3) large (MD more than 20% of the scale). If the effect was quantified using a standardised mean difference (SMD), we used Cohen’s guidance for interpreting the magnitude of the SMD, where 0.2 represents a small difference, 0.5 is moderate, and 0.8 is large.

Main results

A total of 854 systematic reviews were identified as eligible for inclusion in this overview. Of these, 402 systematic reviews covering 16 conditions were considered in the evidence evaluation. For the synthesis 270 RCTs covering 11 prioritised conditions compared WHMs with placebo and 5 RCTs covering 2 prioritised conditions compared WHMs with inactive control (no intervention, wait list or usual care) were considered. Because of the large volume of evidence, it was not feasible to consider the evidence regarding 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome, upper respiratory tract infections). Systematic reviews for these 4 conditions were not critically appraised or included in synthesis (see Appendix D). The Natural Therapies Working Committee (NTWC) was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information). Results for most studies of prioritised conditions with active comparators are presented in Appendix F2, but not in the synthesis, as the wide range of comparators and outcomes did not allow for synthesis as planned in the protocol. Studies comparing WHM to an active treatment in people with depression are included in the main report because the comparator was sufficiently homogenous across studies to support synthesis and the comparator represents an accepted, evidence-based ‘gold standard’ of care for the population in question.

At the time of the search, an additional 199 systematic reviews were awaiting classification, and an additional 39 reviews were recorded as ongoing (registered but not published at the time of the search). Of the reviews awaiting classification, 113 were not published in English and 42 were conference abstracts with the remaining 44 reviews not able to be retrieved and therefore not assessed. Of the ongoing reviews, 39 were registered on PROSPERO or a protocol had been published but results not reported at the time of search. There is no reason to suspect that the results of the reviews would differ substantially from those already included in this overview.

Due to a lack of studies that focus on Western herbalism as a practice, the overview has focused on individual herbal medicines. Although prioritisation focused on conditions seen, and herbs used by Western herbalists in Australia there was no specific matching of herbs and conditions, and extrapolation of the effect of these interventions may or may not reflect Western herbalism as a practice in Australia. Given the broad nature of the overview, it is difficult to specify if the included primary studies examined the individual WHM delivered in a manner that would be considered applicable to the Australian context. The primary studies identified by the reviews were often conducted over a 6 to 12-week time-period, with some studies examining the effect of the WHM for a slightly longer timeframe (24 weeks). Few, if any, provided any longer-term data (WHM administered for longer than 52 weeks).

Studies were assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. GRADE combines information to assess overall how certain systematic review authors can be that the estimates of the effect (reported across a study/s for each critical or important outcome) are correct. High certainty means the authors have a lot of confidence that the true effect is similar to the estimated effect. Moderate certainty means that the true effect is probably close to the estimated effect. Low certainty means the true effect might be markedly different from the estimated effect. Very low certainty means the true effect is probably markedly different from the estimated effect.

This review evaluated 11 prioritised conditions for which there was evidence about the effect of WHM on an outcome considered critical or important by NTWC.

Compared with placebo, the evidence provides:

* moderate certainty evidence that WHM probably results in:
  + a large improvement in pain intensity in people with menstrual conditions (7 RCTs, 601 participants) [WHM included ginger, cinnamon, valerian root or fenugreek]
  + a large increase in patient-reported improvement in people with premenstrual disturbances (6 RCTs, 839 participants) [WHM included chaste tree berry]
  + a moderate increase in the proportion with clinical remission in people with inflammatory bowel disease (14 RCTs, 974 participants) [WHM included green tea extract, curcumin, Boswellia, aloe vera gel, Wormwood, St Mary’s thistle or Andrographis]
  + a moderate increase in the proportion with clinical improvement in people with irritable bowel syndrome (19 RCTs, 1279 participants) [WHM included peppermint oil, curcumin + fennel, Carmint + Psyllium, anise oil, aloe vera juice, ginger or St Jonh’s wort]
  + a moderate improvement in symptom severity in people with symptoms of menopause (16 RCTs, 1680 participants) [WHM included black cohosh extract, alone or in combination with St John’s wort or red clover]
  + a moderate reduction in depressive symptoms in people with depression (33 RCTs, 3910 participants) [WHM included curcumin, saffron or St John’s wort]
  + a slight reduction in anxiety in people with anxiety (20 RCTs, 2087 participants) [WHM included valerian root, kava, Passiflora, saffron, chamomile, ginkgo biloba or lavender].
* low certainty evidence that WHM may result in:
  + a large reduction in depressive symptoms (5 RCTs, 613 participants) and anxiety (2 RCTs, 208 participants), and a large improvement in overall symptoms (8 RCTs, 1133 participants) in people with premenstrual disturbances [WHM included chaste tree]
  + a large reduction in anxiety (5 RCTs, 397 participants) and a slight improvement in emotional functioning (2 RCTs, 358 participants) in people with depression [WHM included curcumin or saffron]
  + a large reduction in disease severity (3 RCTs, 183 participants) and a large increase in patient-reported improvement (1 RCT, 70 participants) in people with acne [WHM included green tea-oral, green tea-topical]
  + a moderate increase in the proportion with a clinical response (8 RCTs, 403 participants) in people with inflammatory bowel disease [WHM included green tea extract or curcumin]
  + a moderate reduction in pain intensity (7 RCTs, 606 participants) and a slight increase in clinical improvement (3 RCTs, 236 participants) in people with irritable bowel syndrome [WHM included peppermint oil or aloe vera juice]
  + a moderate reduction in depressive symptoms (2 RCTs, 129 participants), and a moderate improvement in global improvement (3 RCTs, 670 participants) and emotional functioning (2 RCTs, 508 participants) in people with anxiety [WHM included lavender, saffron, or chamomile]
  + a slight improvement in physical functioning (2 RCTs 508 participants) and sleep quality (2 RCTs, 382 participants) in people with anxiety [WHM included lavender]
  + a moderate reduction in symptoms of fatigue (3 RCTs, 185 participants) in people with chronic fatigue conditions [WHM included Siberian ginseng or panax ginseng]
  + a slight reduction in hot flush frequency (14 RCTs, 1355 participants) in people with symptoms of menopause [WHM included black cohosh, red clover, valerian, valerian root, St John’s wort or St John’s wort + chaste tree].
* moderate certainty evidence that WHM probably results in little (to no) change in:
  + sexual functioning in people with symptoms of menopause (7 RCTs, 887 participants) [WHM included ginseng, withania (ashwagandha), red clover or ginseng]
  + sleep quality in people with insomnia (5 RCTs, 946 participants) [WHM included chamomile, valerian or kava].
* low certainty evidence that WHM may result in little (to no) change in:
  + clinical improvement in people with inflammatory bowel disease (2 RCTs, 151 participants) [WHM included curcumin]
  + symptoms of anxiety in people with insomnia (2 RCTs, 425 participants) [WHM included kava, valerian or chamomile].

The evidence provides very low certainty of the effect of WHM compared with placebo for 6 critical or important outcomes prioritised for analysis in this overview (across 4 conditions: menstrual conditions, symptoms of menopause, depression and acne). For these outcomes, the true effect is probably markedly different from the estimated effect, with more studies needed to determine the true effect. There were 2 conditions assessed in this review where the effect of using WHMs is unknown (reflux and dermatitis/eczema) due to a lack of meaningful data.

Of the 104 outcomes prioritised as critical or important in this overview, there were no studies found reporting on 43 of those outcomes and therefore, the effect of WHM on these outcomes is unknown. The effect of WHM for 27 outcomes across 4 conditions was not assessed due to the volume of evidence. There are numerous systematic reviews examining the effect of WHM on these conditions, but preliminary data suggests the results are limited to one or 2 outcomes per condition.

Compared with inactive control (no intervention, waitlist, usual care [if inactive]), there were no results found for the majority of conditions. For 2 populations (IBD, menstrual conditions) the evidence was very uncertain.

Compared to active control, results for one condition show that WHM (St John’s wort) is probably comparable to antidepressants for improving symptoms of depression in people with depression. Results for all other conditions versus active control were listed but not assessed because they did not meet prespecified criteria.

An assessment of harms of WHM was not conducted for this overview, as it was out of scope of this overview to assess adverse effects of WHM.

Overall, the evidence suggests that WHM probably provides people with some benefit for a range of outcomes considered critical or important by the NTWC, when compared with placebo. There remain many outcomes for which the benefits are unknown.

Limitations

This overview is limited to analysis of conditions prioritised by NTWC, who were guided by relevant patient and/or practitioner reported Australian survey data (where available) and expert advice from NTREAP during the prioritisation process, therefore this report may not cover all the reasons people seek to use WHMs. Because of the large volume of evidence, it was not feasible to consider the evidence regarding 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome, upper respiratory tract infections). The NTWC was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information).

The outcomes assessed in this overview were limited to those deemed critical or important by NTWC for each priority condition. This meant that most conditions were limited to evidence that assessed 1 to 3 of the critical or important outcomes, with two conditions (reflux and dermatitis/eczema) having no useable evidence for critical or important outcomes.

Examination of the effectiveness of WHMs compared with other active interventions was not conducted, except in one condition, due to the wide variety of active comparators, outcomes, and conditions across these studies. It is unknown whether the results of these studies would influence the overall conclusions of this overview.

An additional limitation of this overview is that it has focused on individual herbal medicines, rather than Western herbalism as a health service because of the lack of evidence for the latter. Evidence was synthesised for herbs which met the criteria, but sub-group analysis by single or combination of herbs was generally not conducted. Clinical herbalists are trained to create unique herbal prescriptions for patients, and, as with many complementary therapies, herbalism applies a holistic approach to healthcare, and is often used in conjunction with conventional medicine ([6](#_ENREF_6)). Whether the individual herbs identified in the primary studies for a condition correlate with that typically prescribed by Western herbalists in Australia is not known. As per protocol, detailed descriptions and follow-up about the herbal preparation (e.g., liquid extracts, herbs, tablet or capsule) used within the primary studies was not pursued.

Conclusions

The evidence provides moderate to low certainty that using WHMs is more effective than not using WHMs for many of the prioritised conditions and outcomes assessed in this review. For a few conditions and outcomes, the evidence provides moderate to very low certainty that using WHMs has little (to no) benefit.

# Background

In 2015, a review of Western herbalism as a health service commissioned by NHMRC found no clear evidence demonstrating its efficacy in treating any clinical condition ([6](#_ENREF_6)). The 2015 Overview was underpinned by an overview of systematic reviews that focused solely on the effects of Western herbalism as a health service and were published in the English language between 2008 to May 2013. Systematic reviews examining the therapeutic effects of individual herbs were excluded, as were systematic reviews of Chinese and Ayurvedic herbal medicines. In this Overview, the evidence evaluation was not limited by publication date and a broader, more comprehensive search of the literature was undertaken. Specifically, individual herbal medicines on List A of the core herbal medicines used by the Naturopaths & Herbalists Association of Australia (NHAA; previously National Herbalists Association of Australia), a peak professional association representing appropriately qualified Western herbalists and naturopaths using herbal medicines as their primary treatment modality, were included as were combination herbal medicines that included at least 1 herb from List A, in combination with other herbal ingredients listed on the Therapeutic Goods Administration (TGA) permissible ingredients list. The updated review also included studies that assessed these core herbal medicines for primary prevention. Like the 2015 Overview, systematic reviews evaluating the effectiveness of Chinese and Ayurvedic herbal medicines were excluded, as these remain outside the scope of this review. Eligible comparisons were Western herbal medicines (WHMs) (individual or combination) versus placebo, WHMs (individual or combination) versus inactive control (no intervention) and WHMs (individual or combination) versus other interventions. Studies not published in the English language were not translated, and databases in languages other than English were not searched.

## Description of the condition

Western herbalism is the main form of herbal medicine practised in Australia ([7](#_ENREF_7), [8](#_ENREF_8)). A Western herbalist engages in extemporaneous compounding of herbs for therapeutic purposes for individuals under their care ([8](#_ENREF_8)). Today, the practice of Western herbalism includes a holistic treatment framework based on treating individuals within a wider social, emotional, economical, spiritual and cultural framework and, like naturopathy, adherence to the principle of ‘first do no harm’ ([9](#_ENREF_9)). Western herbalists may practise out of various settings including the home, clinical practices and multimodality centres. A survey of Western herbalists in Australia indicated that most practitioners (97%) have access to a herbal dispensary within their clinic ([10](#_ENREF_10)).

Western herbalism is practised for a range of reasons to improve general health and wellbeing, as well as to treat a variety of clinical and preclinical conditions. Brief summaries of the populations and conditions identified and prioritised for inclusion are provided in Section 4.

## Description of the intervention

Western herbalism is a traditional system of plant-based medicine derived primarily from Europe, the United Kingdom and North America ([9](#_ENREF_9)). While medicinal plants from other herbal traditions, such as Traditional Chinese Medicine and Ayurvedic Medicine can be utilised by Western herbalists, the clinical application of Western herbalism is distinct from these traditions. Western herbal medicine uses plants and plant material to create medicines to help prevent or treat various illnesses. These materials may use some or all parts of a plant such as flowers, roots, stems and rhizomes, fruits and seeds, leaves and bark. WHMs are administered in various preparations including liquid herbal extracts such as tinctures or fluid extracts, oral tablets or capsules, or through topical application, for example, via poultices, creams and pessaries. Most commonly, liquid herbal extracts are prepared using an alcohol solvent, however, glycerol can be used as an alternative, when alcohol-based preparations may not be appropriate (e.g. when prescribing to children). Medicinal herbs can also be extracted in water, and this is commonly referred to as “tea” ([9](#_ENREF_9)).

In Australia, the regulation of herbal medicines differs depending upon the form, preparation and dosage of the herbal medicine. The TGA regulates some medicinal herbal products (tablets, capsules and liquid extracts), including through a list of permissible ingredients for products listed on the Australian Register of Therapeutic Goods (ARTG). Others, such as raw plant materials (dried or fresh) used in teas, are unregulated beyond the guidelines applied to all food substances ([8](#_ENREF_8), [9](#_ENREF_9)); with the exception of herbal medicines listed as a scheduled substance on the Australian poisons standard ([11](#_ENREF_11)).

A survey of Western herbalists in Australia indicated that the most common preparation of herbs prescribed was liquid extracts (90%), followed by dried preparations such as teas (4.3%) and tablets and capsules (3.8%) ([10](#_ENREF_10)). These preparations are usually dispensed as either an individualised mixture of one or multiple herbs or dispensed as proprietary formulae such as premanufactured tablets/capsules. Individual consumers also have access to some premanufactured herbal products through pharmacies, supermarkets and health food stores ([10](#_ENREF_10)).

## How the intervention might work

It is thought that chemical constituents found in plants used for herbal medicine act in a similar manner to pharmaceutical ingredients, noting that some pharmaceutical ingredients were originally derived from plants (e.g. salicylic acid in aspirin). Like pharmaceutical ingredients, the chemical constituents in medicinal plants are thought to work on a cellular level within the body. However, unlike a pharmaceutical medicine, which often uses purified or manufactured chemical constituents, herbal medicine utilises the ‘whole plant’ inclusive of the variety of chemical constituents present in its natural form. Western herbalists therefore use unrefined plant extracts (i.e. fluid extracts, teas, creams etc.) containing several different chemical constituents which are thought to work together synergistically, suggesting that the effect of the ‘whole plant’ is greater than the sum total of the effects of its individual constituents ([12](#_ENREF_12)). Western herbalists also claim that toxicity is reduced when ‘whole plants’ are used instead of purified chemical constituents. Western herbalists claim that this synergy also applies to combinations of plants and claim that combining herbs improves clinical efficacy and reduces adverse effects ([12](#_ENREF_12)).

Western herbalism emphasises the effects of herbs on individual body systems, with the aim of treating the underlying cause of disease. Herbs may be used for, but not limited to, their supposed anti-inflammatory, haemostatic, expectorant, antispasmodic and immuno-stimulatory properties.

## Why it is important to do this review

In Australia, complementary therapies, including Western herbalism, are most often used in conjunction with conventional medicine and other strategies for maintaining good health and wellness. For this reason, it is important to synthesise the evidence for the effectiveness of WHMs, to enable consumers, health care providers and policy makers to make informed decisions about care. The Australian Government will use this review to assist in deciding whether to reinclude Western herbalism as eligible for private health insurance rebates.

The 2015 Overview identified no systematic reviews containing evidence evaluating Western herbalism as a health service. The review noted that while there is a large body of research on the effects of individual herbal agents and remedies, the study of the real life practice and outcomes of herbalism as a health service is a relatively new area of research that has yet to be addressed in systematic reviews ([6](#_ENREF_6)).

# Objectives

To conduct an overview of systematic reviews to evaluate the effectiveness of WHMs in individuals with a described injury, disease, medical condition or preclinical condition, including disease prevention in at-risk individuals. The overview will compile the evidence from systematic reviews of RCTs and quasi-RCTs.

The questions for the overview were as follows:

What is the effectiveness of WHM compared to placebo on outcomes considered critical or important among individuals with any condition, pre-condition, injury or risk factor?

What is the effectiveness of WHM compared to an inactive control (no intervention, waitlist or usual care [if considered inactive]) on outcomes considered critical or important among individuals with any condition, pre-condition, injury or risk factor?

What evidence exists examining the effectiveness of WHM compared to active comparators (including usual care if considered active) on outcomes considered critical or important among individuals with any condition, pre-condition, injury or risk factor?

The intent is to evaluate the evidence representative of the populations (or conditions) commonly seen by Western herbalists in Australia, the intervention(s) commonly used by the herbalists, and outcomes that align with the reasons why people use Western herbs and/or herbalists prescribe WHMs.

Table 1 lists the populations (or conditions) identified and considered in this overview. A prespecified prioritisation process aimed at making best use of the available evidence is described in Appendix A6.

Prioritised populations are listed below, grouped into similar “umbrella” populations groups:

* Digestive disorders
  + Inflammatory bowel diseases
  + Irritable bowel syndrome
  + Gastro-oesophageal reflux disease
* Gynaecological/reproductive
  + Menstrual conditions (e.g. endometriosis, amenorrhea, dysmenorrhoea etc.)
  + Premenstrual disturbances
  + Menopause (symptoms of)
* Nervous system
  + Anxiety (incl. symptoms and disorders)
  + Depressive/mood disorders
  + Insomnia
* Endocrine/metabolic
  + Diabetes
  + Impaired glucose tolerance
  + Metabolic syndrome
* Immune system
  + Fatigue conditions (post viral fatigue, ME/CFS etc.)
  + Upper respiratory tract infections
  + Dermatitis & eczema
  + Acne

# Methods

Methods used to conduct the evidence evaluation were based on that described in the Cochrane Handbook for Systematic Reviews of Interventions ([13](#_ENREF_13)) and relevant sections in the Joanna Briggs Institute Reviewer’s manual ([14](#_ENREF_14)). Covidence (www.covidence.org), a web‐based platform for producing systematic reviews, was used for screening citations and recording decisions made. EndNote and Microsoft Excel were used for managing citations and data extraction, respectively. Where appropriate, RevMan 5.4 ([15](#_ENREF_15)) was used for the main analyses and GRADEpro GDT software (www.gradepro.org) was used to record decisions and derive an overall assessment of the certainty of evidence for each outcome guided by GRADE methodology ([5](#_ENREF_5)).

The criteria for determining the eligibility of reviews were predefined, with the approved protocol registered on the international prospective register of systematic reviews (PROSPERO: CRD42021243337).

Eligible herbs were the individual herbal medicines on List A of the core herbal medicines used by the NHAA for inclusion in the Western herbal medicine curriculum (See Appendix A8), or combination herbal preparations that include at least one herb from List A in combination with other herbal medicines listed on the TGA list of permissible ingredients. Specific herb-populations pairings were not required for inclusion.

Eligible reviews were assigned to an appropriate International Classification of Disease (ICD-11) category based on the primary clinical condition(s) assessed in the review. Reviews that were outcome focused (i.e. included studies in various populations), were listed as umbrella reviews, with each condition assessed within the primary studies of the review listed.

Populations and up to 7 critical or important outcomes were prioritised to inform the data synthesis for the systematic review on the effects of WHMs for preventing and treating health conditions. Throughout the population and outcome prioritisation process, NTWC remained blinded to the screening results (i.e. number of studies identified) and characteristics of included studies (e.g. study design, size, quality) to prevent any influence on decision-making (see **Appendix A6**). For prioritised conditions, the review quality was assessed, appropriate data were extracted into data extraction tables, and the results summarised into appropriate categories according to identified populations, conditions and comparators. Within each condition, eligible reviews are listed according to the publication year (more recent first). If there were multiple reviews published in the same year, they are ordered alphabetically within that year.

Summary of Findings tables included results for up to 7 critical or important outcomes prioritised by NTWC, who were guided by the GRADE framework (see Appendix A6.2 and Appendix B4).

Further details on the methods and approach used to conduct the evidence evaluation are provide in Appendix A and B of the Technical Report, which outline the following:

* Appendix A1 search methods
* Appendix A2 search strategy
* Appendix A3 search results
* Appendix A4 review selection criteria
* Appendix A5 selection of reviews (inclusion decisions)
* Appendix A6 refining the research questions
* Appendix A7 summary of screening results
* Appendix A8 list of core herbal medicines
* Appendix B1 overlap tables
* Appendix B2 critical appraisal and risk of bias process
* Appendix B3 data extraction processes
* Appendix B4 data analysis and synthesis
* Appendix B5 evidence statements

# Results

## Description of studies

### Flow of studies

The literature was searched on 22 April 2021 to identify relevant studies published from database inception to the literature search date. Search details and results of the search are provided in **Appendix A1 – A5** and application of the study selection criteria are provided in **Appendix C1** and **Appendix C2**.

A PRISMA flow diagram summarising the search and screening results is provided in Figure 1. The PRISMA flow diagram shows the number of citations at each stage of search and screening process, including: the initial search; studies considered irrelevant based on the title and/or abstract; studies found not to be relevant when reviewed at full text; studies which met the eligibility criteria for inclusion in the review and the number of studies that were in considered in the analysis for prioritised conditions.

The search retrieved 920 citations corresponding to 850 systematic reviews that were eligible for inclusion. There were 4 additional systematic reviews (not retrieved in the search) that were identified and included from the Department’s public call for evidence (see [Included studies](#_Included_studies)), the remaining studies provided from the Department’s call were already identified in the search and screened for eligibility. A further 199 reviews are awaiting classification (see Studies awaiting classification) and 39 protocols for reviews were registered (see Ongoing studies).

### Excluded studies

There were 875 citations screened at full text that were excluded for not meeting the reviews eligibility criteria. Of these, 217 reviews were of an intervention(s) that was out of scope (e.g. focused on nutraceuticals, pharmaceuticals or herbs not on List A), 245 had a study design out of scope (e.g. the systematic review did not include RCTs or the review was not underpinned by a systematic search), 180 were a publication type out of scope (e.g. were opinion pieces, editorials or commentaries, or were reviews that focused on pharmacokinetics or pharmacodynamics of the intervention), 17 reviews were in a population out of scope (e.g. healthy participants not at risk), 14 reviews were of outcomes out of scope (e.g. focus was toxicity or cost). As per Cochrane guidelines, details of citations which are likely to be considered eligible but are not, are presented in **Appendix C1**. Note that some studies may have been out of scope for more than 1 reason, but only 1 reason is listed for each.

### Studies awaiting classification

Completed reviews identified as potentially eligible for inclusion that could not be retrieved, translated or provided insufficient or inadequate data, are listed in the Characteristics of studies awaiting classification tables (see **Appendix C4**). This includes 42 conference proceedings with incomplete information about the study (**Appendix C4.1**), 113 systematic reviews published in languages other than English (**Appendix C4.2**) that are possibly eligible for inclusion (pending translation into English), and 44 reviews that were not able to be retrieved (**Appendix C4.3**).

Among the 199 systematic reviews awaiting classification, there were 67 reviews that covered a priority population (43 were in a language other than English). The reviews appeared comparable to those included in the evidence synthesis with respect to the interventions and outcomes assessed.

### Ongoing studies

Ongoing reviews that did not have published results at the time of the search are listed in the Characteristics of ongoing studies table (see **Appendix C5**). There were 39 reviews that were registered or had a published protocol. Among these, 11 reviews covered a priority population and appeared comparable to reviews included in the evidence synthesis with respect to the interventions and outcomes assessed.

### Included studies

There were 854 systematic reviews identified as eligible for inclusion in the overview (see Figure 1). After prioritisation of the populations (or conditions) considered most relevant to the practise of Western herbal medicine in Australia (see **Appendix A6.1**), 402 reviews were considered in the evidence evaluation (qualitative synthesis). Because of the large volume of evidence, it was not feasible to complete critical appraisal and synthesis for 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome, upper respiratory tract infections) due to time and resource constraints. Reviews were screened for eligibility, information about population(s), intervention (specific herbs) and outcomes was tabulated, and reviews were prioritised for critical appraisal (see 4.11, 4.12, 4.14 and Appendix D). The NTWC was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information).

An overview of the conditions identified and included in this overview is provided in Table 1.

For the main comparisons, systematic reviews that included RCTs comparing WHM with either a placebo or an inactive control (no intervention, waitlist or usual care, if considered inactive), were considered for quantitative synthesis. Those that included NTWC prioritised critical and important outcome domains and measures, were included in the final analysis. The prioritised outcome domains are highlighted in a blue box in **Appendix F1**. Systematic reviews that included RCTs comparing WHM with other active comparators are included in qualitative descriptions in the report, but results from these studies were not included in the main report, except in the case of depression because the comparator was sufficiently homogenous across studies to support synthesis and the comparator represents an accepted, evidence-based ‘gold standard’ of care for the population in question.

There were 452 systematic reviews that met the eligibility criteria for this review but were not included in the evidence evaluation. This is because they were either conducted in populations (or conditions) not prioritised by NTWC for analysis or synthesis (396 reviews) or they were conducted in populations that were of lower priority (56 reviews). These systematic reviews are listed in an inventory titled Citation details of systematic reviews of low and non-priority populations (**Appendix C3**).

**Appendix D** provides descriptions of the included reviews, including a summary of the PICO criteria, a summary of the critical appraisal (quality) assessment and results of the data synthesis for the main comparison. Detailed descriptions of the included systematic reviews and the primary studies found within can be found in **Appendix E1**.

Figure 1 Literature screening results: Western herbal medicines, systematic reviews




Table 1 List of populations (conditions) identified and considered in this review

| ICD-11 | POPULATION | # reviews including studies in the population | | |
| --- | --- | --- | --- | --- |
| No | Low priority | High priority |
| 01 Certain infectious and parasitic diseases | |  | | |
|  | Anogenital warts | 2 |  |  |
|  | Athlete's foot | 1 |  |  |
|  | Candidiasis | 2 |  |  |
|  | Herpes | 1 |  |  |
|  | Herpes | 2 |  |  |
|  | HIV | 3 |  |  |
|  | Tuberculosis | 5 |  |  |
|  | Viral hepatitis | 6 |  |  |
| 02 Neoplasms | |  | | |
|  | Cancer (inclusive of cancer prevention, cancer fatigue, cancer pain, and insomnia, radiotoxicity or nausea/vomiting associated with cancer)  Cancers covered include: blood, breast, colorectal, gastrointestinal, head and neck, liver, lung, ovarian, prostate, skin & stomach. | 77 |  |  |
| 03 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | | | | |
|  | platelet aggregation | 1 |  |  |
|  | Thalassaemia | 2 |  |  |
| 04 Diseases of the immune system | |  | | |
|  | Chronic fatigue |  |  | 5 |
|  | Systemic lupus erythematosus | 3 |  |  |
| 05 Endocrine, nutritional and metabolic diseases | |  | | |
|  | Diabetes |  |  | 163b |
|  | Dyslipidaemia | 13 |  |  |
|  | Hashimoto's disease |  | 4 |  |
|  | Hypercholesterolaemia | 51 |  |  |
|  | Hyperlipidaemia | 1 |  |  |
|  | Hypothyroidism |  | 1 |  |
|  | Impaired glucose tolerance |  |  | 15 b |
|  | Latent hyperprolactinemia | 1 |  |  |
|  | Metabolic syndrome |  |  | 70 b |
|  | Overweight/obese | 89 |  |  |
|  | Polycystic ovary syndrome |  | 18 |  |
| 06 Mental and behavioural disorders | |  | | |
|  | Adjustment disorder | 1 |  |  |
|  | Anxiety disorders |  |  | 36 |
|  | Symptoms of anxiety |  |  | 6 |
|  | Bodily distress disorders | 2 |  |  |
|  | Mood disorder, depression including bipolar |  |  | 56 |
|  | Neurocognitive decline, inclusive of Alzheimer’s and nervous impairment | 59 |  |  |
|  | Neurodevelopmental disorders | 10 |  |  |
|  | Obsessive compulsive disorders | 8 |  |  |
|  | Post-traumatic stress disorder | 1 |  |  |
|  | Schizophrenia | 24 |  |  |
|  | Smoking cessation | 1 |  |  |
|  | Substance disorders | 4 |  |  |
| 07 Sleep-wake disorders | |  | | |
|  | Bruxism | 2 |  |  |
|  | Insomnia |  |  | 15 |
|  | Restless legs syndrome | 1 |  |  |
|  | Sleep disturbance |  | 7 |  |
| 08 Diseases of the nervous system | |  | | |
|  | Cerebrovascular diseases | 6 |  |  |
|  | Epilepsy | 1 |  |  |
|  | Migraine | 4 |  |  |
|  | Multiple sclerosis | 7 |  |  |
|  | Neuropathic pain | 1 |  |  |
|  | Parkinson's disease | 3 |  |  |
|  | Polyneuropathy | 3 |  |  |
|  | Post viral olfactory dysfunction | 1 |  |  |
|  | Stroke (recovery) | 3 |  |  |
|  | Tardive dyskinesia | 3 |  |  |
| 09 Disease of the visual system | |  | | |
|  | Blepharitis | 1 |  |  |
|  | Diabetic retinopathy | 2 |  |  |
|  | Dry eye syndrome | 1 |  |  |
|  | Glaucoma | 4 |  |  |
|  | Macular degeneration | 2 |  |  |
|  | Ocular hypertension | 1 |  |  |
| 10 Diseases of the ear or mastoid process | |  | | |
|  | Hearing loss | 1 |  |  |
|  | Otitis media | 2 |  |  |
|  | Tinnitus | 4 |  |  |
| 11 Diseases of the circulatory system | |  | | |
|  | Angina | 6 |  |  |
|  | Cardiovascular disease | 2 |  |  |
|  | Claudication, intermittent | 1 |  |  |
|  | Coronary artery disease | 30 |  |  |
|  | Heart failure | 3 |  |  |
|  | Hypertension | 43 |  |  |
|  | Mitral valve disease | 1 |  |  |
|  | Myocardial infarction | 4 |  |  |
|  | Peripheral artery disease | 9 |  |  |
|  | Raynaud's syndrome | 2 |  |  |
|  | Venous insufficiency | 8 |  |  |
| 12 Diseases of the respiratory system | |  | | |
|  | Acute respiratory distress syndrome | 1 |  |  |
|  | Asthma |  | 10 |  |
|  | Bronchitis | 2 |  |  |
|  | Chronic obstructive pulmonary disease | 3 |  |  |
|  | Cystic fibrosis | 1 |  |  |
|  | Idiopathic pulmonary fibrosis | 1 |  |  |
|  | Upper respiratory tract infection |  |  | 28 b |
| 13 Diseases of the digestive system | |  | | |
|  | Anal fissure | 1 |  |  |
|  | Constipation (children, hospital, palliative care, postpartum) |  | 13 |  |
|  | Dental conditions (incl. Caries, Gingivitis. Periodontitis | 13 |  |  |
|  | Dumping syndrome | 1 |  |  |
|  | Functional Dyspepsia |  | 3 |  |
|  | Gastritis | 4 |  |  |
|  | Gastro-oesophageal reflux disease |  |  | 1 |
|  | H. pylori infection &/or stomach ulcers | 5 |  |  |
|  | Haemorrhoids | 1 |  |  |
|  | Hepatic fibrosis or cirrhosis | 6 |  |  |
|  | Infantile colic | 2 |  |  |
|  | Inflammatory bowel diseases |  |  | 26 |
|  | Irritable bowel syndrome |  |  | 19 |
|  | Non-alcoholic fatty liver disease | 50 |  |  |
|  | Oral ulcerative disorders, Oral submucous fibrosis, Oral leukoplakia | 12 |  |  |
|  | Small intestinal bacterial overgrowth |  | 1 |  |
|  | Steatosis | 2 |  |  |
| 14 Diseases of the skin | |  | | |
|  | Acne |  |  | 5 |
|  | Alopecia | 7 |  |  |
|  | Dermatitis & eczema |  |  | 2 |
|  | Keratosis | 2 |  |  |
|  | Onychomycosis | 1 |  |  |
|  | Oral lichen planus | 13 |  |  |
|  | Pigmentation | 5 |  |  |
|  | Pruritus (including Uraemic pruritis) | 6 |  |  |
|  | Psoriasis |  | 12 |  |
|  | Radiodermatitis, cancer | 2 |  |  |
| 15 Diseases of the musculoskeletal system or connective tissue | |  | | |
|  | Arthropathies | 62 |  |  |
|  | Back pain | 6 |  |  |
|  | Fibromyalgia | 3 |  |  |
|  | Osteopathies | 2 |  |  |
| 16 Diseases of the genitourinary system | |  | | |
|  | Amenorrhea |  |  | 1 |
|  | Benign prostatic hyperplasia | 10 |  |  |
|  | Certain specific disorders of breast | 3 |  |  |
|  | Chronic kidney disease | 14 |  |  |
|  | Dysmenorrhoea |  |  | 11 |
|  | Infertility |  | 14 |  |
|  | Oligozoospermia | 2 |  |  |
|  | Menopause |  |  | 87 |
|  | Menstruation |  |  | 3 |
|  | Premenstrual disturbances |  |  | 12 |
|  | Primary vesicoureteral reflux | 1 |  |  |
|  | Urinary tract infection | 12 |  |  |
| 17 Conditions related to sexual health | |  | | |
|  | Erectile dysfunction | 14 |  |  |
|  | Sexual dysfunction | 5 |  |  |
| 18 Pregnancy, childbirth or the puerperium | |  | | |
|  | Breastfeeding |  | 7 |  |
|  | Childbirth | 3 |  |  |
|  | Postpartum | 2 |  |  |
|  | Pre-eclampsia | 1 |  |  |
|  | Pregnancy | 13 |  |  |
|  | Pregnancy, nausea/vomiting | 9 |  |  |
| 20 Developmental anomalies | |  | | |
|  | Neurofibromatosis | 1 |  |  |
| 21 Symptoms, signs or clinical findings, not elsewhere classified | |  | | |
|  | Digestive complaints |  | 3 |  |
|  | Halitosis | 1 |  |  |
|  | Postoperative, nausea/vomiting | 4 |  |  |
|  | Postoperative, pain | 3 |  |  |
|  | Postoperative, wound healing | 2 |  |  |
|  | Radiculopathy | 1 |  |  |
|  | Taste disorder | 1 |  |  |
| 22 Injury, poisoning or certain other consequences of external causes | |  | | |
|  | Altitude sickness | 4 |  |  |
|  | Wound healing (burns, postoperative, pressure ulcer) | 5 |  |  |
|  | Pruritus, chemical | 1 |  |  |
|  | Spinal cord injury | 1 |  |  |
| 24 Factors influencing health status or contact with health services | |  | | |
|  | Abdominal aortic aneurysm repair | 1 |  |  |
|  | Care involving dialysis | 3 |  |  |
|  | Postoperative, nausea/vomiting | 1 |  |  |
|  | Preoperative | 1 |  |  |
|  | Stress |  | 6 |  |
|  | TOTALa | 99 | 867 | 564 |

Abbreviations: ICD-11, International Statistical Classification of Diseases and Related Health Problems 11th Revision;

a. Numbers reflect the population considered within the systematic review and not the number of included reviews (i.e. umbrella reviews that considered more than one population are counted more than once).

b. critical appraisal and synthesis not completed. See section 4.1.5 Included studies.

## Inflammatory bowel disease

### Description of the condition

Inflammatory bowel disease (IBD) encompasses a group of conditions characterised by chronic inflammation in the intestinal tract. The most common chronic immune-mediated IBDs are Crohn's disease and ulcerative colitis ([16](#_ENREF_16)). Crohn's disease is characterised by inflammation of the full thickness of the bowel wall and primarily affects the ileum and colon but may involve other parts of the digestive tract ([17](#_ENREF_17)). Ulcerative colitis causes inflammation of the inner lining of the colon and rectum ([18](#_ENREF_18)). About 5-15% of patients with IBD affecting the colon have features of both conditions ([19](#_ENREF_19)). The cause of IBD remains unknown, with genetic, infectious and environmental factors assumed to play a role in dysregulating intestinal immunity, leading to gastrointestinal injury ([19](#_ENREF_19)). Common symptoms of IBD include bloody diarrhoea, abdominal pain, constipation and weight loss.

The global incidence of IBD has rapidly accelerated as the prevalence has risen to more than 0.3% of the population in several nations, including North America, Europe and Australia ([20](#_ENREF_20)). There are approximately 75,000 Australians living with IBD and over 1,622 new cases diagnosed each year (776 with Crohn's disease and 846 with ulcerative colitis) ([19](#_ENREF_19)). Diagnosis can occur at any age, but commonly occurs during adolescence and early adulthood, leading to lifelong management and treatment ([19](#_ENREF_19)). The disease burden for individuals living with IBD is high, and can involve multiple hospitalisation, the need for multidisciplinary care, significant psychological impacts and inadequate responsiveness to disease deterioration and reduced quality of life ([21](#_ENREF_21)). In 2012, total hospital costs attributed to IBD were estimated to be $100 million, which continues to rise as prevalence continues to accelerate ([21](#_ENREF_21)).

Management of IBD varies according to disease severity and other factors (e.g. age at diagnosis) but the main goal of therapy is centred on achieving clinical and/or patient-reported remission0F[[1]](#footnote-2) using immunomodulators, steroids, biologic agents, or surgical interventions ([18](#_ENREF_18), [19](#_ENREF_19), [22](#_ENREF_22)). Other treatments may focus on relieving acute disease symptoms, improving pain management or preventing hospitalisation. Guidelines do not routinely recommend complementary therapies for IBD noting the limited evidence-base; but, due to adverse effects associated with long-term use of pharmacological therapies, many people with IBD seek out complementary therapies (including herbal and dietary supplements) to provide symptomatic relief (e.g. peppermint oil for bloating, abdominal pain) or to assist with inducing or maintaining remission by promoting anti-inflammatory effects (e.g. curcumin) ([19](#_ENREF_19), [22](#_ENREF_22), [23](#_ENREF_23)).

### Description of reviews

There were 26 citations ([24-49](#_ENREF_24)) corresponding to 26 systematic reviews (Ghassab-Abdollahi 2021, Montazeri 2021, Liu 2021, Morvaridzadeh 2021, Ardiana 2020, Chandan 2020, Coelho 2020, Goulart 2020, Goulart 2020a, Hallajzadeh 2020, Jalali 2020, Mohit 2020, Zheng 2020, Tavakoly 2019, Grammatikopoulou 2018, Iqbal 2018, Restellini 2017, Kafil 2017, Kim 2017, Schneider 2017, Simadibrata 2017, Langhorst 2015, Ng 2013, Rahimi 2013, Kumar 2012, Ernst 2008) identified in the literature search that evaluated the effectiveness of WHMs in people with IBD. There were no additional reviews identified in the Department’s public call for evidence (see Appendix C2), 3 systematic reviews ([50-52](#_ENREF_50)) awaiting classification (see Appendix C4) and one ongoing review ([53](#_ENREF_53)) (see Appendix C5).

A summary of the PICO criteria of the 26 eligible systematic reviews is provided in Appendix D1.1.1.

The populations eligible for inclusion in the reviews were participants with ulcerative colitis (Chandan 2020, Goulart 2020, Zheng 2020, Grammatikopoulou 2018, Iqbal 2018, Simadibrata 2017), Crohn’s disease (Schneider 2017), collagenous colitis (Kafil 2017), or participants with any form of IBD (Liu 2021, Coelho 2020, Goulart 2020a, Restellini 2017, Kim 2017, Langhorst 2015, Ng 2013, Rahimi 2013, Kumar 2012).

Nine (9) reviews had no population restrictions but searched for studies that focused on the effect of a single herb (Boswellia) for any clinical condition (Ernst 2008) or included studies that measured oxidative stress and/or inflammatory biomarkers as an outcome (Ghassab-Abdollahi 2021, Montazeri 2021, Morvaridzadeh 2021, Ardiana 2020, Hallajzadeh 2020, Jalali 2020, Mohit 2020, Tavakoly 2019).

Seven (7) systematic reviews (Liu 2021, Chandan 2020, Coelho 2020, Goulart 2020, Zheng 2020, Grammatikopoulou 2018, Iqbal 2018) were prioritised for critical appraisal and data extraction as they were published in 2018 or after and presented results in a meta-analysis. Three (3) other reviews (Kafil 2017, Kim 2017, Langhorst 2015) identified additional RCTs and were included in the qualitative synthesise. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 27 RCTs that met our PICO criteria (see Appendix F1). Of these, 20 RCTs were conducted in people with ulcerative colitis (active or quiescent), 6 RCTs were in people with Crohn’s disease and one RCT was in people with collagenous colitis.

An overlap table of the RCTs within the included systematic reviews is shown in Table 2.

The RCTs used different herbs1F[[2]](#footnote-3) (see Appendix D1.1.1) and doses to either induce or maintain disease remission with the intervention period ranging from 4 weeks up to 12 months. Ten (10) of the 12 identified herbs matched to the Tier 1 herbs included in the Western herbal medicine curriculum for the Digestive system (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).The studies were conducted in a variety of countries including Canada, China, Cyprus, Germany, Hong Kong, India, Iran, Israel, Japan, Romania, Ukraine, the UK and the US with sample sizes ranging from 20 to 224 participants (total 1613 participants).

There were 22 RCTs that examined the effect of WHM compared with placebo (Kumar 2019, Sadeghi 2019, Sugimoto 2019, Masoodi 2018, Shapira 2018, Banerjee 2017, Kedia 2017, Lang 2015, Rastegarpanah 2015, Singla 2014, Dryden 2013, Sandbom 2013, Suskind 2013, Holtmeier 2011, Shivakumar 2011, Sandbom 2010, Madisch 2007, Omer 2007, Hanai 2006, Langmead 2004, Atkinson 2002, Hallert 1991), usually delivered as an adjunct to standard therapy (e.g. mesalazine, 5- aminosalicylic acid or corticosteroids). Two (2) RCTs (Krebs 2012, Fernandez-Banares 1999) examined the effect of WHM compared with no intervention and 3 RCTs (Langhorst 2013, Tang 2011, Gerhardt 2001) examined the effect of WHM compared with standard therapy (i.e. mesalazine).

Results for the Primary Comparison: WHM versus placebo and Secondary Comparison: WHM versus inactive control (no intervention, waitlist, usual care [if inactive]) are provided in the Summary of Findings tables (see Section 4.2.5). Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

The reviews by Kim 2017, Kafil 2017 and Coelho 2020 were used to inform the evidence synthesis as they used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and provided the most comprehensive information to make a judgement.

Several of the eligible RCTs (Kumar 2019, Sugimoto 2019, Shapira 2018, Dryden 2013, Suskind 2013, Krebs 2012, Atkinson 2002, Fernández-Bañares 1999) were judged by the included systematic reviews to be at overall high risk of bias.

Table 2 List of included systematic reviews and overlap with eligible RCTs (per outcome): Inflammatory bowel disease

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Kumar 2019 | Sadeghi 2019 | Sugimoto 2019 | Masoodi 2018 | Shapira 2018 | Banerjee 2017 | Kedia 2017 | Lang 2015 | Rastegarpanah 2015 | Singla 2014 | Dryden 2013 | Langhorst 2013 | Sandbom 2013 | Suskind 2013 | Krebs 2012 | Holtmeier 2011 | Shivakumar 2011 | Tang 2011 | Sandborn 2010 | Madisch 2007 | Omer 2007 | Hanai 2006 | Langmead 2004 | Atkinson 2002 | Gerhardt 2001 | Fernandez-Banares 1999 | Hallert 1991 |
| Liu 2021 | † | Patient reported improvement | Y | -- | Y | Y | -- | Y | Y | Y | Y | Y | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Chandan 2020 | ✓ | -- | -- | -- | Y | -- | Y | Y | Y | -- | Y | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Coelho 2020 | † | -- | Y | -- | Y | # | # | Y | Y | -- | Y | -- | -- | -- | # | -- | -- | -- | -- | -- | -- | -- | Y | -- | # | -- | -- | -- |
| Goulart 2020 | ✓ | -- | Y | # | Y | -- | # | Y | Y | -- | # | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | # | -- | -- | -- | -- | -- |
| Zheng 2020 | ✓ | -- | -- | -- | Y | -- | Y | Y | Y | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Grammatikopoulou 2018 | ✓ | -- | -- | -- | -- | -- | Y | Y | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Iqbal 2018 | † | -- | -- | -- | -- | -- | Y | -- | Y | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Kafil 2017 | † | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- |
| Kim 2017 | ✓ | -- | -- | -- | -- | -- | -- | -- | Y | Y | -- | Y | -- | Y | -- | Y | Y | -- | -- | Y | -- | Y | Y | Y | -- | -- | Y | Y |
| Langhorst 2015 | † | -- | -- | -- | -- | -- | -- | -- | -- | Y | Y | -- | Y | Y | -- | Y | Y | -- | Y | -- | -- | Y | Y | Y | -- | Y | Y | -- |
| Schnieder 2017 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Simadibrata 2017 | \* | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Ng 2013 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | Y | -- | -- | -- | -- | Y | Y | Y | -- | Y | Y | -- |
| Rahimi 2013 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | Y | -- |
| Kumar 2012 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- |
| Ernst 2008 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- |

Abbreviations: RCT, randomised controlled trial

Notes:

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is reported for the listed outcome measure [result available]

# RCT is included in the systematic review, meets our PICO criteria but a study result is not available for the listed outcome measure as the SR did not include it in their data synthesis due to high risk of bias or heterogeneity [data are incomplete; result may be available in another SR]

-- RCT is not included in systematic review.

### Summary of findings and evidence statement

#### Primary Comparison (vs placebo)

There were 22 RCTs found by the included systematic reviews that compared WHM with placebo in people with IBD. Of these, 17 RCTs (Kumar 2019, Sadeghi 2019, Masoodi 2018, Banerjee 2017, Kedia 2017, Lang 2015, Rastegarpanah 2015, Singla 2014, Dryden 2013, Sandbom 2013, Holtmeier 2011, Shivakumar 2011, Sandbom 2010, Madisch 2007, Omer 2007, Hanai 2006, Langmead 2004) contributed data relevant to at least one critical or important outcome.

Four (4) RCTs (Sugimoto 2019, Shapira 2018, Suskind 2013, Atkinson 2002) did not contribute any data because the review authors had judged the studies to be at high risk of bias (no data reported) and one RCT (Hallert 1991) did not report results prior to crossover so were not able to be used in the synthesis.

| WHM compared to placebo for Inflammatory bowel disease | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Inflammatory bowel disease  **Setting:** Community  **Intervention:** WHM (curcumin, green tea extract, boswellia, wormwood, St Mary’s thistle, andrographis) delivered as an adjunct to standard therapy  **Comparison:** Placebo | | | | | | | |
| Outcomes | Anticipated absolute effects\* (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement | |
| Risk with Placebo | Risk with WHM |
| Clinical improvement assessed with: CDAI, UCDAI or other  Scale: range varies (higher is worse) follow-up: range 4 to 24 weeks | - | SMD **0.37 SD lower^**  (0.77 lower to 0.04 higher) | - | 151 (2 studies) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM may result in little to no difference in disease activity in people with IBD. |
| Clinical response assessed with: CDAI, UCDAI (response rate) Scale: % with change in score by n points follow-up: range 4 to 24 weeks | 342 per 1,000 | **567 per 1,000** (393 to 824) | **RR 1.66** (1.15 to 2.41) | 403 (8 RCTs) †† | ⨁⨁◯◯ LOW a,b,c,e,f | WHM may result in a clinical response in people with IBD. # |
| Clinical remission assessed with: CDAI, UCDAI (remission rate) Scale: % achieve score indicating inactive disease follow-up: range 4 to 24 weeks | 326 per 1,000 | **503 per 1,000** (405 to 620) | **RR 1.54** (1.24 to 1.90) | 974 (14 RCTs) ††† | ⨁⨁⨁◯ MODERATE a,b,c,e,g | WHM probably results in maintenance of clinical remission in people with IBD. # |
| Pain | - | - | - | (0 studies) | - | The effect of WHM on pain in people with IBD is unknown. |
| HRQoL | - | - | - | (0 studies) \*\* | - | The effect of WHM on HRQoL in people with IBD is unknown. |
| Emotional functioning | - | - | - | (0 studies) \*\*\* | - | The effect of WHM on emotional functioning in people with IBD is unknown. |
| Physical functioning | - | - | - | (0 studies) | - | The effect of WHM on physical functioning in people with IBD is unknown. |
| Stool quality/ frequency | - | - | - | (0 studies) | - | The effect of WHM on stool quality or frequency in people with IBD is unknown. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # A 25% relative risk improvement was considered important (i.e. RR > 1.25).  † Data from 20 RCTs (> 1100 participants) not included here because results were not adequately reported [missing information].  †† Data from 14 RCTs (> 763 participants) not included here because results were not adequately reported [missing information].  ††† Data from 8 RCTs (> 192 participants) not included here because results were not adequately reported [missing information].  \*\* Data from 4 RCTs (236 participants) not included here because results were not adequately reported [missing information].  \*\*\* Data from one RCT (40 participants) not included here because results were not adequately reported [missing information].  **CDAI:** Crohn’s disease activity index; **CI:** confidence interval; **RR:** risk ratio; **UCDAI:** ulcerative colitisdisease activity index; **WHM:** Western herbal medicine | | | | | | |
| **GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Certainty of evidence not downgraded.

b. No serious inconsistency. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people with inflammatory bowel disease and is directly generalisable to the Australian population with few caveats. The herbs used in the identified studies are comparable to those commonly used in Australia (>80% matched) or could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bound overlaps with both large and no important difference). Certainty of evidence downgraded.

e. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

f. Serious imprecision. Wide confidence intervals (lower bound overlaps with no important difference). Certainty of evidence downgraded.

g. No serious imprecision. Certainty of evidence not downgraded.

#### Secondary Comparison (vs inactive control)

There were 2 RCTs found by the included systematic reviews that compared WHM with no intervention in people with either Crohn’s disease (Krebs 20122F[[3]](#footnote-4)) or ulcerative colitis (Fernández-Bañares 19993F[[4]](#footnote-5)). The RCTs contributed data relevant to one outcome. The available evidence is summarised below.

| WHM compared to inactive control for Inflammatory bowel disease | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Inflammatory bowel disease  **Setting:** Community  **Intervention:** WHM (wormwood, psyllium seed) delivered as an adjunct to standard therapy  **Comparison:** Control (no intervention) | | | | | | | |
| Outcomes | Anticipated absolute effects\* (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement | |
| Risk with Control | Risk with WHM |
| Clinical improvement | - | - | - | (0 studies) | - | The effect of WHM on clinical improvement in people with IBD is unknown. |
| Clinical response | - | - | - | (0 studies) | - | The effect of WHM on clinical response in people with IBD is unknown. |
| Clinical remission assessed with: CDAI, UCDAI  Scale: % achieve set score indicating inactive disease follow-up: range 4 to 52 weeks | 553 per 1,000 | **1,000 per 1,000** (260 to 1,000) | **RR 1.82** (0.47 to 7.02) | 87 (2 RCTs) | ⨁◯◯◯ Very Low a,b,c,d,e | The evidence is very uncertain about the effect to WHM on clinical remission in people with IBD. # |
| Pain | - | - | - | (0 studies) | - | The effect of WHM on pain in people with IBD is unknown. |
| HRQoL | - | - | - | (0 studies) \*\* | - | The effect of WHM on HRQoL in people with IBD is unknown. |
| Emotional functioning | - | - | - | (0 studies) \*\* | - | The effect of WHM on emotional functioning in people with IBD is unknown. |
| Physical functioning | - | - | - | (0 studies) | - | The effect of WHM on physical functioning in people with IBD is unknown. |
| Stool quality/ frequency | - | - | - | (0 studies) | - | The effect of WHM on stool quality or frequency in people with IBD is unknown. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # A 25% relative risk reduction/increase was considered important (i.e. RR < 0.75 or RR > 1.25).  \*\* Data from one RCT (20 participants) not included here because results were not adequately reported [missing information].  **CDAI:** Crohn’s disease activity index; **CI:** confidence interval; **RR:** risk ratio; **UCDAI:** ulcerative colitisdisease activity index; **WHM:** Western herbal medicine | | | | | | |
| **GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanation

a. No serious risk of bias. Certainty of evidence not downgraded.

b. Serious inconsistency. Statistical heterogeneity is high (I2 = 77%). Certainty of evidence downgraded.

c. No serious indirectness. The available evidence is in people with inflammatory bowel disease and is directly generalisable to the Australian population with few caveats. The herbs used in the identified studies are comparable to those commonly used in Australia and can be sensibly applied. Certainty of evidence not downgraded.

d. Very serious imprecision. Wide confidence intervals (upper and lower bound overlaps with both large and no important difference). Certainty of evidence downgraded 2 levels.

e Publication bias not suspected. Certainty of evidence not downgraded.

#### Tertiary Comparison (vs active control)

There were 3 RCTs found by the included systematic reviews that compared WHM with active comparators (mesalazine) in people with Crohn’s disease (1 RCT) or ulcerative colitis (2 RCTs) and contributed data relevant to at least one critical or important outcome (see Appendix F2).

### Forest plots

Outcome results related to people with inflammatory bowel disease are presented in Figure 2 (disease activity index), Figure 3 (clinical response), and Figure 4 (clinical remission).

Figure 2 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – disease activity index

P2191#yIS1

Abbreviations: DAI, disease activity index, UCDAI, Ulcerative colitis disease activity index

Figure 3 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – Clinical response in disease activity (response rate)

P2194#yIS1

Figure 4 Forest plot of comparison: WHM vs placebo: Inflammatory bowel disease – Clinical remission (remission rate)

P2197#yIS1

Note: Kim 2017 reports the proportion of participants who fail to achieve (or maintain) remission. The data are “inverted” in our evidence synthesis to correlate with other reviews that report the proportion of participants who achieve (or maintain) remission.

## Irritable bowel syndrome

### Description of the condition

Irritable bowel syndrome (IBS) is a symptom-based condition associated with abdominal pain or discomfort and changes in bowel habits that persist over an extended period. Individuals with IBS also experience bowel sensitivity, causing uneven contractions, pain and bloating ([56](#_ENREF_56), [57](#_ENREF_57)). IBS presents with similar symptoms to several other gastrointestinal diseases and is often confused with inflammatory bowel disease (IBD), as both IBS and IBD can affect the oesophagus, intestines and stomach ([58](#_ENREF_58)). General symptoms include abdominal pain, bloating, constipation, diarrhoea, and flatulence ([56](#_ENREF_56), [59](#_ENREF_59)). The cause of IBS is not well understood; however, altered gut motility, an imbalance of ‘good’ and ‘bad’ bacteria and a slightly inflamed or ‘leaky’ gut are thought to be involved ([60](#_ENREF_60)). Certain foods may induce IBS symptoms prompting affected individuals to modify their diet ([60](#_ENREF_60)). Episodes of gastroenteritis, chronic stress and food poisoning may also trigger IBS and worsen IBS in individuals experiencing periods of high stress ([59](#_ENREF_59)).

Approximately 10-15% of the global population are affected by IBS, with 1 in 5 people experiencing IBS at some time in their lives ([56](#_ENREF_56), [59](#_ENREF_59)). In Australia, up to 30% of the population are thought to have IBS, which is diagnosed more frequently in females than males ([59](#_ENREF_59)). IBS is a chronic condition that can substantially reduce the quality of life and work productivity and has been associated with indirect costs (e.g. loss of income), imposing a substantial burden on individuals with IBS ([61](#_ENREF_61)).

Treatment for IBS typically includes a modified diet (e.g. low FODMAP4F[[5]](#footnote-6), increased consumption of soluble fibre) combined with symptom management ([62](#_ENREF_62)). Complementary and alternative therapies that aim to provide anti-inflammatory effects, such as peppermint (Mentha piperita) and Psyllium (Plantago ovata) are popular herbal medicines used for reducing abdominal pain, inflammation and relieving constipation ([61](#_ENREF_61), [63](#_ENREF_63)).

### Description of reviews

There were 19 citations ([64-83](#_ENREF_64)) corresponding to 19 SRs identified in the literature search that evaluated the effectiveness of WHMs in people with IBS (Anh 2020, Black 2020, Hawrelak 2020, Tan 2020, Alammar 2019, Hong 2018, Ng 2018, Anheyer 2017a, Korterink 2015, Lakhan 2015, Khanna 2014, Ruepert 2011, Shen 2009, Ford 2008, Huertas-Ceballos 2008, Liu 2006, Grigoleit 2005, Jailwala 2000, Pittler 1998). No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were 6 reviews awaiting classification ([84-89](#_ENREF_84)) (see Appendix C4) and one ongoing review ([90](#_ENREF_90)) (see Appendix C5).

A summary of the PICO criteria of eligible systematic reviews is provided in Appendix D1.2.1.

The populations eligible for inclusion in the reviews were participants with IBS (Black 2020, Hawrelak 2020, Alammar 2019, Hong 2018, Ng 2018, Khanna 2014, Ruepert 2011, Shen 2009, Ford 2008, Huertas-Ceballos 2008, Liu 2006, Grigoleit 2005, Jailwala 2000, Pittler 1998) or participants with functional gastrointestinal disorders (Tan 2020, Anheyer 2017a, Korterink 2015). Two reviews had no population restrictions but searched for studies that focused on the effect of a single herb (ginger) for any clinical condition (Anh 2020) or presented results where pain was measured as an outcome (Lakhan 2015).

Six (6) systematic reviews (Black 2020, Hawrelak 2020, Tan 2020, Alammar 2019, Hong 2018, Ng 2018) were prioritised for critical appraisal and data extraction as they were published in 2018 or after and presented results in a meta-analysis. One other review (Anheyer 2017a) identified an additional RCT and was included in the qualitative synthesis.

Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 40 RCTs that met our PICO criteria (see Appendix F1). Of these, 19 RCTs (Weerts 2019, Cash 2016, Mosaffa-Jahromi 20165F[[6]](#footnote-7), Alam 2013, Merat 2009, Cappello 2007, Capanni 2005, Kline 2001, Liu 1997, Schneider 1990, Carling 1989, Lawson 1988, Lech 1988, Weiss 1988, Wildgrube 1988, Nash 1986, Dew 1984, Evans 1982, Rees 1979) were focused on the use of peppermint oil to relieve symptoms of IBS. Another 21 RCTs (Portincasa 2016, Shulman 2016, Brown 2015, Storsrud 2015, Tilburg 2014, Bortolotti 2011, Hutchings 2011, Saito 2010, Bijkerk 2009, Davis 2006, Vejdani 2006, Brinkhaus 2005, Bundy 2004, Madisch 2004, Pedersen 1998, Jalihal 1990, Prior 1987, Nigam 1984, Arthurs 1983, Longstreth 1981, Ritchie 1979) examined the effect of a variety of WHMs6F[[7]](#footnote-8) (see Appendix D1.1.1). Five (5) of the 13 identified herbs (~38%) were matched to the Tier 1 herbs included in the Western herbal medicine curriculum for the Digestive system (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

An overlap table of the RCTs within the included systematic reviews is shown in Table 3 (peppermint oil) and Table 4 (WHMs other than peppermint)7F[[8]](#footnote-9).

All included RCTs examined the effect of WHM compared with placebo and were conducted in a variety of countries including Bangladesh, China, Germany, India, Iran, Italy, Sweden, the Netherlands, UK or the US with participants generally diagnosed using the Rome I-IV criteria, Manning diagnostic criteria, Kruis criteria or via detailed clinical examination. Sample sizes ranged from 20 to 208 (total 2040 participants). Several RCTs had crossover designs with a washout period defined as recurrence of active IBS symptoms (Dew 1984, Rees 1979), after at least 1 week (Carling 1989, Schneider 1990) or not reported (Hutchings 2011).

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.3.5). Additional details are provided in Appendix F2. There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, waitlist, usual care [if inactive]) and no results available for the Tertiary Comparison (versus active comparators).

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

All reviews used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to assess bias within the included RCTs and provided comprehensive information to make a judgement.

Several of the eligible RCTs were consistently judged by the included systematic reviews to be at high risk of bias relating to selection bias (Portincasa 2016), attrition bias (Bortolotti 2011, Hutchings 2011, Cappello 2007, Davis 2006, Vejdani 2006, Kline 2001, Liu 1997, Schneider 1990, Lawson 1988, Lech 1988, Weiss 1988) or outcome reporting (Merat 2010, Arthurs 1983, Cappani 2005, Longstreth 1981).

The other RCTs where judged to be at low risk of bias (11 RCTs: Weerts 2019, Cash 2016, Mosaffa-Jahromi 2016, Storsrud 2015, Merat 2010, Saito 2010, Bijkerk 2009, Madisch 2004, Lawson 1988, Dew 1984, Rees 1979) or have unclear risk of bias (14 RCTs: Shulman 2016, Brown 2015, Tilburg 2014, Alam 2013, Brinkhaus 2005, Pedersen 1998, Jalihal 1990, Carling 1989, Wildgrube 1988, Prior 1987, Nash 1986, Nigam 1984, Evans 1982, Ritchie 1979).

Table 3 List of included systematic reviews and overlap with eligible RCTs (per outcome): Irritable bowel syndrome (peppermint oil)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | | | | | | | |
| Weerts 2019 | Cash 2016 | Mosaffa-Jahromi 2016 c | Alam 2013 | Merat 2009 | Cappello 2007 | Capanni 2005 | Kline 2001 | Liu 1997 | Schneider 1990 | Carling 1989 | Lawson 1988 | Lech 1988 | Weiss 1988 | Wildgrube 1988 | Nash 1986 | Dew 1984 | Evans 1982 | Rees 1979 |
| Black 2020 | ✓ | Global symptom improvement | ? | ? | ? | -- | ! | ? | ? | -- | ! | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | -- | ? | ? | ? | ? | Y | Y | Y | Y | ? | Y | ? | Y | Y | ? | Y | ! | ? | Y |
| Tan 2020 | ✓ | -- | -- | Y | -- | Y | Y | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Alammar 2019 | ✓ | -- | Y | -- | ! | ! | Y | Y | -- | ! | ! | ! | -- | Y | Y | -- | -- | Y | -- | Y |
| Black 2020 | ✓ | Abdominal pain | ? | ? | ! | -- | ? | ! | ! | -- | ? | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | -- | ? | Y | ? | ? | ? | ! | Y | ! | ? | ! | ? | ! | ? | ? | ! | Y | ? | ! |
| Tan 2020 | ✓ | -- | -- | ? | -- | ? | ? | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Alammar 2019 | ✓ | -- | Y | -- | ! | Y | ! | Y | -- | Y | Y | ! | -- | Y | ! | -- | -- | ! | -- | ! |
| Anheyer 2017a | † | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Koterink 2015 | \* | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | Bloating etc. | -- | ? | Y | ? | ? | ? | ! | ! | ! | ? | ! | ? | ! | ? | ? | ! | ! | ? | ! |
| Hawrelak 2020 | ✓ | Emotional functioning | -- | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! |
| Hawrelak 2020 | ✓ | Stool frequency/ bowel transit time | -- | ? | ! | ? | ? | ? | ! | ! | ! | ? | Y | ? | Y | ? | ? | ! | Y | ? | Y |
| Hawrelak 2020 | ✓ | HRQoL | -- | ! | ? | ! | ? | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! | ! |

Abbreviations: HRQoL, health-related quality of life; IBS, irritable bowel syndrome; RCT, randomised controlled trial

Notes:

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

c. RCT has two intervention arms (peppermint oil and anise oil)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is reported for the listed outcome measure [result available].

? RCT is included in the systematic review & meets our PICO criteria, but a study result is not available for the listed outcome [data is incomplete; result may be available in another SR]

! RCT is included in the systematic review, but the SR indicates the study does not measure (or report) the listed outcome [not measured]

-- RCT is not included in systematic review.

Table 4 List of included systematic reviews and overlap with eligible RCTs (per outcome): Irritable bowel syndrome (WHM other than peppermint oil)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | | | | | | | | | |
| Mosaffa-Jahromi 2016 c | Portincasa 2016 | Shulman 2016 | Brown 2015 | Storsrud 2015 | Tilburg 2014 | Bortolotti 2011 | Hutchings 2011 | Saito 2010 | Bijkerk 2009 | Davis 2006 | Vejdani 2006 | Brinkhaus 2005 | Madisch 2004 | Pedersen 1998 | Jalihal 1990 | Prior 1987 | Nigam 1984 | Arthurs 1983 | Longstreth 1981 | Ritchie 1979 |
| Anh 2020 | † | Global symptom improvement | ? | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Black 2020 | ✓ | ! | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | ? | ? | ? | ? | ? | ? |
| Hawrelak 2020 | ✓ | ? | ? | -- | ! | ? | ? | ! | ? | ? | -- | ? | ! | ? | ? | ? | -- | -- | -- | -- | -- | -- |
| Tan 2020 | ✓ | Y | Y | -- | -- | Y | Y | -- | -- | ? | -- | Y | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Black 2020 | ✓ | Abdominal pain | ? | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | ! | ? | ! | ! | ! | ! |
| Hawrelak 2020 | ✓ | ? | ? | -- | ! | ! | ? | ? | ! | ? | -- | ? | ? | ? | ? | ! | -- | -- | -- | -- | -- | -- |
| Tan 2020 | ✓ | ? | ? | -- | -- | ? | ? | -- | -- | ? | -- | ? | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Anheyer 2017a | † | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Lakhan 2015 | † | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hong 2018 | ✓ | Patient reported improvement | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ng 2018 | † | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | Health-related quality of life | ? | ? | -- | ! | ! | ! | ! | ? | ! | -- | ? | ! | ! | ! | ! | -- | -- | -- | -- | -- | -- |
| Hong 2018 | ✓ | -- | -- | -- | -- | ! | -- | -- | ? | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ng 2018 | † | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | Emotional functioning | ! | ? | -- | ! | ? | ! | ! | ! | ! | -- | ! | ! | ? | ! | ! | -- | -- | -- | -- | -- | -- |
| Hong 2018 | ✓ | -- | -- | -- | -- | ? | -- | -- | ! | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | Bloating etc. | ? | ? | -- | ? | ! | ! | ? | ! | ? | -- | ? | ? | ! | ! | ! | -- | -- | -- | -- | -- | -- |
| Hawrelak 2020 | ✓ | Stool frequency/  bowel transit time | ? | ? | -- | ? | Y | ! | ? | ! | ? | -- | ! | ! | ! | ! | ! | -- | -- | -- | -- | -- | -- |

Abbreviations: HRQoL, health-related quality of life; IBS, irritable bowel syndrome, RCT, randomised controlled trial; WHM, Western herbal medicine

Notes:

a. Only critical or important outcome domains with available data included here (see Appendix D1.2.3).

b. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

c. RCT has two intervention arms (peppermint oil and anise oil).

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is reported for the listed outcome measure [result available].

? RCT is included in the systematic review & meets our PICO criteria, but a study result is not available for the listed outcome [data are incomplete; result may be available in another SR]

! RCT is included in the systematic review, but the SR indicates the study does not measure (or report) the listed outcome [not measured]

-- RCT is not included in systematic review.

### Summary of findings and evidence statement

#### Primary Comparison (vs placebo)

There were 40 RCTs found by the included systematic reviews that compared WHM with placebo in people with IBS. Of these, 21 RCTs (Cash 2016, Mosaffa-Jahromi 2016, Portincasa 2016, Storsrud 2015, Tilburg 2014, Hutchings 2011, Saito 2010, Merat 2009, Cappello 2007, Davis 2006, Vejdani 2006, Capanni 2005, Kline 2001, Liu 1997, Schneider 1990, Carling 1989, Lech 1988, Weiss 1988, Nash 1986, Dew 1984, Rees 1979) contributed data relevant to 2 critical or important outcomes.

The other 19 RCTs (Weerts 2019, Shulman 2016, Brown 2015, Alam 2013, Bortolotti 2011, Bijkerk 2009, Brinkhaus 2005, Bundy 2004, Madisch 2004, Jalihal 1990, Nigam 1990, Lawson 1988, Pedersen 1998, Prior 1987, Wildgrube 1988, Arthurs 1983, Evans 1982, Longstreth 1981, Ritchie 1979) could have contributed data but there was insufficient information reported by the primary studies or the included systematic reviews to make an assessment.

| WHM compared to placebo for Irritable bowel syndrome | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Irritable bowel syndrome  **Setting:** Community  **Intervention:** WHM (peppermint oil, aloe vera, turmeric, psyllium, St John’s wort, capsicum, ginger, anise oil, senna or fixed dose herbal combinations)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\* (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| Clinical improvement assessed with: IBS-SSS, GSRS or other Scale: range varies (higher is worse) follow-up: range 4 to 20 weeks | - | SMD **0.44 SD lower^**  (0.70 lower to 0.18 lower) | - | 236 (3 studies) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM may result in a slight reduction IBS symptom severity with people with IBS. |
| Clinical response assessed with: IBS-SSS, GSRS or other (response rate) Scale: % with change in score by n points follow-up: range 4 to 24 weeks | 285 per 1,000 | **508 per 1,000** (391 to 665) | **RR 1.78** (1.37 to 2.33) | 1279 (19 RCTs) †† | ⨁⨁⨁◯ MODERATE c,f,g,h,i | WHM probably results in a clinical response in people with IBS. |
| Abdominal pain (response rate)  follow-up: range 2 to 18 weeks | 271 per 1,000 | **501 per 1,000** (406 to 617) | **RR 1.85** (1.50 to 2.28) | 606 (7 RCTs) ††† | ⨁⨁◯◯ Low b,c,h,e,j | WHM may result in an improvement in abdominal pain in people with IBS. |
| Health-related quality of life | - | - | - | (0 RCTs) \*\* | - | The effect of WHM on quality of life in people with IBS is unknown. |
| Emotional functioning | - | - | - | (0 RCTs) \*\*\* | - | The effect of WHM on emotional functioning in people with IBS is unknown. |
| Bloating, distention or cramping | - | - | - | (0 RCTs) \*\*\*\* | - | The effect of WHM on bloating, distension or cramping in people with IBS is unknown. |
| Stool frequency or quality | - | - | - | (0 RCTs) \*\*\*\*\* | - | The effect of WHM on stool frequency or quality in people with IBS is unknown. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # A 25% relative risk reduction/increase was considered important (i.e. RR < 0.75 or RR > 1.25).  † Data from 22 RCTs (1606 participants) [not reported] not included here because results were not adequately reported [missing information].  †† Data from 6 RCTs (563 participants) not included here because results were not adequately reported [missing information]. 3 RCTs suggest an effect favouring WHM and 3 RCTs suggest there is no important difference between groups.  ††† Data from 13 RCTs (983 participants) not included here because results were not adequately reported [missing information]. 9 RCTs suggest an effect favouring WHM and 4 RCTs suggest there is no difference between groups.  \*\* Data from 4 RCTs (411 participants) not included here because results were not adequately reported [missing information]. 2 RCTs suggest an effect favouring WHM and 2 RCTs suggest there is no difference between groups.  \*\*\* Data from 2 RCTs (144 participants) not included here because results were not adequately reported [missing information]. Both RCTs suggest there is no difference between groups.  \*\*\*\* Data from 6 RCTs (243 participants) not included here because results were not adequately reported [missing information]. 4 RCTs suggest an effect favouring WHM and 2 RCTs suggest there is no difference between groups.  \*\*\*\*\* Data from 9 RCTs (518 participants) not included here because results were not adequately reported [missing information]. 2 RCTs suggest an effect favouring WHM and 5 RCTs suggest there is no difference between groups. Data were not reported for 2 RCTs.  **CI:** confidence interval; **GSRS:** gastrointestinal rating scale; **IBS:** irritable bowel syndrome; **IBS-SSS:** IBS symptom severity scale; **RR:** risk ratio; **WHM:** Western Herbal Medicine | | | | | | |
| **GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanation

a. No serious risk of bias. One RCT contributing >40% of data at high risk of bias. In a sensitivity analysis, the size and direction of effect did not materially change (SMD –0.39; 95% CI –0.75, –0.04; p = 0.03; I2 = 0%). Certainty of evidence not downgraded.

b. No serious inconsistency. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people with irritable bowel syndrome and is directly generalisable to the Australian population with few caveats. The herbs used in the identified studies are comparable to those commonly used in Australia (~38%) or could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both moderate and no important difference). Certainty of evidence downgraded.

e. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

f. Serious risk of bias. 8 RCTs contributing ~40% of data at high risk of bias that overstates the size of the effect. Certainty of evidence downgraded.

g. No serious inconsistency. Statistical heterogeneity (I2=67%) judged likely to be related to differences in study characteristics (e.g. differences in the intervention, participants, setting). Certainty of evidence not downgraded.

h. No serious imprecision. Certainty of evidence not downgraded.

i. Publication bias not detected. Certainty of evidence not downgraded.

j. Serious risk of bias. 6 RCTs contributing >90% of data were at high risk of bias that overstates the size of the effect. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no RCTs found by the included systematic reviews that compared WHM with inactive control (no intervention, waitlist or usual care [if inactive]) in people with IBS. The effect of WHM compared with inactive control in people with IBS is unknown.

#### Tertiary Comparison (vs active control)

There were 2 RCTs found by the included systematic reviews that compared WHM with active comparators, but individual study data were not provided (see Appendix F2).

### Forest plots

Outcome results related to people with irritable bowel syndrome are presented in Figure 5 (symptom severity), Figure 6 (global symptom improvement), and Figure 7 (abdominal pain).

Figure 5 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Symptom severity

P3205#yIS1

Figure 6 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Global improvement in IBS symptoms (response rate\*)

P3208#yIS1

\* the proportion of participants who achieved a global improvement in IBS symptoms.

Figure 7 Forest plot of comparison: WHM vs placebo: Irritable bowel syndrome – Abdominal pain (response rate\*)

P3211#yIS1

\* the proportion of participants who achieved improvement in abdominal pain symptoms

## Gastro-oesophageal reflux disease

### Description of the condition

Gastro-oesophageal reflux disease (GORD) is a condition where the stomach contents are squeezed back into the oesophagus, resulting in symptoms of heartburn, regurgitation, ulcers and further complications such as peptic oesophagitis ([91](#_ENREF_91)). GORD occurs when there is a defective function of the lower oesophagus sphincter, leading to excessive stomach acid exposure in the oesophagus ([91](#_ENREF_91), [92](#_ENREF_92)). The pathogenesis of GORD is multifactorial, with no definite cause for the disease's development. Risk factors for GORD include smoking, obesity, use of non-steroidal anti-inflammatory drugs or aspirin, and a low socioeconomic background ([93](#_ENREF_93)). The general implications of developing GORD are based on lower oesophageal sphincter (LES) dysregulation, transient LES relaxation and impaired oesophageal acid clearance ([91](#_ENREF_91), [94](#_ENREF_94)).

Globally, approximately 1 in 6 individuals experience GORD symptoms ([93](#_ENREF_93)), with reports of GORD being more frequent in men than in women ([91](#_ENREF_91)). In Australia, approximately 11.6% of the population has been diagnosed with GORD. Undiagnosed prevalence of GORD is estimated at 10-20% of the general population ([95](#_ENREF_95)).

GORD has a significant impact on quality of life, with most people diagnosed with GORD requiring long term management. Medications that slow or stop acid production in the stomach such as antacids, H2-receptor antagonists or proton pump inhibitors (PPI) are commonly used when diet and lifestyle adjustments are ineffective. Acid suppression is an effective form of therapy but does not cure the condition and there are concerns about overuse of PPIs for long term management of GORD ([92](#_ENREF_92), [95](#_ENREF_95)). To mitigate adverse effects, diet and lifestyle changes remain an important tool in the management of GORD. Common herbal medicines used to manage symptoms of heartburn include chamomile, ginger, liquorice root, lemon balm and milk thistle.

### Description of reviews

There was one citation ([96](#_ENREF_96)) corresponding to one systematic review (Sadeghi 2020) identified in the literature search that examined the effectiveness of WHM in people with GORD. No additional systematic reviews were identified in the Department’s public call for evidence (see Appendix C2). There was one review ([97](#_ENREF_97)) awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the eligible systematic reviews is provided in Appendix D1.3.1.

Sadeghi 2020 investigated the effectiveness of herbal medicines in people with GORD. Of the 13 RCTs identified by the systematic review, one RCT (Moeini 2016) met our PICO criteria. The other RCTs examined other herbal medicines not on List A (e.g. Chinese, Ayurvedic) (see Appendix A8).

### Description of studies

Within the eligible systematic reviews, there was one RCT that met our PICO criteria (see Appendix F1). Moeini 2016 evaluated the gastroprotective effects of hawthorn compared with placebo in 80 participants with GORD. Treatment duration was 4 weeks. The RCT was reported to assess the severity of symptoms, but no usable data were provided. Hawthorn is not on the list of herbs included in the Western herbal medicine curriculum for the Digestive system (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

An overlap table of the RCTs within the included systematic reviews is shown in Table 5.

Result for the Primary Comparison: WHM vs placebo are provided in Section 4.4.5.

There were no studies found for the Secondary Comparison: WHM vs inactive control (no intervention, waitlist, usual care [if inactive]) or the Tertiary Comparison (versus active comparators).

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Moeini 2016 was assessed by Sadeghi 2020 using the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)). The RCT was judged to be at high risk of bias for 3 domains (allocation concealment, performance bias and detection bias). Risk of bias was unclear for random sequence generation and selective reporting and the study was at low risk of bias for incomplete outcome data.

Table 5 List of included systematic reviews and overlap with eligible RCTs (per outcome): Gastro-oesophageal reflux disease

|  |  |  |  |
| --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID |
| Moeini 2016 |
| Sadeghi 2020 | ✓ | GORD symptoms | ? |
| Regurgitation | ? |

Abbreviations: RCT, randomised controlled trial

Notes:

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

? RCT is included in the systematic review & meets our PICO criteria, but a study result is not available for the listed outcome [data is incomplete; result may be available in another SR].

### Summary of findings and evidence statement

#### Primary Comparison (vs placebo)

One RCT (Moeini 2016) was found by the included systematic review (Sadeghi 2020) that compared hawthorn with placebo in people with GORD. The RCT could have contributed data to at least one outcome (symptom severity), but the systematic review authors did not adequately report data for inclusion in the synthesis.

In the absence of usable data, the effect of WHM compared with placebo on the following outcomes in people with GORD is unknown:

* GORD symptoms (heartburn, oesophagitis, (silent) acid reflux, dysphagia and belching)
* Pain
* HRQoL
* Emotional functioning
* Physical functioning
* Patient reported improvement
* Regurgitation

#### Secondary Comparison (vs inactive control)

No studies were found by the included systematic reviews that compared WHM with an inactive control in people with GORD. Therefore, the effect of WHM compared with inactive control (no intervention, waitlist or usual care [if inactive]) on the prioritised outcomes in people with GORD is unknown.

Tertiary Comparison (vs active control)

No studies found. The effect of WHM compared with active controls on the prioritised outcomes in people with GORD is unknown.

## Menstrual conditions

### Description of the condition

Menstrual conditions is an umbrella term used in this overview to encompass a range of disorders characterised by pain in the pelvic region and irregularities in the menstrual cycle such as dysmenorrhoea, amenorrhea and endometriosis. Lifestyle, dietary patterns, environment and genetic factors may influence the risk of menstrual conditions. Dysmenorrhoea has several underlying causes that can be classified as either primary or secondary ([98](#_ENREF_98)). Primary dysmenorrhoea describes painful menstrual bleeding, with some surveys reporting that it is experienced by 50-90% of people with menstrual cycles. Secondary dysmenorrhoea is attributed to underlying pelvic conditions such as endometriosis or fibroids in females who have menstruated previously ([98](#_ENREF_98)). Amenorrhoea is the absence of menstruation, commonly due to a lack of hormonal function in the ovaries, which may result in infertility ([99](#_ENREF_99)). The most common causes of amenorrhoea include polycystic ovarian syndrome, hypothalamic amenorrhoea, ovarian failure and hyperprolactinemia ([99](#_ENREF_99)). Endometriosis is a chronic inflammatory condition characterised by abnormal growth of endometrial-like tissue outside the uterine cavity ([100](#_ENREF_100)). The aetiology behind endometriosis is not known.

The prevalence of moderate to severe dysmenorrhoea is estimated to affect 44.2% of Australian women aged 18 to 39 ([101](#_ENREF_101)). At the same time, amenorrhoea not due to pregnancy, lactation or menopause affects between 3% and 4% of females ([99](#_ENREF_99)). Endometriosis affects 10-15% of all females of reproductive age and 70% of females with chronic pelvic pain ([102](#_ENREF_102)). Typically, the diagnosis of endometriosis is often delayed, impairing the quality of life for many females, and resulting in unnecessary pain and, in some cases, infertility.

Therapeutic options for most menstrual conditions include nonsteroidal anti-inflammatory drugs and hormonal contraceptives ([98](#_ENREF_98)). The primary aim of treatment is to provide symptomatic relief and improve quality of life by reducing pain and discomfort. A variety of WHM such as withania, chamomile, curcumin, ginger, lavender and peppermint are suggested to help relieve symptoms associated with menstrual conditions, but specific treatments or recommendations are lacking ([103](#_ENREF_103), [104](#_ENREF_104)).

### Description of reviews

There were 14 citations ([64](#_ENREF_64), [73](#_ENREF_73), [105-116](#_ENREF_105)) corresponding to 14 systematic reviews identified in the literature search that evaluated WHMs in people with menstrual conditions (Negi 2021, Anh 2020, Mollazadeh 2020, Shinjyo 2020, Xu 2020, Pellow 2018, Chen 2016, Javan 2016, Pattanittum 2016, Ursoniu 2016, Daily 2015, Lakhan 2015, Terry 2011, Ulbricht 2011). No additional reviews were identified through the Department’s public call for evidence (see Appendix C2). There were 2 reviews awaiting classification ([117](#_ENREF_117), [118](#_ENREF_118)) that were not in English (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of included reviews is provided in Appendix D2.1.1.

The populations eligible for inclusion in the reviews were participants with dysmenorrhoea (Negi 2021, Xu 2020, Pellow 2018, Chen 2016, Pattanittum 2016, Daily 2015), heavy menstrual bleeding (Javan 2016) or prespecified gynaecologic and pelvic conditions (Mollazadeh 2020). Two reviews (Lakhan 2015, Terry 2011) included studies of participants with any pain condition and 3 reviews (Anh 2020, Ursoniu 2016, Ulbright 2011) had unclear or no population restrictions but presented RCTs of participants with dysmenorrhoea or amenorrhoea. One umbrella review (Shinjyo 2020) searched for studies of participants with sleep or related health problems and included a study of participants with dysmenorrhoea.

Six (6) systematic reviews (Negi 2021, Anh 2020, Chen 2016, Daily 2015, Lakhan 2015, Terry 2011) searched for evidence on ginger or zingiberaceae family extracts, 3 reviews searched for evidence on medicinal plant preparations (Pellow 2018, Javan 2016) or dietary supplements (Pattanittum 2016), one review searched for evidence on cinnamon, ginger or fennel (Xu 2020), and one review searched for evidence on Chaste tree (vitex) (Mollazadeh 2020), valerian root (Shinjyo 2020), saffron (Ulbricht 2011) or flaxseed (Ursoniu 2016).

Seven (7) systematic reviews (Negi 2021, Mollazadeh 2020, Xu 2020, Pellow 2018, Chen 2016, Pattanittum 2016, Daily 2015) included evidence from at least one RCT that met our PICO criteria and presented a study result available for inclusion in the synthesis. These reviews were prioritised for critical appraisal and data extraction.

Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 24 RCTs that met our PICO criteria (see Appendix F1). The RCTs used different herbs8F[[9]](#footnote-10) (see Appendix D2.1.1) and doses with the intervention period ranging from one to 3 menstrual cycles. Most studies were focused on measuring pain intensity among females with moderate to severe dysmenorrhoea, and one study measured blood loss among females with heavy menstrual bleeding. All but 4 of the RCTs were conducted in secondary or tertiary school students at learning institutions in Iran or India; the settings of 4 RCTs (Abadi 2020, Pakniat 2019, Rad 2018, Gupta 2013) were not specified.

An overlap table of the RCTs that met our PICO criteria from the included systematic reviews is shown in Table 6.

There were 15 RCTs that examined the effect of WHM versus placebo. Two RCTs (Shobeiri 2014, Sah Hosseini 2005) tested the effect of chaste tree on heavy menstrual bleeding and the other 13 RCTs examined the use of ginger (Abadi 2020, Jenabi 2013, Kashefi 2014, Rahnama 2012, Rahnama 2010), cinnamon (Jahangirifar 2018, Jaafarpour 2015, Akhavan Amjadi 2009), fenugreek (Heshmati 2016, Younesy 2014, Akbari 2012) or valerian root (Mirabi 2011, Dolation 2010) on pain intensity. Of these, only one herb (chaste tree) is listed as a Tier 1 herb included in the Western herbal medicine curriculum for Gynaecological / reproductive disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

Three (3) RCTs tested the effect of WHM against no treatment on pain intensity, with 2 RCTs (Modaress 2011, Jenabi 2010) examining the use of chamomile and one RCT (Gupta 2013) examining the use of ginger. The remaining 6 RCTs compared the effect of WHM against an active comparator; being either progressive muscle relaxation (Halder 2012) or non-steroidal anti-inflammatory drugs9F[[10]](#footnote-11) (Pakniat 2019, Rad 2018, Shirvani 2015, Jenabi 2012, Ozgoli 2009).

In total, 14 RCTs (Pakniat 2019, Jahangirifar 2018, Rad 2018, Jaafarpour 2015, Kashefi 2014, Shobeiri 2014, Gupta 2013, Jenabi 2013, Akbari 2012, Jenabi 2012, Rahnama 2012, Modaress 2011, Dolation 2010, Jenabi 2010) had adequately reported results available for inclusion in the evidence synthesis. The other 10 RCTs (Abadi 2020, Heshmati 2016, Shirvani 2015, Younesy 2014, Halder 2012, Mirabi 2011, Rahnama 2010, Akhavan Amjadi 2009, Ozgoli 2009, Sah Hosseini 2005) had results that were not adequately reported by the included systematic reviews.

Results for the Primary Comparison: WHM vs placebo and the Secondary Comparison: WHM vs inactive control (no intervention, waitlist, usual care [if inactive]) are provided in the Summary of Findings tables (see Section 4.5.5). Additional details are provided in Appendix F2. Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

The reviews by Mollazadeh 2019, Pattanittum 2016 and Daily 2015 were used to inform the evidence synthesis as they used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and provided the most comprehensive information to make a judgement. Four (4) RCTs (Kashefi 2014, Jenabi 2013, Akbari 2012, Dolation 2010) were judged to be at low risk of bias while 8 RCTs (Shirvani 2015, Shobheiri 2014, Halder 2012, Rahnama 2012, Modaress 2011, Jenabi 2010, Ozgoli 2009, Sah Hosseini 2005) were judged to be at high risk of bias in at least one domain.

Table 6 List of included systematic reviews and overlap with eligible RCTs (per outcome): Menstrual conditions

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | | | | | | | | | | | | |
| Abadi 2020 | Pakniat 2019 | Jahangirifar 2018 | Rad 2018 | Heshmati 2016 | Jaafarpour 2015 | Shirvani 2015 | Kashefi 2014 | Shobeiri 2014 | Younesy 2014 | Gupta 2013 | Jenabi 2013 | Akbari 2012 | Halder 2012 | Jenabi 2012 | Rahnama 2012 | Mirabi 2011 | Modaress 2011 | Dolation 2010 | Jenabi 2010 | Rahnama 2010 | Akhavan Amjadi 2009 | Ozgoli 2009 | Sah Hosseini 2005 |
| Negi 2021 | ✓ | Pain intensity | ! | Y | -- | Y | -- | -- | ! | Y | -- | -- | -- | Y | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | ! | -- |
| Xu 2020 | ✓ | -- | Y | ? | -- | -- | ? |  | Y | -- | -- | -- | Y | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- |
| Pellow 2018 | † | -- | -- | -- | -- | ? | -- | -- | Y | -- | ? | -- | Y | -- | -- | -- | Y | ? | -- | -- | -- | -- | -- | ? | -- |
| Chen 2016 | ✓ | -- | -- | -- | -- | -- | -- | X | Y | -- | -- | -- | Y | -- | ! | -- | Y | -- | -- | -- | -- | -- | -- | ! | -- |
| Pattanittum 2016 | ✓ | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | Y | Y | -- | Y | Y | -- | Y | Y | Y | ? | ! | -- | -- |
| Daily 2015 | ✓ | -- | -- | -- | -- | -- | -- | X | Y | -- | -- | Y | Y | -- | ! | -- | Y | -- | -- | -- | -- | -- | -- | ! | -- |
| Mollazadeh 2020 | ✓ | Patient-reported blood loss | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! |

Abbreviations: RCT, randomised controlled trial

Notes:

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

Y RCT is included in the systematic review, meets our PICO criteria & a study result is reported for the listed outcome measure [result available].

? RCT is included in the systematic review & meets our PICO criteria, but a study result is not available for the listed outcome [data are incomplete; result may be available in another SR]

! RCT is included in the systematic review, but the SR indicates the study does not measure (or report) the listed outcome [not measured]

-- RCT is not included in systematic review.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 13 RCTs found by the included systematic reviews that compared WHM with placebo in people with dysmenorrhea or heavy menstrual bleeding. Of these, 7 RCTs (Akbari 2012, Dolation 2010, Jenabi 2013, Kashefi 2014, Rahnama 2012) contributed data relevant to one outcome (pain intensity) and one RCT (Shobeiri 2014) contributed data relating to blood loss. Another 5 RCTs did not contribute any data because their results were not adequately reported, either by the primary study or the included systematic reviews.

| Western herbal medicine compared to placebo for menstrual conditions | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Menstrual conditions  **Setting:** Community  **Intervention:** WHM (ginger, cinnamon, fenugreek, valerian, chaste tree, German chamomile)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| Pain intensity assessed with: VAS, SF-MPQ  Scale: 0 to 10 cm (higher is worse) follow-up: range 1 to 3 menstrual cycles | The mean pain score was **6.09 cm** | **MD 2.34** cmlower (2.92 lower to 1.76 lower) | -- | 601 (7 RCTs) † | ⨁⨁⨁◯ Moderate a,b,c,d,e | WHM probably results in a large reduction in pain intensity in people with menstrual conditions \*\* |
| Global improvement (patient-reported) | - | - | -- | (0 studies) | -- | The effect of WHM on patient-reported improvement in people with menstrual conditions is unknown |
| Health-related quality of life | - | - | -- | (0 studies) | -- | The effect of WHM on quality of life in people with menstrual conditions is unknown |
| Emotional functioning | - | - | -- | (0 studies) | -- | The effect of WHM on emotional functioning in people with menstrual conditions is unknown |
| Physical functioning | - | - | - | (0 studies) | -- | The effect of WHM on physical functioning in people with menstrual conditions is unknown |
| Menstrual regularity | - | - | - | (0 studies) | -- | The effect of WHM on menstrual regularity in people with menstrual conditions is unknown |
| Patient-reported blood loss assessed with: Higham score Scale: 0 to >21 (higher is worse) follow-up: 1 menstrual cycle | The mean Higham score was **24.6 points** | **MD 1.0** point higher (5.32 lower to 7.32 higher) | -- | 60 (1 RCT) †† | ⨁◯◯◯ Very low f,g,h,i,j | The evidence is very uncertain about the effect of WHM on patient-reported blood loss in people with menstrual conditions |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  \*\* MCID of 1.0 cm in females with endometriosis (74). MCID is not established in people with primary dysmenorrhoea.  † Data from 4 RCTs (total 396 participants) not included here because results were not adequately reported [missing information]. All 4 RCTs suggested an effect favouring WHM.  †† Data from one RCT (total 60 participants) not included here because results were not adequately reported [missing information].  **CI:** confidence interval; **MD:** mean difference; **SF-MPQ:** short-form McGill Pain Questionnaire; **VAS:** visual analogue scale | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. One RCT (< 10% weight) at high risk of bias that does not materially influence the estimate of effect. Certainty of evidence not downgraded.

b. Serious inconsistency. Point estimates vary and confidence intervals of some studies do not overlap. Substantial statistical heterogeneity (I2 = 90%) that cannot be explained. Certainty of evidence downgraded.

c. No serious indirectness. The available evidence is in students in Iran or India with moderate to severe dysmenorrhoea and can be sensibly applied to the Australian population. It is possible that the herbs used in the studies are contrary to what is prescribed in Australia, but the evidence could be sensibly applied. Certainty of evidence not downgraded.

d. No serious imprecision. Certainty of evidence not downgraded.

e. Publication bias not suspected. Missing data from 4 RCTs (396 participants) that could have contributed data to this outcome, all of which reported an effect favouring WHM. Certainty of evidence not downgraded.

f. Serious risk of bias. One study (100% weight) at high risk of bias. Certainty of evidence downgraded.

g. Inconsistency not assessed. One study contributing data. Certainty of evidence not downgraded.

h. No serious indirectness. The available evidence is in students in Iran with heavy menstrual bleeding and can be sensibly applied to the Australian population. The herb used in the study (chaste tree berry) is matched to what is likely used in Australia. Certainty of evidence not downgraded.

i. Very serious imprecision. Single study. Wide confidence intervals (upper and lower bounds overlap with both a large and no important difference). Certainty of evidence downgraded 2 levels.

j. Publication bias not suspected. Certainty of evidence not downgraded.

#### Secondary Comparison (vs inactive control)

There were 3 RCTs (Gupta 2013, Jenabi 2010, Modaress 2011) found by the included systematic reviews that compared WHM with control (no treatment) in people with dysmenorrhea or heavy menstrual bleeding that contributed data relevant to one outcome (pain intensity). The available evidence is summarised below.

| Western herbal medicine compared to inactive control for menstrual conditions | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Menstrual conditions  **Setting:** Community  **Intervention:** Western herbal medicine  **Comparison:** inactive control (no treatment) | | | | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | | Relative effect (95% CI) | No. of participants (studies) | | Certainty of the evidence (GRADE) | | Evidence statement |
| Risk with Control | Risk with WHM | |
| Pain intensity assessed with: VAS, NRS, SF-MPQ  Scale: 0 to 10 cm (higher is worse) follow-up: range 2 to 3 menstrual cycles | | The mean pain score was **5.14** | | **MD 2.29** lower (4.49 lower to 0.09 lower) | -- | 304 (3 RCTs) | ⨁◯◯◯  VERY LOW a,b,c,d,e | | The evidence is very uncertain about the effect of WHM on pain intensity in people with menstrual conditions \*\* | |
| Global improvement (patient-reported) | | - | | - | -- | (0 studies) | -- | | The effect of WHM on patient-reported improvement in people with menstrual conditions is unknown | |
| Health-related quality of life | | - | | - | -- | (0 studies) | -- | | The effect of WHM on quality of life in people with menstrual conditions is unknown | |
| Emotional functioning | | - | | - | -- | (0 studies) | -- | | The effect of WHM on emotional functioning in people with menstrual conditions is unknown | |
| Physical functioning | | - | | - | - | (0 studies) | -- | | The effect of WHM on physical functioning in people with menstrual conditions is unknown | |
| Menstrual regularity | | - | | - | - | (0 studies) | -- | | The effect of WHM on menstrual regularity in people with menstrual conditions is unknown | |
| Patient-reported blood loss | | - | | - | - | (0 studies) | -- | | The effect of WHM on patient-reported blood loss in people with menstrual conditions is unknown | |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  \*\* MCID of 1.0 cm in females with endometriosis (74). MCID is not established in people with primary dysmenorrhoea.  **CI:** confidence interval; **MD:** mean difference; **NRS:** numeric rating scale; **SF-MPQ:** short-form McGill Pain Questionnaire; **VAS:** visual analogue scale | | | | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | | | | |

Explanations

a. Serious risk of bias. Three studies (100% weight) at high risk of bias. Certainty of evidence downgraded.

b. Serious inconsistency. Point estimates vary and confidence intervals of some studies do not overlap. Substantial statistical heterogeneity (I2 = 89%) that cannot be explained. Certainty of evidence downgraded.

c. No serious indirectness. The available evidence is in students in Iran with moderate to severe dysmenorrhoea and can be sensibly applied to the Australian population. It is possible that the herbs used in the studies are contrary to what is prescribed in Australia, but the evidence could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and no important difference). Certainty of evidence downgraded.

e. Publication bias not suspected. Certainty of evidence not downgraded.

#### Tertiary Comparison (vs active control)

There were 7 RCTs found by the included systematic reviews that compared WHM with active comparators in people with dysmenorrhea or heavy menstrual bleeding. The comparators included progressive muscle relaxation, nutritional supplements, or non-steroidal anti-inflammatory drugs (see Appendix F2).

### Forest plots

Outcome results related to people with menstrual conditions are presented in Figure 8 (pain intensity) and Figure 9 (patient-reported blood loss).

Figure 8 Forest plot of comparison: WHM vs placebo or control: Menstrual conditions - pain intensity (VAS)

P3744#yIS1

Abbreviations: SF-MPQ, short-form McGill Pain Questionnaire; VAS, visual analogue score.

Figure 9 Forest plot of comparison: WHM vs placebo: Menstrual conditions – menstrual blood loss (Higham score)

P3747#yIS1

## Premenstrual disturbances

### Description of the condition

Premenstrual disturbances encompasses disorders associated with menstruation that affect the psychological and emotional wellbeing of females of reproductive age ([119](#_ENREF_119)). Specifically, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). PMS is characterised by psychological and somatic symptoms during the luteal phase of the menstrual cycle ([119](#_ENREF_119)). PMDD is a severe form of PMS, with emotional, behavioural and physical symptoms that can be extreme and sometimes disabling ([120](#_ENREF_120)). PMS and PMDD are cyclic in pattern, occurring prior to menstruation and typically resolving after the menstrual period. There are no definite causes of PMS and PMDD, although it is posited that reproductive hormones, genetics and psychosocial symptoms such as anxiety and stress or a combination of factors are potential contributors to the aetiology and development of PMS and PMDD ([121-123](#_ENREF_121)).

Up to 80% of individuals who have menstrual cycles experience some form of PMS ([123](#_ENREF_123)). Up to 90% of women experience at least 1 symptom of PMS in most months, and 50% experience several symptoms each month. An estimated 20-40% of premenopausal women may experience moderately severe symptoms of PMS. Furthermore, approximately 2-9% of premenopausal women experience disabling symptoms; individuals with disabling symptoms may be considered to have premenstrual dysphoric disorder (PMDD), the severe form of PMS ([123](#_ENREF_123)).

Current treatments are aimed toward symptomatic relief, with treatment options guided by PMS severity. Conservative management includes regular exercise, relaxation techniques, vitamin and mineral supplementation (e.g., Vitamin B6 and calcium) and cognitive behavioural therapy ([121](#_ENREF_121), [122](#_ENREF_122)). For more severe presentations, combined oral contraceptives, antidepressants (selective serotonin reuptake inhibitors) and hormone agonists gonadotrophin-releasing hormone) may be prescribed ([121](#_ENREF_121), [122](#_ENREF_122)). Complementary and alternative medicines, including herbal medicines such as chaste tree berry, ginkgo biloba, St John’s wort and curcumin are also suggested to be beneficial in treating premenstrual disturbances ([121](#_ENREF_121)), however they are not currently recommended in routine clinical practice ([121-123](#_ENREF_121)).

### Description of reviews

There were 12 citations ([116](#_ENREF_116), [124-134](#_ENREF_124)) corresponding to 12 systematic reviews (Ghaderi 2020, Shinjyo 2020, Csupor 2019, Khalesi 2019, Cerqueira 2017, Verkaik 2017, Hausenblas 2015, Su Hee 2014, van Die 2013, Dante 2011, Ulbricht 2011, Whelan 2009) identified in the literature search that evaluated the effectiveness of WHMs in people with premenstrual disturbances. There were no additional reviews identified in the Department’s public call for evidence (see Appendix C2). There was one review ([135](#_ENREF_135)) awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the 12 eligible systematic reviews is provided in Appendix D2.2.1.

Eight (8) reviews searched specifically for studies in people with PMS (Csupor 2019, Khalesi 2019, Su Hee 2014, van Die 2013, Dante 2011), both PMS or PMDD (Cerqueira 2017, Verkaik 2017, Whelan 2009), or any female reproductive disorder (van Die 2013). Two (2) reviews were focused on the effectiveness of a specific herb across any clinical condition (Hausenblas 2015, Ulbricht 2011), and 2 reviews were focused on the effect of a specific herb on specific outcomes, being either sleep-related health problems (Shinjyo 2020) or mental health and inflammatory biomarkers (Ghaderi 2020).

There were 4 systematic reviews that searched for evidence on chaste tree berry (Csupor 2019, Cerqueira 2017, Verkaik 2017, van Die 2013), 3 reviews searched for evidence specific to saffron (Ghaderi 2020, Hausenblas 2015, Ulbricht 2011), and one review assessed the evidence specific to either chamomile (Khalesi 2019) or valerian (Shinjyo 2020). Three (3) reviews did not specify the herbal medicine of interest (Su Hee 2014, Dante 2011, Whelan 2009).

Five (5) systematic reviews (Ghaderi 2020, Shinjyo 2020, Csupor 2019, Verkaik 2017, van Die 2013) were prioritised for critical appraisal and data extraction as they presented results in a meta-analysis. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 29 RCTs that met our PICO criteria (see Appendix F1). The studies examined the effect of several herbs including chaste tree berry, chamomile, St John’s wort, ginkgo biloba, saffron and valerian. Of these, only one herb (chaste tree) is listed as a Tier 1 herb included in the Western herbal medicine curriculum for Gynaecological / reproductive disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

An overlap table of the RCTs that met our PICO criteria from the included systematic reviews is shown in Table 7.

The RCTs were conducted in a variety of countries including China (Ma 2012, He 2009), Germany (Shellenberg 2012, Shellenberg 2001, Lauritzen 1997), Iran (Zamani 2012, Pakgohar 2009, Agha-Hoesseini 2008), Italy (Ciotta 2011, Di Pierro 2009), Turkey (Atmaca 2003) the United Kingdom (Turner 1993) or not specified. Sample sized ranged from 47 to 268 (total 5749 participants), with the interventions being delivered over various time periods (8 weeks to 3 months) (or not specified).

There were 18 RCTs that examined the effect of WHM compared with placebo (Najafi 2018, Behboodi Moghadam 2016, Kaplanoglu 201510F[[11]](#footnote-12), Mousavi 2015, Schellenberg 2012, Zamani 2012, Risoleti 2011k, Canning 2010, Ma 2010, He 2009, Ozgoli 2009, Pakgohar 2009, Agha-Hosseini 2008, Hicks 2004, Delavar 2002, Schellenberg 2001, Tamborini 1993, Turner 1993).

There were 13 RCTs examined the effect of WHM compared with an active comparator (Kaplanoglu 2015k, Sharifi 2014, Karimian 2013, Salehi 201311F[[12]](#footnote-13), Ciotta 2011, Modaress 2011, Risoleti 2011k, Masumeh 2010, Di Pierro 2009, Scaldarella 2008, Atmaca 2003, Onaran 2003, Lauritzen 1997) being either mefenamic acid (NSAID), magnesium oxide, pyridoxine-HCL (vitamin B6), oral contraceptive pill or fluoxetine.

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.6.5).

There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, waitlist, usual care [if inactive]). Additional details are provided in Appendix F2. Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

The reviews by Verkaik 2017 and van Die 2013 were used to inform the evidence synthesis as they used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and provided the most comprehensive information to make a judgement.

There were 8 RCTs (Salehi 2013, Schellenberg 2012, Zamani 2012, Ma 2010, He 2009, Pakgohar 2009, Atmaca 2003, Schellenberg 2001) with some concerns of bias, as the information provided was unclear.

Eleven (11) RCTs (Kaplanoglu 2015, Mousavi 2015, Cioatta 2011, Risoleti 2011, Di Pierro 2009, Pakgohar 2009, Scaldarella 2008, Onaran 2003, Delavar 2002, Lauritzen 1997, Turner 1993) were judged to be at high risk of bias in at least one domain. Information about risk of bias for the other 10 RCTs were not provided.

Table 7 List of included systematic reviews and overlap with eligible RCTs (per outcome): Premenstrual disturbances

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Najafi 2018 | Behboodi Moghadam 2016 | Kaplanoglu 2015 | Mousavi 2015 | Sharifi 2014 | Karimian 2013 | Salehi 2013 | Schellenberg 2012 | Zamani 2012 | Modaress 2011 | Ciotta 2011 | Risoleti 2011 | Canning 2010 | Ma 2010 | Masumeh 2010 | Di Pierro 2009 | He 2009 | Pakgohar 2009 | Ozgoli 2009 | Agha-Hosseini 2008 | Scaldarella 2008 | Hicks 2004 | Atmaca 2003 | Onaran 2003 | Delvar 2002 | Schellenberg 2001 | Lauritzen 1997 | Tamborini 1993 | Turner 1993 | |
| Csupor 2019 | ✓ | PMS Symptoms | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | |
| Khalesi 2019 | † | ? | -- | -- | -- | ? | ? | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Verkaik 2017 | ✓ | -- | -- | ? | ? | -- | -- | ? | ? | ? | -- | ? | ? | -- | -- | -- | ? | ? | ? | -- | -- | ? | -- | ? | ? | ? | ? | ? | -- | ? | |
| Cerqueira 2017 | \* | -- | -- | -- | -- | -- | -- | -- | ? | Y | -- | Y | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | -- | Y | -- | -- | Y | Y | -- | -- | |
| Hausenblas 2015 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Su Hee 2014 | \* | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | ? | ? | ? | -- | ? | -- | ? | ? | -- | ? | ? | -- | -- | -- | -- | -- | -- | |
| Van Die 2013 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | -- | -- | Y | -- | Y | Y | Y | -- | -- | -- | -- | Y | -- | -- | Y | Y |  | Y | |
| Dante 2011 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | ? | -- | -- | ? | -- | ? | ? | -- | ? | ? | -- | -- | ? | ? | ? | ? | |
| Ulbricht 2011 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Whelan 2009 | \* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? |  | ? | ? | -- | -- | ? | ? | ? | ? | |
| Ghaderi 2020 | ✓ | Depression | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Shinjyo 2020 | ✓ | Anxiety | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |

Abbreviations: RCT, randomised controlled trial

Notes:

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is reported for the listed outcome measure [result available].

? RCT is included in the systematic review & meets our PICO criteria, but a study result is not available for the listed outcome [data are incomplete; result may be available in another SR]

! RCT is included in the systematic review, but the SR indicates the study does not measure (or report) the listed outcome [not measured]

-- RCT is not included in systematic review.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 18 RCTs identified in the included systematic reviews that compared WHM with placebo in people with premenstrual disturbances. Of these, 13 RCTs contributed data relevant to at least one critical or important outcome (Agha-Hosseini 2008, Behboodi Moghadam 2016, Kaplanoglu 201512F[[13]](#footnote-14), Mousavi 2015, Schellenberg 2012, Zamani 2012, Risoleti 2011m, Ma 2010, He 2009, Pakgohar 2009, Delavar 2002, Schellenberg 2001, Turner 1993).

Five (5) RCTs (Najafi 2018, Canning 2010, Ozgoli 2009, Hicks 2004, Tamborini 1993) did not contribute data because study results were not adequately reported, either by the primary study or the included systematic reviews.

| Western herbal medicine compared to placebo for premenstrual disturbances | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Premenstrual disturbances (PMS or PMDD)  **Setting:** Community  **Intervention:** WHM (chaste tree)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| PMS Symptoms assessed with: PMSD, MDQ, DSR, PMS-VAS  follow-up: range 2 to 6 menstrual cycles | - | **SMD 1.31 SD lower** (1.82 lower to 0.8 lower) **^** | - | 1133 (8 RCTs)† | ⨁⨁◯◯ LOW a,b,c,d,e | WHM may result in a large reduction in PMS symptom severity in people with premenstrual disturbances. |
| Global improvement (patient-reported) assessed with: PMS-VAS, PMSD, DSR (response rate)  follow-up: range 2 to 6 menstrual cycles | 316 per 1,000 | **626 per 1,000** (481 to 816) | **RR 1.98** (1.52 to 2.58) # | 839 (6 RCTs) †† | ⨁⨁⨁◯ MODERATE c,d,e,f,g | WHM probably results in a large improvement in PMS symptoms in people with premenstrual disturbances. |
| Depression  assessed with: VAS, BDI, MDQ-negative affect follow-up: range 2 to 6 menstrual cycles | - | **SMD 1.02 SD** **lower**  (1.67 lower to 0.38 lower) **^** | - | 613 (5 RCTs) ††† | ⨁⨁◯◯ LOW b,c,d,e,f | WHM may result in a large improvement in depressive symptoms in people with premenstrual disturbances. |
| Anxiety assessed with: VAS follow-up: range 3 to 6 menstrual cycles | - | **SMD 1.44 SD** **lower** (1.91 lower to 0.97 lower) **^** | - | 208 (2 RCTs) †††† | ⨁⨁◯◯ LOW c,d,e,g,h | WHM may result in a large improvement in anxiety in people with premenstrual disturbances. |
| Emotional functioning | - | - | - | (0 studies) | -- | The effect of WHM on emotional functioning in people with premenstrual disturbances is unknown. |
| Physical functioning | - | - | - | (0 studies) | -- | The effect of WHM on physical functioning in people with premenstrual disturbances is unknown. |
| Health-related quality of life | - | - | - | (0 studies) | -- | The effect of WHM on quality of life in people with premenstrual disturbances is unknown. |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # A 25% relative risk reduction/increase was considered important (i.e. RR < 0.75 or RR > 1.25).  † Data from one RCT (total 67 participants) (SMD –0.96; 95% –1.38, –0.54) not added to the pooled analysis. Data from 5 other RCTs (~400 participants) not included here due to inadequate reporting [missing information].  †† Data from 9 other RCTs (~735 participants) not included here due to inadequate reporting [missing information].  ††† Data from one RCT (total 47 participants) (SMD 6.23; 95% CI 5.21, 7.25) not able to be added to the pooled analysis. Data from 12 other RCTs (~990 participants) not included here due to inadequate reporting [missing information].  †††† Data from one RCT (total 100 participants) (SMD 1.9; 95% CI 1.44, 2.39) not added to the pooled analysis. Data from 15 other RCTs (~1290 participants) not included due to inadequate reporting [missing information].  **BDI:** Beck depression inventory; **CI:** confidence interval; **DSR:** daily symptom rating scale; **MD:** mean difference; **MDQ:** menstrual distress questionnaire; **PMDD:** premenstrual dysphoric disorder; **PMS:** premenstrual syndrome; **PMSD:** PMS daily diary’; **VAS:** visual analogue scale | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Sensitivity analysis suggest studies at overall high risk of bias do not materially influence the estimate of effect. Certainty of evidence not downgraded.

b. Serious inconsistency. Point estimates vary and confidence intervals of some studies do not overlap. Substantial statistical heterogeneity (I2 > 90%) that cannot be explained. Certainty of evidence downgraded.

c. No serious indirectness. The available evidence is in people with PMS or PMDD and is directly generalisable to the Australian population with few caveats. The herbs used in the identified studies are comparable to those commonly used in Australia and can be sensibly applied. Certainty of evidence not downgraded.

d. No serious imprecision. Certainty of evidence not downgraded.

e. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

f. No serious risk of bias. One study contributing <15% of data at high risk of bias. In a sensitivity analysis, the size and direction of effect did not materially change. Certainty of evidence not downgraded.

g. No serious inconsistency. Certainty of evidence not downgraded.

h. Serious risk of bias. One study contributing >50% of data at high risk of bias. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no RCTs found by the included systematic reviews that compared WHM with inactive control (no intervention, waitlist or usual care) in people with premenstrual disturbances. In the absence of evidence, the effect of WHM compared with control on the prioritised outcomes is unknown.


#### Tertiary Comparison (vs active control)

There were 13 RCTs found by the included systematic reviews that compared WHM with active comparators, of which 9 had data adequately reported by the included systematic reviews (see Appendix F2).

### Forest plots

Outcome results related to people with premenstrual disturbances are presented in Figure 10 (PMS symptoms, anxiety, depression) and Figure 11 (patient reported improvement).

Figure 10 Forest plot of comparison: WHM vs placebo: Premenstrual disturbances - PMS symptoms, anxiety, depression



Source: [Verkaik, Kamperman (129)](#_ENREF_129)

Figure 11 Forest plot of comparison: WHM vs placebo: Premenstrual disturbances – patient reported improvement

P4340#yIS1

## Symptoms of menopause

### Description of the condition

Natural menopause is defined as the permanent cessation of menses and is a normal process of ageing that is typically confirmed after menstrual periods have been absent for 12 months ([136-139](#_ENREF_136)). Symptoms of menopause are characterised by the pathological changes that occur during the transition period (perimenopause) and are related to the gradual loss of ovarian follicular function and decline in circulating blood oestrogen levels ([136](#_ENREF_136), [140](#_ENREF_140)). Perimenopause is estimated to last around 4 years and is the period when troublesome symptoms such as hot flushes13F[[14]](#footnote-15), headache, sleep disturbance, lack of concentration, depressed mood, atrophic genital changes and bone loss can begin, with women who experience a longer transition period more likely to seek help ([139](#_ENREF_139)). Women with artificial menopause, induced after the surgical removal of ovaries, or through interventions such as chemotherapy or radiation therapy, are also more likely to experience bothersome or disabling symptoms of menopause ([138](#_ENREF_138)); as are women who experience premature (before 40 years of age) or early menopause (aged between 40 and 45 years) ([137](#_ENREF_137)).

Natural menopause is estimated to occur between the ages of 47 and 53 years, with education, lifestyle factors (such as smoking, high physical activity), and ethnicity reported to play a role ([137](#_ENREF_137), [141](#_ENREF_141), [142](#_ENREF_142)). Globally, between 2% and 3.7% of women are estimated to experience premature menopause and between 7.6% and 12.2% of women are estimated to undergo early menopause ([141](#_ENREF_141), [143](#_ENREF_143)), which places them at increased risk of chronic conditions later in life. In Australia, natural menopause is estimated to occur at a mean age of 52 years ([142](#_ENREF_142)), with about 1.2% of women undergoing premature menopause and 5.8% experiencing early menopause ([141](#_ENREF_141)).

Treatment and management of troublesome and disruptive symptoms associated with menopause centre on minimising the effects of declining oestrogen levels through hormone replacement therapy ([136](#_ENREF_136), [144-146](#_ENREF_144)). Other treatments may focus on managing or preventing specific symptoms such as localised oestrogen cream for vaginal atrophy, blood pressure medications for hot flushes, antidepressants for mood changes, or calcium and Vitamin D for bone loss ([144](#_ENREF_144), [146-148](#_ENREF_146)). Given the risks associated with long-term hormone replacement therapy (e.g., thromboembolic or coronary events, breast cancer) ([138](#_ENREF_138), [144-146](#_ENREF_144)), and the variability of symptom severity, many women experiencing mild or moderate symptoms of menopause seek lifestyle and behavioural therapies as an alternative. These include acupuncture ([149](#_ENREF_149)), herbal medicines ([150](#_ENREF_150)), relaxation therapies ([151](#_ENREF_151)) and exercise therapies ([152](#_ENREF_152)). The Australasian Menopause Society notes that the evidence for the effectiveness of lifestyle or behavioural changes is mixed and limited ([144](#_ENREF_144)), but note that some may improve general wellbeing and help women manage their symptoms.

### Description of reviews

There were 85 citations ([33](#_ENREF_33), [113](#_ENREF_113), [124](#_ENREF_124), [125](#_ENREF_125), [150](#_ENREF_150), [153-233](#_ENREF_153)) corresponding to 85 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with symptoms of menopause. One additional review ([180](#_ENREF_180)) was identified in the Department’s public call for evidence (see Appendix C2). There were 17 reviews awaiting classification (see Appendix C4) and 2 ongoing reviews (see Appendix C5).

A summary of the PICO criteria of included reviews is provided in Appendix D2.3.1.

The populations eligible for inclusion in the reviews were often specific to those experiencing symptoms associated with menopause in either the perimenopausal or postmenopausal period (or both), with studies in participants with early menopause (natural or associated with treatment for cancer) also eligible for inclusion.

A large number of the identified systematic reviews were umbrella reviews that included at least one study in people with symptoms of menopause, but which focused on the effect of a specific WHM on a particular outcome that was often considered not critical or important for this Overview (such as lipid profiles, liver function, blood pressure, or measures of obesity). These reviews included evidence relating to the following WHMs: black cumin, black cohosh, garlic, ginseng, green tea, linseed, psyllium and turmeric.

Nine (9) systematic reviews (Castelo-Branco 2021, Firoozeei 2021, Kanadys 2021, Ghaderi 2020, Shinjyo 2020, Ghorbani 2019, Shahmohammadi 2019, Najafi 2018a, Franco 2016) were prioritised for critical appraisal and data extraction as they presented results in a meta-analysis and were considered the best available evidence. Six (6) reviews (Castelo-Branco 2021, Kanadys 2021, Ghorbani 2019, Shahmohammadi 2019, Najafi 2018a, Franco 2016) were focused on symptoms associated with menopause and 3 reviews (Firoozeei 2021 Ghaderi 2020, Shinjyo 2020) searched for studies specific to a WHM (saffron, lavender, valerian root).

Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews there were 42 RCTs that met our PICO criteria (see Appendix F1). All 42 RCTs examined the effect of WHM compared with placebo14F[[15]](#footnote-16).

Ten (10) other RCTs (Wang 2019, Zhang 2015, Chen 2014, Xi 2014, Huang 2013, Chen 2013, Sun 2012, Bai 2007, Nappi 2005, Liske 2002) were identified by one review (Castelo-Branco 2021) that examined the effect of black cohosh compared with an active comparator (hormone therapy, vitamins/minerals, fluoxetine or other antidepressants). The review provided limited information about these studies; therefore, they were not considered further in this overview.

An overlap table of the RCTs that met our PICO criteria from the included systematic reviews is shown in Table 8.

The studies examined the effect of several herbs including: withania (ashwagandha; Chung 2015), black cohosh (Jiang 2015, Shahnazi 2013, Li 2011, Newton 2006, Pockaj 2006, Frei-Kleiner 2005, Osmers 2005, Jacobson 2001, Stoll 1987), fennel (black cumin) (Ghazanfarpour 2018, Rahimi Kian 2017), fenugreek (Shamshad Begum 2016, Steels 2017), panax ginseng (Oh 2010, Kim 2009, Dongre 2015, Wiklund 1999), hops (Aghamiri 2016), Kava (Warnecke 1991, Warnecke 1990); red clover (Lambert 2017, Clifton-Bligh 2015, Shakeri 2015, Lipovac 2012, del Giorno 2010, Hidalgo 2005, Atkinson 2004, Tice 2003, Jeri 2002, van de Weijer 2002, Baber 1999, Knight 1999), saffron (Kashani 2018), St John’s wort (Abdali 2010), valerian root (Jenabi 2017, Mirabi 2011), or a combination of St John’s wort with either black cohosh (Chung 2007, Uebelhack 2006) or chaste tree berry (van Die 2009). Of these, only 2 herbs (black cohosh and chaste tree) are marked as a Tier 1 herb included in the Western herbal medicine curriculum for Gynaecological / reproductive disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

The RCTs were conducted in a variety of countries including Austria (Lipovac 2012), Australia (Clifton-Bligh 2015, van Die 2009, Baber 1999, Knight 1999), Brazil (del Giorno 2010), Ecuador (Ehsanpour 2012, Hidalgo 2005), Denmark (Lambert 2017), Germany (Warnecke 1991, Warnecke 1990), India (Dongre 2015), Iran (Kashani 2018, Kamalifard 2017, Shakeri 2015, Shahnazi 2013, Abdali 2010), Korea (Chung 2015, Oh 2010, Kim 2009, Chung 2007), the Netherlands (van de Weijer 2002), Peru (Jeri 2002), Sweden (Wiklund 1999), Switzer land (Frei-Kleiner 2005), the United Kingdom (Atkinson 2004), and the United States (Newton 2006, Pockaj 2006, Tice 2003). The country setting was not specified for 25 studies (Ghazanfarpour 2018, Jenabi 2017, Rahimi Kian 2017, Steels 2017, Aghamiri 2016, Shamshad 2016, Jiang 2015, Charandabi 2013, Mirabi 2013, Li 2011, Geller 2009, Uebelhack 2006, Osmers 2005, Jacobson 2001, Stoll 1987). Sample sized ranged from 24 to 384 participants (total > 1200 participants), with the interventions being delivered over various time periods (8 weeks to 24 months) (or not specified).

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.7.5).

There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, waitlist, usual care [if inactive]) or the Tertiary Comparison (versus active comparators), therefore there are no additional details to provide in Appendix F2.

Table 8 List of included systematic reviews and overlap with eligible RCTs (per outcome): Symptoms of menopause

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domainb | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ghazanfarpour 2018 | Kashani 2018 | Jenabi 2017 | Kamalifard 2017 | Lambert 2017 | Rahimi Kian 2017 | Steels 2017 | Aghamiri 2016 | Shamshad 2016 | Chung 2015 | Clifton-Bligh 2015 | Dongre 2015 | Jiang 2015 | Shakeri 2015 | Charandabi 2013 | Mirabi 2013 | Shanazi 2013 | Ehsanpour 2012 | Lipovac 2012 | Li 2011 | Abdali 2010 | del Giorno 2010 | Oh 2010 | Geller 2009 | Kim 2009 | Van Die 2009 | Chung 2007 | Newton 2006 (BC) | Pockaj 2006 | Uebelhack 2006 | Frei-Kliener 2005 | Hidalgo 2005 | Osmers 2005 | Atkinson 2004 | Tice 2003 | Jeri 2002 | van de Weijer 2002 | Jacobson 2001 (BC) | Baber 1999 | Knight 1999 | Wiklund 1999 | Stoll 1987 |
| Castelo-Branco 2021 c | ✓ | Symptom Severity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | ? | -- | -- | -- | -- | ! | -- | -- | -- | ? |
| Kanadys 2021 | ✓ | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | ! | ! | Y | -- | Y | Y | -- | -- |
| Castelo-Branco 2021 c | ✓ | Hot flushes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | ! |
| Kanadys 2021 | ✓ | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | Y | Y | Y | -- | Y | Y | -- | -- |
| Shinjyo 2020 | ✓ | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Franco 2016 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | ? | -- | ? | -- | Y | -- | Y | -- | ? | -- | -- | -- | -- | ? | ? | Y | Y | -- | Y | -- | -- | Y | Y | Y | Y | -- | Y | Y | -- | -- |
| Ghorbani 2019 | ✓ | Sexual function | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- |
| Najafi 2018a | † | -- | -- | -- | -- | -- | ? | ? | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Castelo-Branco 2021 c | ✓ | HRQoL | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | ! | -- | -- | -- | -- | ! | -- | -- | -- | ! |
| Ghorbani 2019 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- |
| Ghorbani 2019 | ✓ | Emotional functioning | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- |
| Shahmohammadi 2019 | ✓ | ! | -- | -- | -- | Y | Y | Y | ! | ! | -- | -- | -- | -- | Y | Y | -- | -- | Y | ! | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- |

Table 8 List of included systematic reviews and overlap with eligible RCTs (per outcome): Symptoms of menopause (cont’d)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | | Best available a | Prioritised outcome domainb | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ghazanfarpour 2018 | Kashani 2018 | Jenabi 2017 | Kamalifard 2017 | Lambert 2017 | Rahimi Kian 2017 | Steels 2017 | Aghamiri 2016 | Shamshad 2016 | Chung 2015 | Clifton-Bligh 2015 | Dongre 2015 | Jiang 2015 | Shakeri 2015 | Charandabi 2013 | Mirabi 2013 | Shanazi 2013 | Ehsanpour 2012 | Lipovac 2012 | Li 2011 | Abdali 2010 | del Giorno 2010 | Oh 2010 | Geller 2009 | Kim 2009 | Van Die 2009 | Chung 2007 | Newton 2006 (BC) | Pockaj 2006 | Uebelhack 2006 | Frei-Kliener 2005 | Hidalgo 2005 | Osmers 2005 | Atkinson 2004 | Tice 2003 | Jeri 2002 | van de Weijer 2002 | Jacobson 2001 (BC) | Baber 1999 | Knight 1999 | Wiklund 1999 | Stoll 1987 |
| Castelo-Branco 2021 c | ✓ | Depression | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | ! | -- | -- | -- | -- | ! | -- | -- | -- | ! |
| Firoozeei 2021 | ✓ | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ghaderi 2020 | ✓ | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shahmohammadi 2019 | ✓ | Y | -- | -- | -- | ! | ! | ! | Y | Y | -- | -- | -- | -- | ! | ! | -- | -- | ! | Y | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- |
| Castelo-Branco 2021 c | ✓ | Anxiety | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | ! | -- | -- | -- | -- | ! | -- | -- | -- | ? |
| Shahmohammadi 2019 | ✓ | Y | -- | -- | -- | ! | ! | ! | Y | Y | -- | -- | -- | -- | ! | ! | -- | -- | ! | Y | -- | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- |

Abbreviations: BC, includes breast cancer patients; QoL, quality of life; RCT, randomised controlled trial

Notes:

a. Only critical or important outcome domains with available data reported here (see Appendix D1.1)

b. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Framework for selecting the systematic review from which to extract data [Appendix B1]).

c. 10 RCTs comparing black cohosh with an active comparator not included here: Wang 2019, Zhang 2015, Chen 2014, Xi 2014, Huang 2013, Chen 2013, Sun 2012, Bai 2007, Nappi 2005, Liske 2002

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review & meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, only the information presented in the systematic review is reported.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Five (5) reviews (Castelo-Branco 2021, Firoozeei 2021, Kanadys 2021, Ghorbani 2019, Franco 2016) used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and provided comprehensive information to make a judgement. The other reviews assessed quality of the RCTs using the Jaded Scale ([234](#_ENREF_234)) or the Oxford Centre for Evidence-Based Medicine Checklist .

Twelve (12) RCTs (Kamalifard 2017, Lambert 2017, Clifton-Bligh 2015, Dongre 2015, Shakeri 2015, del Giorno 2010, Newton 2006, Uebelhack 2006, Osmers 2005, Atkinson 2004, Tice 2003, Stoll 1987) were judged by the review authors to be at overall low risk of bias. There were concerns of bias in 6 RCTs (Jiang 2015, Charandabi 2013, Shanazi 2013, Pockaj 2006, Jacobson 2001, Wiklund 1999) and for 15 RCTs (Chung 2015, Aghamiri 2016, Lipovac 2012, Li 2011, Abdali 2010, Oh 2010, Kim 2009, van Die 2009, Chung 2007, Frei-Kleiner 2005, Hidalgo 2005, Jeri 2002, van de Weijer 2002, Knight 1999, Baber 1999) the risk of bias was high (mostly related to attrition bias or selective reporting of results).

Risk of bias information for 12 RCTs (Ghazanfarpour 2018, Kashani 2018, Jenabi 2017, Rahimi Kian 2017, Steels 2017, Shamshad Begum 2016, Mirabi 2013, Ehsanpour 2012, Geller 2009, Warnecke 1991, Warnecke 1990) were incomplete, and were assumed to have some concerns of bias.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 42 RCTs found by the included systematic reviews that compared WHM with placebo in people with symptoms of menopause. Of these, 34 RCTs contributed data relevant to 6 outcomes (symptoms severity, hot flushes, sexual function, emotional functioning, depression, anxiety) (Ghazanfarpour 2018, Kashani 2018, Lambert 2017, Aghamiri 2016, Clifton-Bligh 2015, Chung 2015, Dongre 2015, Jiang 2015, Shakeri 2015, Shahnazi 2013, Ehsanpour 2012, Lipovac 2012, Li 2011, Abdali 2010, del Giorno 2010, Oh 2010, Geller 2009, Kim 2009, van Die 2009, Newton 2006, Pockaj 2006, Uebelhack 2006, Frei-Kleiner 2005, Hidalgo 2005, Osmers 2005, Atkinson 2004, Tice 2003, Jeri 2002, van de Weijer 2002, Jacobson 2001, Baber 1999, Knight 1999, Wiklund 1999, Stoll 1987).

Another 10 RCTs did not contribute any data because their results were not adequately reported, either by the primary study or the included systematic reviews.

| Western herbal medicine compared to placebo for symptoms of menopause | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Symptoms of menopause  **Setting:** Community  **Intervention:** WHM (black cohosh, red clover, withania/ashwagandha, fenugreek, valerian, St John's wort, chaste tree berry)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| Symptom severity assessed with: GCS, KMI, MRS follow-up: range 8 weeks to 24 months | - | **SMD 0.56 SD lower ^** (0.87 lower to 0.25 lower) | -- | 1680 (16 RCTs) | ⨁⨁⨁◯ Moderate a,b,c,d,e | WHM probably results in a reduction in symptom severity in people with symptoms of menopause. |
| Hot flush daily frequency  follow-up: range 8 weeks to 24 months | - | **SMD 0.46 SD lower ^** (0.80 lower to 0.12 lower) | -- | 1355 (14 RCTs)  † | ⨁⨁◯◯ LOW c,e,f,g,h | WHM may result in a slight reduction in hot flush daily frequency in people with symptoms of menopause |
| Sexual functioning assessed with: GCS, KMI, MRS, MenQoL, FSFI follow up: range 6 weeks to 16 weeks | - | **SMD 0.25 SD lower ^** (0.58 lower to 0.08 higher) | -- | 887 (7 RCTs)  †† | ⨁⨁⨁◯ Moderate c,e,h,i,j | WHM probably results in little to no difference in sexual functioning in people with symptoms of menopause |
| Health-related quality of life | - | - | -- | (0 studies) | -- | The effect of WHM on quality of life in people with symptoms of menopause is unknown |
| Emotional functioning assessed with: GCS, KMI, MRS  follow up: range 6 weeks to 12 weeks | - | **SMD 0.47 SD lower ^** (1.33 lower to 0.39 higher) | -- | 114 (2 RCTs)  ††† | ⨁◯◯◯ Very LOW c,g,k,l,o | The evidence is very uncertain about the effect of WHM on emotional functioning in people with symptoms of menopause |
| Depression  assessed with: GCS, KMI, MRS, HAM-D follow up: range 8 weeks to 12 months | - | **SMD 0.26 SD lower ^** (1.00 lower to 0.48 higher) | -- | 585 (5 RCTs)  †††† | ⨁◯◯◯ Very LOW c,e,l,m,n | The evidence is very uncertain about the effect of WHM on symptoms of depression in people with symptoms of menopause |
| Anxiety assessed with: GCS, KMI, MRS, HAM-A follow up: range 8 weeks to 12 months | - | **SMD 0.90 SD lower ^** (1.79 lower to 0.01 lower) | -- | 560 (5 RCTs)  ††††† | ⨁◯◯◯ Very LOW c,e,l,m,n | The evidence is very uncertain about the effect of WHM on anxiety in people with symptoms of menopause |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # A 25% relative risk reduction/increase was considered important (i.e. RR < 0.75 or RR > 1.25).  † Data from 2 RCTs (total 128 participants) not included here because results were not adequately reported [missing information]. Both RCTs suggested an effect favouring WHM.  †† Data from 4 RCTs (total 365 participants) not included here because results were not adequately reported [missing information]. 2 RCTs suggested no difference between groups and 2 RCTs suggested an effect favouring the WHM.  ††† Data from 4 RCTs (total 360 participants) not included here because results were not adequately reported [missing information]. All 4 RCTs suggested an effect favouring the WHM.  †††† Data from 3 RCTs (total 242 participants) not included here because results were not adequately reported [missing information]. All 3 RCTs suggested an effect favouring the WHM.  ††††† Data from 3 RCTs (total 231 participants) not included here because results were not adequately reported [missing information]. 2 RCTs suggested an effect favouring the WHM, 1 RCT suggested no important difference between groups.  **CI:** confidence interval; **MD:** mean difference; **FSFI:** Female Sexual Function Index; **GAQ:** Global assessment questionnaire; **GCS:** Greene Climacteric Scale; **HAM-A:** Hamilton anxiety rating scale; **HAM-D:** Hamilton depression rating scale; **KMI:** Kupperman Menopausal Index; **MenQoL:** Menopause quality of life; **MRS**: Menopause Rating Scale, **SF-36:** 36-item short form health survey; **WHQ:** Women’s health questionnaire; **PGWBI:** Psychological general well-being index. | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Five RCTs at high risk of bias (~30% weight) that do not seriously influence the estimate of effect. Certainty of evidence not downgraded.

b. No serious inconsistency. Point estimates vary and confidence intervals of some studies do not overlap. Substantial statistical heterogeneity (I2 = 89%) that can be partially explained by difference in study characteristics. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in both perimenopausal or menopausal women and can be sensibly applied to the Australian population. The herbs used in the identified studies are comparable to those commonly used in Australia or could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and small important differences). Certainty of evidence downgraded.

e. Publication bias not suspected. Certainty of evidence not downgraded.

f. Serious risk of bias. 8 RCTs at high risk of bias (>50% weight) that likely overstate the size of effect. Certainty of evidence downgraded.

g. No serious inconsistency. Point estimates are consistent. Statistical heterogeneity is high (I2 > 80%) but likely explained through differences in the PICO of included studies. Certainty of evidence not downgraded.

h. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both important and no important difference). Certainty of evidence downgraded.

i. No serious risk of bias. Three RCTs at high risk of bias (~36% weight) that do not seriously influence the estimate of effect. Certainty of evidence not downgraded.

j. No serious inconsistency. Point estimate and confidence intervals of one study do not overlap. Statistical heterogeneity is high (I2 = 78%) likely explained through differences in the PICO of included studies. Certainty of evidence not downgraded.

k. No serious risk of bias. Certainty of evidence not downgraded.

l. Very serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and no important differences). Certainty of evidence downgraded 2 levels.

m. Serious risk of bias. Two RCTs at high risk of bias (~40% weight) that overstates the direction or size of the effect. Certainty of evidence downgraded.

n. No serious inconsistency. Point estimates vary and statistical heterogeneity is high (I2 > 90%) but likely explained through differences in the PICO of included studies. Certainty of evidence not downgraded.

o. Publication bias suspected. Evidence is limited to 2 small trials. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no RCTs found by the included systematic reviews that compared WHM with inactive control (no intervention, waitlist or usual care) in people with symptoms of menopause. In the absence of evidence, the effect of WHM compared with inactive control on the prioritised outcomes is unknown.

#### Tertiary Comparison (vs active control)

There were 11 RCTs found by the included systematic reviews that compared WHM with active comparators in people with symptoms of menopause, but details about these studies were lacking and no data were provided (see Appendix F2).

### Forest plots

Outcome results related to people with symptoms of menopause are presented in Figure 12 (total symptoms), Figure 13 (hot flush daily frequency), Figure 14 (sexual functioning) and Figure 15 (emotional functioning, anxiety, depression)

Figure 12 Forest plot of comparison: WHM vs placebo: Symptoms of menopause - improvement in KMI, MRS or GCS total symptoms scores

P5439#yIS1

Note: Raw data (mean, N) not shown as data were not provided by the SR authors.

Figure 13 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – hot flush, daily frequency

P5442#yIS1

Note: Raw data (mean, N) not shown as data were not provided by the SR authors.

Figure 14 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – sexual functioning

P5445#yIS1

Figure 15 Forest plot of comparison: WHM vs placebo: Symptoms of menopause – emotional functioning, anxiety, depression

P5448#yIS1

Note: Raw data (mean, N) not shown as data were not provided by the SR authors.

## Anxiety

### Description of the condition

Anxiety is the most common mental health condition in Australia and the sixth largest contributor to burden of disease, with 1 in 4 people experiencing anxiety at some stage in their life ([235](#_ENREF_235), [236](#_ENREF_236)). While it is normal to feel anxious or stressed in certain situations, those with an anxiety disorder experience these symptoms more frequently and persistently without an obvious cause. These feelings of anxiety can impact their quality of life and day-to-day functioning ([235](#_ENREF_235)). There are different types of anxiety presenting with different symptoms, including generalised anxiety disorder, social anxiety, specific phobias, and panic disorders.

Each type of anxiety disorder has its own features, however there are some common symptoms including excessive fear or worrying, panic attacks, racing heart, tightening of the chest, shortness of breath, and avoidance of situations that cause anxiety, which can impact on daily life.

Treatments for anxiety focus on controlling symptoms to minimise their impact on daily life. This can include psychological treatments such as Cognitive Behavioural Therapy, medical treatments such as antidepressants, or an anxiety management strategy ([235](#_ENREF_235)). Research examining other psychotherapies including alternative herbal treatments has been identified, however more high-quality evidence and efficacy studies are needed to implement herbal therapies into routine clinical practice for managing anxiety ([237](#_ENREF_237)).

### Description of reviews

There were 36 citations ([124](#_ENREF_124), [125](#_ENREF_125), [214](#_ENREF_214), [225](#_ENREF_225), [238-269](#_ENREF_238)) corresponding to 36 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with anxiety (Ghaderi 2020, Janda 2020, Sayed 2020, Shinjyo 2020, Donelli 2019, Hieu 2019, Marx 2019, Moller 2019, Yap 2019, Baric 2018, Ooi 2018, Smith 2018, Brondino 2013, Hidalgo 2007, Miyasaka 2007, Miyasaka 2006, Witte 2005, Pittler 2003, Pittler 2000, Lopresti 2021, Lopresti 2022, Tandon 2020, Kim 2018, Sarris 2018, Pratte 2014, Miroddi 2013, Sarris 2013, Perry 2012, Sarris 2012, Sarris 2011, Lakhan 2010, Provino 2010, Sarris 2009, Sarris 2007, Ernst 2006, Jorm 2004). No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were two systematic reviews awaiting classification ([270](#_ENREF_270), [271](#_ENREF_271)) that were published in a language other than English (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the included reviews is provided in Appendix D3.1.1.

The populations eligible for inclusion in the reviews were typically participants with anxiety or psychiatric conditions, with some reviews requiring participants be diagnosed with a specific anxiety disorder (Janda 2020, Donelli 2019, Hieu 2019, Marx 2019, Moller 2019, Baric 2018, Ooi 2018, Smith 2018, Sayed 2020, Yap 2019, Brondino 2013, Hidalgo 2007, Miyasaka 2007, Miyasaka 2006, Witte 2005, Pittler 2003, Pittler 2000, Sarris 2018, Pratte 2014, Sarris 2013, Sarris 2012, Sarris 2011, Lakhan 2010, Provino 2010, Sarris 2009, Sarris 2007, Ernst 2006, Jorm 2004). Other reviews had no population restrictions and were focused on the efficacy of a particular herb across various conditions (Ghaderi 2020, Lopresti 2021, Tandon 2020, Miroddi 2013) or presented results for RCTs where anxiety was measured as an outcome (Lopresti 2022, Lopresti 2021, Kim 2018, Perry 2012).

There were 10 reviews published in 2018 or after that were prioritised for critical appraisal and data extraction (Ghaderi 2020, Janda 2020, Shinjyo 2020, Donelli 2019, Hieu 2019, Marx 2019, Moller 2019, Baric 2018, Ooi 2018, Smith 2018). One review published prior to 2018 (Brondino 2013) was also included, Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 32 RCTs that met our PICO criteria, almost all of which examined the effect of WHM compared with placebo in participants with anxiety, either diagnosed as generalised anxiety disorder or having met a threshold indicative of symptoms of anxiety or stress. Studies in participants with acute anxiety associated with surgery or other conditions (e.g. childbirth, dental procedures) were not included here, but included with studies relating to the underlying condition (e.g. dysmenorrhea, insomnia).

An overlap table of the RCTs within the included systematic reviews is shown in Table 9.

There were 13 RCTs that focused on the effectiveness of kava (Savage 2015, Sarris 2013, Sarris 2009, Connor 2006, Geier 2004, Lehrl 2004, Boerner 2003, Gastpar 2003, Connor 2002, Malsch 2001, Singh 1998, Volz 1997, Kinzler 1991). The other WHMs considered by the included RCTs were Withania (Lopresti 2019, Kyati 2013, Auddy 2008, Andrade 2000), German chamomile (Amsterdam 2009, Mao 2016), ginkgo biloba (Woelk 2007), lavender oil (oral) (Kasper 2017, Kasper 2016, Kasper 2015, Kasper 2014, Kasper 2010, Woelk 2010), passiflora (Akhondzadeh 2001), rhodiola (Cropley 2015), saffron (Lopresti 2018, Jafarnia 2017, Mazidi 2016), and Valerian root (Andreatini 2002). Only 4 of these 9 herbs are marked as a Tier 1 herb included in the Western herbal medicine curriculum for Nervous system disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

Many of the included RCTs were conducted in Germany (Kasper 2017, Kasper 2016, Kasper 2015, Kasper 2014, Kasper 2010, Woelk 2010, Woelk 2007, Boerner 2003), with other countries such as Australia (Lopresti 2018, Savage 2015, Sarris 2013, Sarris 2009), Brazil (Andreatini 2002), India (Lopresti 2019, Khyati 2013, Auddy 2008, Andrade 2000), Iran (Jafarnia 2017, Mazidi 2016, Akhonzadeh 2001) and the United States (Amsterdam 2009, Mao 2016, Connor 2006, Connor 2002) also represented. Sample sizes ranged from 24 to 539 (total >2500 participants).

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.8.5).

There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, usual care). Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Nine (9) reviews (Ghaderi 2020, Janda 2020, Sayad 2020, Donelli 2019, Hieu 2019, Moller 2019, Baric 2018, Ooi 2018, Brondino 2013) used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and provided comprehensive information to make a judgement. The other 2 reviews (Shinjyo 2020, Marx 2019) assessed quality of the RCTs using the Jadad Scale ([234](#_ENREF_234)).

Many of the eligible RCTs were judged by the included systematic reviews to be at overall high risk of bias (Kasper 2017, Kasper 2016, Mao 2016, Kasper 2015, Woelk 2010, Amsterdam 2009, Connor 2006, Akhondzadeh 2001) with concerns of bias relating to non-blinding of participants, selective reporting and high rates of attrition. In most other studies, the risk of bias was unclear (Kasper 2014, Andreatini 2002, Connor 2002, Malsch 2001, Singh 1998, Volz 1997, Kinzler 1991) or not assessed (Lopresti 2018 Jafarnia 2017 Mazidi 2016, Cropley 2015, Sarris 2009, Geier 2004, Lehrl 2004, Gastpar 2003).

There were 8 RCTs judged to be at overall low risk of bias (Lopresti 2019, Khyati 2013, Sarris 2013, Kasper 2010, Auddy 2008, Woelk 2007, Boerner 2003, Andrade 2000).

Table 9 List of included systematic reviews and overlap with eligible RCTs (per outcome): Anxiety

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domainb | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Lopresti 2019 | Lopresti 2018 | Jafarnia 2017 | Kasper 2017 | Kasper 2016 | Keefe/Mao 2016 c | Mazidi 2016 | Cropley 2015 | Kasper 2015 | Savage 2015 d | Kasper 2014 | Khyati 2013 | Sarris 2013 | Kasper 2010 | Woelk 2010 | Amsterdam 2009 | Sarris 2009 | Auddy 2008 | Woelk 2007 | Connor 2006 | Jacobs 2005 e | Geier 2004 | Lehrl 2004 | Boerner 2003 | Gastpar 2003 | Andreatini 2002 | Connor 2002 | Akhondzadeh 2001 | Malsch 2001 | Andrade 2000 | Singh 1998 | Volz 1997 | Kinzler 1991 | Warnecke 1991 f | Warnecke 1990 f |
| Ghaderi 2020 | ✓ | Anxiety | -- | -- |  | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Janda 2020 | † | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- |
| Sayed 2020 | -- | -- | -- | -- |  |  | -- | -- | -- |  | -- |  | -- | -- |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shinjyo 2020 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Donelli 2019 | ✓ | -- | -- | -- |  |  | -- | -- | -- |  | -- |  | -- | -- |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hieu 2019 | ✓ | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Lopresti 2019 | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- |
| Marx 2019 | ✓ | -- |  |  | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Moller 2019 | ✓ | -- | -- | -- | -- |  | -- | -- | -- |  | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Yap 2019 | -- | -- | -- | -- | -- |  | -- | -- | -- |  | -- |  | -- | -- |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Baric 2018 | ✓ | -- | -- | -- | -- | -- |  | -- | -- | -- | -- |  | -- |  | -- |  |  | -- | -- | -- | -- | -- | -- | -- |  | -- |  |  |  |  | -- | -- |  | -- | -- | -- |
| Kim 2018 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | ? | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ooi 2018 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- |  | -- | -- | -- | -- | -- | -- |  | -- | -- | -- |  | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- |
| Sarris 2018 | -- | -- | -- | -- | -- | -- | ? | -- | ? | -- | -- | -- | -- | ? | -- | -- | ? | ? | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- |
| Smith 2018 | † | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- |  | -- | -- | -- | -- |  |  | -- |  | -- |  | -- |  | -- | -- | -- | -- | -- | -- |
| Brondino 2013 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Witte 2005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  |  | -- | -- | -- | -- | -- |  | -- | -- |  |  |  | -- |
| Pittler 2003 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  |  | -- |  | -- |  | -- |  | -- |  |  |  |  |  |

Table 9 List of included systematic reviews and overlap with eligible RCTs (per outcome): Anxiety (cont’d)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | | Best available a | Prioritised outcome domainb | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Lopresti 2019 | Lopresti 2018 | Jafarnia 2017 | Kasper 2017 | Kasper 2016 | Keefe/Mao 2016 c | Mazidi 2016 | Cropley 2015 | Kasper 2015 | Savage 2015 d | Kasper 2014 | Khyati 2013 | Sarris 2013 | Kasper 2010 | Woelk 2010 | Amsterdam 2009 | Sarris 2009 | Auddy 2008 | Woelk 2007 | Connor 2006 | Jacobs 2005 e | Geier 2004 | Lehrl 2004 | Boerner 2003 | Gastpar 2003 | Andreatini 2002 | Connor 2002 | Akhondzadeh 2001 | Malsch 2001 | Andrade 2000 | Singh 1998 | Volz 1997 | Kinzler 1991 | Warnecke 1991 f | Warnecke 1990 f |
| Ghaderi 2020 | ✓ | Depression | -- | -- | ! | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Donelli 2019 | ✓ | -- | -- | -- | ! | ? | -- | -- | -- | ! | -- | ? | -- | -- | ! | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hieu 2019 | ✓ | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Marx 2019 | ✓ | -- |  | ! | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hieu 2019 | ✓ | CGI - severity | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Moller 2019 | ✓ | CGI - global | -- | -- | -- | -- |  | -- | -- | -- |  | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Moller 2019 | ✓ | HRQoL | -- | -- | -- | -- | ? | -- | -- | -- | ! | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Janda 2020 | † | Sleep quality | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- |
| Shinjyo 2020 | ✓ | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hieu 2019 | ✓ | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Moller 2019 | ✓ | -- | -- | -- | -- | ! | -- | -- | -- | ? | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |

Notes:

a. Only critical or important outcome domains with available data reported here (see Appendix D1.1)

b. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Framework for selecting the systematic review from which to extract data [Appendix B1]).

c. Single RCT with short (8 week) and longer-term (34 weeks) data.

d. Protocol only. RCT complete but results not published.

e. Mixed population. RCT included in the evidence synthesis for insomnia.

f. RCT included in the evidence synthesis for women with symptoms of menopause.

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review & meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, only the information presented in the systematic review is reported.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 30 RCTs found by the included systematic reviews that compared WHM with placebo in people with symptoms of anxiety. Of these, 21 RCTs contributed data relevant to 6 outcomes (anxiety, depression, global improvement, HRQoL-mental, HRQoL-physical, sleep quality) (Lopresti 2018, Jafarnia 2017, Kasper 2017, Kasper 2016, Mao 2016, Mazidi 2016, Kasper 2015, Kasper 2014, Sarris 2013, Kasper 2010, Amsterdam 2009, Sarris 2009, Woelk 2007, Geier 2004, Lehrl 2004, Gastpar 2003, Andreatini 2002, Connor 2002, Akhondzadeh 2001, Malsch 2001, Volz 1997).

Two RCTs did not provide any data, either because the RCT results are not published (Savage 2015) or the study was discontinued (Connor 2006). Another 7 RCTs did not contribute any data because their results were not adequately reported , either by the primary study or by the systematic reviews (Lopresti 2019, Cropley 2015, Khyati 2013, Auddy 2008, Andrade 2000, Singh 1998, Kinzler 1991).

| Western herbal medicine compared to placebo for Symptoms of anxiety | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Anxiety  **Setting:** Community  **Intervention:** WHM (kava, lavender, saffron, Withania, valerian, Passiflora, gingko biloba, German chamomile)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| Anxiety assessed with: HAM-A, BAI, ASI, RCADS follow-up: range 3 weeks to 24 weeks | - | **SMD 0.43 SD lower ^** (0.59 lower to 0.28 lower) | -- | 2087 (20 RCTs) † | ⨁⨁⨁◯ Moderate a,b,c,d,e | WHM probably results in a slight reduction in anxiety in people with symptoms of anxiety |
| Depression assessed with: HAM-D, BDI, follow-up: range 8 weeks to 12 weeks | - | **SMD 0.58 SD lower ^** (0.93 lower to 0.22 lower) | -- | 129 (2 RCTs) †† | ⨁⨁◯◯ LOW b,c,f,g,h | WHM may result in a reduction in depressive symptoms in people with symptoms of anxiety |
| Global improvement assessed with: CGI follow-up: range 8 weeks to 10 weeks | - | **SMD 0.49 SD lower ^** (0.81 lower to 0.17 lower) | -- | 670 (3 RCTs)  ††† | ⨁⨁◯◯ LOW b,c,f,g,h | WHM may result in a reduction in overall symptoms in people with symptoms of anxiety |
| HRQoL - mental assessed with SF-36 (higher is better) scale range: 0 to 100 follow-up: 10 weeks | - | **MD 10.19** **higher** (5.78 higher to 14.61 higher) | -- | 508 (2 RCTs) | ⨁⨁◯◯ LOW b,c,f,g,h | WHM may result in an improvement in quality of life (emotional) in people with symptoms of anxiety # |
| HRQoL - physical assessed with SF-36 (higher is better) scale range: 0 to 100 follow-up: 10 weeks | - | **MD 7.32 higher** (3.88 higher to 10.77 higher) | -- | 508 (2 RCTs) | ⨁⨁◯◯ LOW b,c,f,g,h | WHM may result in a slight improvement in quality of life (physical) in people with symptoms of anxiety # |
| Sleep quality assessed with PSQI scale range: 0 to 21 (higher is worse) follow-up: 10 weeks | - | **MD 1.36 lower** (2.28 lower to 0.44 lower) | -- | 382 (2 RCTs) | ⨁⨁◯◯ LOW b,c,f,g,h | WHM may result in a slight improvement in sleep quality in people with symptoms of anxiety # |
| Fatigue | - | - | -- | (0 studies) | -- | The effect of WHM on fatigue in people with symptoms of anxiety is unknown |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # Effect estimates were considered on three levels: small (MD <10% of the scale), moderate (MD between 10% to 20% of the scale) or large (MD more than 20% of the scale).  † Data from 5 RCTs (total 390 participants) not included here because results were not adequately reported [missing information]. 3 RCTs suggested an effect favouring the WHM and 2 RCTs suggested no important difference.  †† Data from 2 RCTs (total 651 participants) not included here because results were not adequately reported [missing information].  ††† Data from one RCT (total 57 participants) not included here because results were not adequately reported [missing information].  **ASI:** Anxiety Status Inventory; **BAI**: Beck Anxiety Inventory; **BDI**: Beck Depression Inventory; **CI:** confidence interval; **MD:** mean difference; **HAM-A:** Hamilton anxiety rating scale; **HAM-D:** Hamilton depression rating scale; **RCADS:** Revised Child Anxiety & Depression Scale; **SF-36:** 36-item short form health survey | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Six RCTs at high risk of bias (~35% weight) that do not seriously influence the estimate of effect. Certainty of evidence not downgraded.

b. No serious inconsistency. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people with diagnosed anxiety or symptoms of anxiety and can be sensibly applied to the Australian population. The herbs used in the identified studies are comparable to those commonly used in Australia or could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both moderate and small important differences). Certainty of evidence downgraded.

e. Publication bias not suspected. Certainty of evidence not downgraded.

f. No serious risk of bias. Certainty of evidence not downgraded.

g. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and small important differences). Certainty of evidence downgraded.

h. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no RCTs found by the included systematic reviews that compared WHM with inactive control (no intervention, waitlist or usual care) in people with symptoms of anxiety. In the absence of evidence, the effect of WHM compared with inactive control on the prioritised outcomes is unknown.

#### Tertiary Comparison (vs active control)

There were 6 RCTs found by the included systematic reviews that compared WHM with active comparators (see Appendix F2).

### Forest plots

Outcome results related to people with symptoms of anxiety are presented in Figure 16 (anxiety), Figure 17 (depression) and Figure 18 (clinical global improvement). Forest plots for HRQoL and sleep quality are not provided as individual study data was not provided by the systematic review reporting the pooled results.

Figure 16 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – anxiety

P6827#yIS1

Figure 17 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – depression

P6830#yIS1

Figure 18 Forest plot of comparison: WHM vs placebo: Symptoms of anxiety – Global improvement

P6833#yIS1

## Depression

### Description of the condition

Depression is a highly prevalent mood disorder having the third highest burden of all diseases in Australia ([272](#_ENREF_272)), affecting 1 in every 16 Australians ([273](#_ENREF_273)) and more than 300 million people worldwide ([274](#_ENREF_274)). Depression is characterised by intense feeling of sadness that impact one’s physical and mental health for extended periods of time. Those experiencing depression will often report symptoms of low mood, loss of interest or pleasure in most activities, sleep disturbances, changes in appetite or unintentional changes of weight, decreased energy, either slowed or agitated movement, decreased concentration and, in some cases, feelings of guilt, worthlessness and thought of suicide ([275](#_ENREF_275)). Depressive symptoms can become chronic, leading to substantial impairment in an individual’s ability to function in everyday life ([276](#_ENREF_276)).

There are several different types of depressive disorders that are characterised by the specific symptoms experienced by the person, as well as the severity of the symptoms - either mild, moderate, or severe. Major depressive disorder is the most commonly diagnosed depressive disorder in Australia, however, several other types including bipolar disorder, cyclothymic disorder, dysthymic disorder and seasonal affective disorder are also recognised within the Australian healthcare context ([277](#_ENREF_277)). A variety of social, psychological, and biological factors contribute to depression. In particular, people who have experienced adverse life events are at higher risk of developing depression. In Australia, females are more likely to be diagnosed ([273](#_ENREF_273)).

There are many known and effective treatments for depression that are highly dependent on the severity and pattern of depressive episodes. Traditional treatments offered by health-care providers include psychological treatments such as behavioural activation, cognitive behavioural therapy and interpersonal psychotherapy, and/or antidepressant medication ([274](#_ENREF_274)). Alternative interventions such as yoga, mindfulness, relaxation, breathing exercises and herbalism are becoming increasingly popular worldwide ([278](#_ENREF_278), [279](#_ENREF_279)).

### Description of reviews

There were 51 citations ([116](#_ENREF_116), [124](#_ENREF_124), [130](#_ENREF_130), [156](#_ENREF_156), [214](#_ENREF_214), [242](#_ENREF_242), [258](#_ENREF_258), [266](#_ENREF_266), [267](#_ENREF_267), [280-315](#_ENREF_280)) corresponding to 51 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with depression. No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were 6 systematic reviews ([316-321](#_ENREF_316)) awaiting classification that were published in a language other than English (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the eligible systematic reviews is provided in Appendix D3.2.1.

The populations eligible for inclusion in the reviews were often specific to those experiencing symptoms of depression or major depressive disorder, with many reviews also including people with depression associated with other underlying comorbidities (e.g. diabetes, coronary artery disease, symptoms of menopause). Other reviews had no population restrictions but had focused on the effect of a specific WHM and presented results that included at least one study in people with depression. Seventeen (17) reviews were focused on the evidence relating to St John’s wort (Apaydin 2016, Ng 2017, Cui 2016, Maher 2016, Linde 2009, Sarris 2009, Gahlsdorf 2007, Clement 2006, Jorm 2006, Frazer 2005, Whiskey 2001, Gaster 2000, Williams 2000, Kim 1999, Stevinson 1999, Volz 1997, Ernst 1995).

The other reviews included evidence relating to saffron (Dai 2020, Ghaderi 2020, Khaksarian 2019, Marx 2019, Toth 2019, Yang 2018, Karimi 2021, Mousavi 2021, Pourmasoumi 2019, Hausenblas 2015, Hausenblas 2013, Ulbricht 2011), turmeric (Wang 2021, Fusar-Poli 2020, Hallajzadeh 2019, Sahebkar 2016c, Ng 2017a, Al-Karawi 2016, Matias 2021), lavender (Firoozeei 2021), rhodiola (Hung 2011, Ulbricht 2011a), gingko biloba (Jorm 2002) or any herbal or complementary medicine (Lopresti 2022, Asher 2017, Kim 2018a, McCloskey 2018, Sarris 2018, Yeung 2018, Dhingra 2012, Dwyer 2011, Sarris 2011a, Morgan 2008, Sarris 2007). Six (6) reviews (Lopresti 2022, Karimi 2021, Mousavi 2021, Hallajzadeh 2019, Pourmasoumi 2019, Sahebkar 2016c) were focused on outcomes not critical or important to this review (e.g. liver enzymes, stress biomarkers, endothelial function, cardiovascular risk factors).

Ten (10) systematic reviews (Firoozeei 2021, Wang 2021, Dai 2020, Fusar-Poli 2020, Ghaderi 2020, Khaksarian 2019, Marx 2019, Toth 2019, Yang 2018, Apaydin 2016) were prioritised for critical appraisal and data extraction as they presented results in a meta-analysis and were judged to provide the best available evidence. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 64 RCTs that met our PICO criteria. Most primary studies were conducted in people with major depressive disorder (diagnosed according to DSM-IV criteria) or symptoms of depression that met a threshold pre-specified by the study investigators. Two RCTs (Kashani 2016, Tabeshpour 2017) were in people with post-partum depression, one RCT (Lingaerde 1999) was in people with seasonal affective disorder, and one RCT (Kell 2017) was in people with low mood but who did not have a diagnosis of depression. Studies in participants with depression associated with surgery (e.g. after cardiopulmonary bypass or percutaneous intervention), mixed with anxiety or other conditions were not included here. These studies are included with the evidence synthesis relating to the underlying condition (e.g. dysmenorrhea, menopause, metabolic syndrome).

An overlap table of the RCTs that met our PICO criteria from the included systematic reviews is shown in Table 10.

There were 35 RCTs that focused on the effectiveness of St John’s wort in people with major depressive disorder that had been comprehensively reviewed by other systematic reviews (see Ng 2017, Apaydin 2016, Cui 2016). Due to time and resource constraints, studies assessing St John’s wort were not individually considered in this Overview. Instead, the meta-analysis results presented by the best available systematic review (Apaydin 2016) are reported.

The other 29 RCTs considered WHMs such as saffron (Jelodar 2018, Ghajar 2017, Kashani 2016, Kell 2017, Tabeshpour 2017, Sahraian 2016, Talaei 2015, Kashani 2013, Modabbernia 2012, AkhondzadehBasti 2008, AkhondzadehBasti 2007, Moshiri 2006, Akhondzadeh 2005, Noorbala 2005, Akhondzadeh 2004), turmeric (Kanchanatawan 2018, Lopresti 2017, Panahi 2015, Yu 2015, Lopresti 2014, Sanmukhani 2014, Bergman 2013), lavender (Araj-Khodaei 2020, Nikfarjam 2017, Nikfarjam 2013, Akhondzadeh 2003), gingko (Lindgaerde 1999) and rhodiola (Mao 2015, Darbinyan 2007). Of these, only 2 (St John’s wort and lavender) are marked as a Tier 1 herb included in the Western herbal medicine curriculum for Nervous system disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

The majority of included studies (18) were conducted in Iran (Araj-Khodaei 2020, Jelodar 2018, Ghajar 2017, Kashani 2017, Nikfarjam 2017, Tabeshpour 2017, Sahraian 2016, Talaei 2015, Kashani 2013, Nikfarjam 2013, Modabbernia 2012, AkhondzadehBasti 2008, Akhondzadeh Basti 2007, Moshiri 2006, Akhondzadeh 2005, Noorbala 2005, Akhondzadeh 2004, Akhondzadeh 2003) with other countries such as Australia (Kell 2017, Lopresti 2017, Lopresti 2014), China (Yu 2015), India (Sanmukhani 2014), Israel (Panahi 2015, Bergman 2013) and Thailand (Kanchanatawan 2018) also represented. The country was not specified for 3 RCTs (Mao 2015, Darbinyan 2007 Lingaerde 1999). The interventions were typically delivered over 6 to 8 weeks.

Twenty-one (21) RCTs compared WHM with placebo (Jelodar 2018, Kanchanatawan 2018, Kell 2017, Lopresti 2017, Tabeshpour 2017, Sahraian 2016, Mao 2015, Talaei 2015, Panahi 2015, Yu 2015, Lopresti 2014, Sanmukhani 2014, Bergman 2013, Kashani 2013, Modabbernia 2012, Akhondzadeh Basti 2008, Darbinyan 2007, Moshiri 2006, Akhondzadeh 2005, Akhondzadeh 2003, Lingaerde 1999). Two RCTs compared WHM with an inactive control (Nikfarjam 2017, Nikfarjam 2013) but no data were provided. Seven (7) RCTs compared WHM directly with an active intervention (Araj-Khodaei 2020, Ghajar 2017, Kashani 2017, Akhondzadeh Basti 2007, Noorbala 2005, Akhondzadeh 2004, Akhondzadeh 2003).

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.7.5).

There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, usual care). Results for the Tertiary Comparison (versus active comparators) are provided in in the Summary of Findings tables and Appendix F2.

Table 10 List of included systematic reviews and overlap with eligible RCTs (per outcome): Depression

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domainb | Study ID | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Araj-Khodaei 2020 | Jelodar 2018 | Kanchanatawan 2018 | Ghajar 2017 | Kell 2017 c | Lopresti 2017 | Nikfarjam 2017 | Tabeshpour 2017 d | Kashani 2016 d | Sahraian 2016 | Mao 2015 | Talaei 2015 | Panahi 2015 | Yu 2015 | Lopresti 2014 | Sanmukhani 2014 | Bergman 2013 | Kashani 2013 e | Nikfarjam 2013 | Modabbernia 2012 | Akhondzadeh Basti 2008 | Akhondzadeh Basti 2007 | Darbinyan 2007 | Moshiri 2006 | Akhondzadeh 2005 | Noorbala 2005 | Akhondzadeh 2004 | Akhondzadeh 2003 (lavender) | Lingaerde 1999 f |
| Firoozeei 2021 |  | Depressive symptoms |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Wang 2021 |  | -- | -- |  | -- | -- |  | -- | -- | -- | -- | -- | -- | -- |  |  |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Dai 2020 |  | -- | -- | -- |  | -- | -- | -- |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- |  |  |  | -- | -- | -- |
| Fusar-Poli 2020 |  | -- | -- |  | -- | -- |  | -- | -- | -- | -- | -- | -- |  |  |  |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ghaderi 2020 |  | -- |  | -- | -- | ! | -- | -- |  | -- |  | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  |  | -- | -- | -- | -- |
| Khaksarian 2019 |  | -- | -- | -- | -- | -- | -- | -- | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  |  | -- |  |  | -- | -- | -- | -- |
| Marx 2019 |  | -- |  | -- |  |  | -- | -- |  |  |  | -- |  | -- | -- | -- | -- | -- |  | -- |  | -- |  | -- |  |  |  |  | -- | -- |
| Toth 2019 |  | -- | -- | -- |  | -- | -- | -- |  |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- |  |  |  |  | -- | -- |
| Yang 2018 |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |  | -- |  |  |  |  | -- | -- |
| Matias 2021 | \* | -- | -- | ? | -- | -- | ? | -- | -- | -- | -- | -- | -- | ? | ? | ? | ? | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| McCloskey 2018 | \* | -- | -- | -- | -- | -- | -- | -- | ? | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Sarris 2018 | \* | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | ? | -- | -- | -- | ? | -- | -- | -- | -- | ? | ? |
| Fusar-Poli 2020 |  | Anxiety | -- | -- |  | -- | -- |  | -- | -- | -- | -- | -- | -- |  | ! |  | ! | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Ghaderi 2020 |  | -- | ! | -- | -- | ! | -- | -- | ! | -- | ! | -- |  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ! | ! | -- | -- | -- | -- |
| Marx 2019 |  | -- | ! | -- | ? |  | -- | -- | ! | ! | ! | -- |  | -- | -- | -- | -- | -- | ! | -- | ! | -- | ! | -- | ! | ! | ! | ! | -- | -- |
| Fusar-Poli 2020 |  | CGI | -- | -- | ! | -- | -- | ! | -- | -- | -- | -- | -- | -- | ! | ! | ! | ! | ! | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Apaydin 2016 |  |  | 35 RCTs examining the efficacy of St John’s wort not included here | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Abbreviations: CGI, Clinical global impression; RCT, randomised controlled trial; SR, systematic review

Notes:

a. Only critical or important outcome domains with available data reported here (see Appendix D1.1)

b. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Framework for selecting the systematic review from which to extract data [Appendix B1]).

c. Participants described as being healthy adults with low mood.

d. Participants with postpartum depression.

e. Participants with major depression and sexual dysfunction attributed to fluoxetine use.

f. Participants with seasonal affective disorder.

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review & meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, only the information presented in the systematic review is reported.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Most of the included systematic reviews used the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) to asses bias within the included RCTs and comprehensive information to make a judgement.

Five (5) RCTs were judged to be at low risk of bias (Kanchanatawan 2018, Ghajar 2017, Lopresti 2017, Lopresti 2014, Akhondzadeh 2004). There were some concerns of bias in 10 RCTs, as the information provided was missing or unclear (Jelodar 2018, Kashani 2017, Kell 2017, Tabeshpour 2017, Sahraian 2016, Kashani 2013, Modabbernia 2012, Akhondzadeh Basti 2007, Moshiri 2006, Noorbala 2005).

Eight (8) RCTs (Araj-Khodaei 2020, Panahi 2015, Talaei 2015, Yu 2015, Bergman 2013, Sanmukhani 2014, Akhondzadeh Basti 2008, Akhondzadeh 2005) were judged to be at high risk of bias in at least one domain. Information about risk of bias for the other 6 RCTs were not provided (Nikfarjam 2017, Mao 2015, Nikfarjam 2013, Darbinyan 2007, Akhondzadeh 2003, Lindgaerde 1999).

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 21 RCTs found by the included systematic reviews that compared WHM (other than St Jonn’s Wort) with placebo in people with depression (or symptoms of depression). Of these, 18 RCTs contributed data relevant to 2 outcomes (anxiety, depression). (Jelodar 2018, Kanchanatawan 2018, Kell 2017, Lopresti 2017, Tabeshpour 2017, Sahraian 2016, Talaei 2015, Panahi 2015, Yu 2015, Lopresti 2014, Sanmukhani 2014, Bergman 2013, Kashani 2013, Modabbernia 2012, Akhondzadeh Basti 2008, Moshiri 2006, Akhondzadeh 2005, Akhondzadeh 2003).

Three RCTs (Mao 2015, Darbinyan 2007, Lingaerde 1999) did not contribute any data because their results were not adequately reported by the systematic reviews.

A further 16 RCTs comparing St John’s wort with placebo provided data relevant to 3 outcomes (depression, emotional functioning and physical functioning).

| Western herbal medicine compared to placebo for depression and mood disorders | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Depression and mood disorders  **Setting:** Community  **Intervention:** WHM (saffron, curcumin, St John’s wort)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with Placebo | Risk with WHM |
| Depression assessed with: HAM-D, BDI, HADS, MDRS, DASS-21  follow-up: range 6 weeks to 12 weeks | - | **SMD 0.60 SD lower ^** (0.89 lower to 0.31 lower) | -- | 1022 (17 RCTs) | ⨁⨁⨁◯ MODERATE a,b,c,d,e | WHM probably results in a reduction in depressive symptoms in people with depression |
| **St John’s Wort: SMD 0.49 SD lower ^** (0.74 lower to 0.23 lower) | 2888 (16 RCTs) | ⨁⨁⨁◯ MODERATE h |
| Anxiety assessed with: HAM-A, BAI, STAI, DASS-21 follow-up: range 6 weeks to 12 weeks | - | **SMD 1.49 SD lower ^** (2.39 lower to 0.59 lower) | -- | 397 (5 RCTs) † | ⨁⨁◯◯ LOW c,d,e,f,g | WHM may result in a large reduction in anxiety in people with depression |
| Stress assessed with: DASS-21  follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) †† | -- | The effect of WHM on stress in people with depression is unknown |
| HRQoL | - | - | -- | (0 studies) | -- | The effect of WHM on quality of life in people with depression is unknown |
| Emotional functioning  assessed with: SF-36 MCS range: 0 to 100 (higher is better) follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) | -- | WHM may result in a slight increase in emotional functioning in people with depression |
| **St John’s Wort: SMD 0.48 SD higher ^** (0.24 higher to 0.73 higher) | 358 (2 RCTs) | ⨁⨁◯◯ LOW i |
| Global improvement assessed with: CGI follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) ††† | -- | The effect of WHM on global improvement in people with depression is unknown |
| Physical functioning assessed with: SF-36 PCS range: 0 to 100 (higher is better) follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) | -- | The evidence is very uncertain about the effect of WHM on physical functioning in people with depression |
| **St John’s Wort: SMD 0.28 SD higher ^** (1.03 lower to 0.47 higher) | 358 (2 RCTs) | ⨁◯◯◯ Very LOW j |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  † Data from one RCT (total 66 participants) not included here because results were not adequately reported [missing information].  †† Data from one RCT (total 121 participants) not included here because results were not adequately reported [missing information].  ††† Data from 2 RCTs (total 80 participants) not included here because results were not adequately reported [missing information].  **BAI**: Beck Anxiety Inventory; **BDI**: Beck Depression Inventory; **CI:** confidence interval; **DASS-21**: depression, anxiety, stress scale; **HADS:** Hospital anxiety and depression scale; **HAM-A:** Hamilton anxiety rating scale; **HAM-D:** Hamilton depression rating scale; **IDS-SR30**: Self-rated Inventory of Depressive Symptomatology; **MADRS**: Montgomery-Åsberg Depression Rating Scale; **MCS:** mental component score; **MD:** mean difference; **PCS:** physical component score; | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Seven RCTs at high risk of bias (~40% weight) that do not seriously influence the estimate of effect. Certainty of evidence not downgraded.

b. No serious inconsistency. Statistical heterogeneity is high (I2=78%) but likely explained by differences in PICO of included studies. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people diagnosed with major depression or with symptoms of depression that can be sensibly applied to the Australian population. It is possible the herbs used in the identified studies are not comparable to those commonly used in Australia but they could be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and small important differences). Certainty of evidence downgraded.

e. Publication bias not suspected. Certainty of evidence not downgraded.

f. No serious risk of bias. Certainty of evidence not downgraded.

g. Serious inconsistency. Statistical heterogeneity is high (I2=93%) and confidence intervals of studies do not overlap. Certainty of evidence downgraded.

h. GRADE assessed by Apaydin 2016 ([290](#_ENREF_290)) Downgraded for inconsistency (due to heterogeneity; direction of effects; no replication).

i. GRADE assessed by Apaydin 2016 ([290](#_ENREF_290)) Downgraded for study limitations (no good quality study; effect not present when excluding poor quality studies; studies not designed or not powered to assess outcome).

j. GRADE assessed by Apaydin 2016 ([290](#_ENREF_290)) Downgraded for inconsistency (due to heterogeneity; direction of effects; no replication) and study limitations (no good quality study; effect not present when excluding poor quality studies; studies not designed or not powered to assess outcome).

#### Secondary Comparison (vs inactive control)

There were no RCTs identified by the included systematic reviews that compared WHM with inactive control (no intervention, waitlist or usual care) in people with depression. In the absence of evidence, the effect of WHM compared with inactive control on the prioritised outcomes is unknown:

#### Tertiary Comparison (vs active control)

There were 6 RCTs found by the included systematic reviews that compared WHM (other than St John’s Wort) with selective serotonin reuptake inhibitors (fluoxetine, citalopram) or a tricyclic antidepressant (imipramine) in people with depression (Araj-Khodaei 2020, Ghajar 2017, Kashani 2017, Akhondzadeh Basti 2007, Noorbala 2005, Akhondzadeh 2004). Five (5) RCTs contributed data relevant to one outcome.

A further 14 RCTs comparing St John’s wort with antidepressants provided data relevant to 3 outcomes.

| Western herbal medicine compared to antidepressant for depression and mood disorders | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Depression and mood disorders  **Setting:** Community  **Intervention:** WHM (saffron, lavender, St John’s wort)  **Comparison:** selective serotonin reuptake inhibitors (fluoxetine, citalopram) or tricyclic antidepressants (imipramine) | | | | | | |
| Outcomes | Anticipated absolute effects\*  (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with antidepressants | Risk with WHM |
| Depression assessed with: HAM-D (higher is worse)  follow-up: range 6 weeks to 8 weeks | - | **SMD 0.15 SD lower ^** (0.15 lower to 0.46 higher) | -- | 224 (5 RCTs) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM probably results in a little to no difference in depressive symptoms in people with depression |
| **St John’s Wort: SMD 0.03 SD higher ^** (0.15 lower to 0.21 higher) | 2248 (14 RCTs) | ⨁⨁⨁◯ MODERATE |
| Anxiety assessed with: HAM-A follow-up: range 6 weeks to 8 weeks | - | **-** | -- | (0 studies) †† | -- | The effect of WHM on anxiety in people with depression is unknown |
| Stress assessed with: DASS-21  follow-up: range 6 weeks to 8 weeks | - | - | -- | (0 studies) | -- | The effect of WHM on stress in people with depression is unknown |
| HRQoL | - | - | -- | (0 studies) | -- | The effect of WHM on quality of life in people with depression is unknown |
| Emotional functioning  assessed with: SF-36 MCS range: 0 to 100 (higher is better) follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) | -- | The evidence is very uncertain about the effect of WHM on emotional functioning in people with depression |
| **St John’s Wort: SMD 0.11 SD lower ^** (0.15 lower to 0.38 higher) | -- | 216 (1 RCT) | ⨁◯◯◯ Very lOW g |
| Global improvement assessed with: CGI follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) | -- | The effect of WHM on global improvement in people with depression is unknown |
| Physical functioning assessed with: SF-36 PCS range: 0 to 100 (higher is better) follow-up: range 6 weeks to 12 weeks | - | - | -- | (0 studies) | -- | The evidence is very uncertain about the effect of WHM on physical functioning in people with depression |
| **St John’s Wort: SMD 0.35 SD higher ^** (0.01 higher to 0.70 higher) | -- | 153 (1 RCT) | ⨁◯◯◯ Very LOW g |
| \* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  † Data from one RCT (total participants unclear) not included here because results were not adequately reported [missing information].  †† Data from one RCT (total 66 participants) not included here because results were not adequately reported [missing information].  **CI:** confidence interval; **HAM-D:** Hamilton depression rating scale; **HAM-A:** Hamilton anxiety rating scale; **MD:** mean difference; | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Five RCTs at low or unclear risk of bias. Certainty of evidence not downgraded.

b. No serious inconsistency. Statistical heterogeneity is low (I2=24%) Point estimate for one study does not overlap with the others, but likely explained by differences in PICO. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people diagnosed with major depression, postpartum depression or mild-moderate depression that can be sensibly applied to the Australian population. It is possible the herbs used in the identified studies are not comparable to those commonly used in Australia, but they could be sensibly applied. Certainty of evidence not downgraded.

d. Very serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both benefit and harms). Certainty of evidence downgraded 2 levels.

e. Publication bias not suspected. Certainty of evidence not downgraded.

f. GRADE assessed by Apaydin 2016 ([290](#_ENREF_290)) Downgraded for inconsistency (due to heterogeneity; direction of effects; no replication).

g. GRADE assessed by Apaydin 2016 ([290](#_ENREF_290)) Downgraded for inconsistency (due to heterogeneity; direction of effects; no replication) and study limitations (no good quality study; effect not present when excluding poor quality studies; studies not designed or not powered to assess outcome).

### Forest plots


Outcome results related to people with depression compared with placebo are presented in Figure 19 (depressive symptoms – WHM other than St John’s wort), Figure 20 (depressive symptoms – St John’s wort), and Figure 21 (anxiety).

Outcome results related to people with depression compared with an active intervention are presented in Figure 22 (depressive symptoms – WHM other than St John’s wort) and Figure 23 (depressive symptoms – St John’s wort).

Figure 19 Forest plot of comparison: WHM vs placebo: Depression – depressive symptoms

P7721#yIS1

Figure 20 Forest plot of comparison: St John’s wort vs placebo: Depression – depressive symptoms



Source: [Apaydin, Maher (290)](#_ENREF_290)


Figure 21 Forest plot of comparison: WHM vs placebo: Depression – anxiety, stress, and global improvement

P7728#yIS1

Figure 22 Forest plot of comparison: WHM vs active intervention: Depression – depressive symptoms

P7731#yIS1

Figure 23 Forest plot of comparison: St John’s wort vs active intervention: Depression – depressive symptoms



Source: [Apaydin, Maher (290)](#_ENREF_290)

## Insomnia

### Description of the condition

Sleep problems are common across the adult Australian population and can range from experiencing mild sleep disturbances each week to being diagnosed with clinical insomnia ([322](#_ENREF_322)). Sleep problems and insomnia are characterised by an inability to fall asleep or lack of sleep which can cause daytime impairment. Insomnia can present in different forms such as onset insomnia, defined as difficulty initiating sleep, or maintenance insomnia, defined as difficulty maintaining sleep through the night or early awakening ([323](#_ENREF_323)). In short term cases, precipitating factors such as shift work, stressors, or comorbid conditions may trigger insomnia. In other cases, insomnia is paired with hyperarousal which can distort sleep perception or interrupt sleep. If left untreated, maladaptive behaviours like daytime napping or sedative dependence may form alongside neurocognitive responses such as conditioned night-time arousal or cognitive alterations, eventually developing into chronic insomnia. If symptoms of sleeplessness and impaired daytime function occur ≥3 times a week for more than 3 months, patients are considered to have chronic insomnia disorder according to the International Classification of Sleep Disorders (ICSD-3) criteria ([324](#_ENREF_324)).

In Australia, 14.8% of adults are reported to have chronic insomnia and 59.4% report sleep problems more than 3 times a week ([322](#_ENREF_322)). Women are more likely to report chronic insomnia and daytime consequences than men. In both men and women, the prevalence of chronic insomnia increases with age; adults over 75 report the highest rates of chronic insomnia (23.1%) in Australia. Older people are also significantly more likely to report maintenance insomnia. Despite these significant numbers, less than 1/3 of people seek treatment. Even when treatment is initiated, it can take a relatively heterogenous approach ([322](#_ENREF_322)).

Current treatment options for insomnia include pharmacological interventions, hormonal or herbal supplements (such as melatonin or valerian), and cognitive behavioural therapy (CBT) for insomnia. CBT is recommended for first line management for patients with insomnia since improvements can be maintained for up to 3 years and medications are only recommended for short term usage ([322](#_ENREF_322), [325](#_ENREF_325)). However, CBT can be time consuming (4-8 weeks) and limited by accessibility of clinicians. New evidence has suggests that exercise interventions and mindfulness based interventions can be helpful in improving sleep quality ([325](#_ENREF_325)).

### Description of reviews

There were 15 citations ([107](#_ENREF_107), [214](#_ENREF_214), [227](#_ENREF_227), [241](#_ENREF_241), [255](#_ENREF_255), [257](#_ENREF_257), [304](#_ENREF_304), [326-333](#_ENREF_326)) corresponding to 15 systematic reviews (Feizi 2019, Fernandez-San-Martin 2010, Hieu 2019, Kim 2018a, Leach 2015, Lopresti 2021, Sarris 2011, Sarris 2011b, Shinjyo 2020, Sys 2020, Stevinson 2000, Tandon 2020, Taibi 2007, Taslaman 2014, Ulbricht 2012) identified in the literature search that evaluated the effectiveness of WHMs in people with insomnia. There were no additional reviews identified in the Department’s public call for evidence (see Appendix C2). There was one systematic review ([334](#_ENREF_334)) awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the eligible systematic reviews is provided in Appendix D3.3.1.

The populations eligible for inclusion in the reviews was usually participants with insomnia or sleep problems (Shinjyo 2020, Sys 2020, Feizi 2019, Kim 2018a, Leach 2015, Taslaman 2014, Sarris 2011b, Fernandez-San-Martin 2010, Taibi 2007, Stevinson 2000). Two reviews also searched for studies in people with anxiety (Hieu 2019, Sarris 2011). Three reviews had no population restrictions but presented results where stress biomarkers were measured as an outcome (Lopresti 2021) or were focused on specific WHM (Tandon 2020, Ulbricht 2012) and included studies in people with insomnia.

Four (4) of the reviews (Shinjyo 2020, Hieu 2019, Leach 2015, Fernandez-San-Martin 2010) presented results in a meta-analysis and were prioritised for critical appraisal and data extraction. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 13 RCTs that met our PICO criteria, examining the effects of a variety of herbs such as chamomile, valerian, kava, Withania or hops compared with placebo or other interventions among people with insomnia. Of these, 4 herbs (are marked as a Tier 1 herb included in the Western herbal medicine curriculum for Nervous system disorders (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

Eleven (11) RCTs compared WHM with placebo (Langade 2019, Taavoni 2011, Zick 2011, Taibi 2009, Koetter 2007, Oxman 2007, Jacobs 2005, Morin 2005, Coxeter 2003, Farag 2003, Donath 2000) and 3 RCTs (Maroo 2013, Morin 2005, Ziegler 2002) compared WHM with an active intervention.

The RCTs were conducted in a variety of countries including Australia (Coxeter 2003), Germany (Donath 2000, Ziegler 2002), Norway (Oxman 2007) and the United States (Jacobs 2005, Taibi 2009, Zick 2011) (or not specified). Sample sizes ranged from 6 to 405 (total 1562 participants), with the interventions being delivered over various time periods (range 14 days to 6 months).

An overlap table of the RCTs that met our PICO criteria from within the included systematic reviews is shown in Table 11.

Results for Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.10.5).

There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, usual care). Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

Table 11 List of included systematic reviews and overlap with eligible RCTs (per outcome): Insomnia

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available a | Prioritised outcome domain b | Study ID | | | | | | | | | | | | |
| Langade 2019 | Maroo 2013 | Taavoni 2011 | Zick 2011 | Taibi 2009 # | Koetter 2007 ## | Oxman 2007 | Jacobs 2005 | Morin 2005 | Coxeter 2003 | Farag 2003 | Ziegler 2002 | Donath 2000 |
| Lopresti 2021 | † | Sleep quality | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shinjyo 2020 | ✓ | -- | Y | Y | -- | Y | ! | Y | Y | ! | ! | ! | Y | Y |
| Sys 2020 | † | -- | -- | -- | -- | ? | -- | -- | -- | -- | -- | -- | -- | -- |
| Tandon 2020 | † | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Feizi 2019 | † | -- | -- | -- | ? | -- | -- | ? | -- | -- | ? | -- | -- | ? |
| Hieu 2019 | ✓ | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Kim 2018a | † | -- | -- | -- | ? | ? | -- | ? | -- | -- | ? | -- | ? | ? |
| Leach 2015 | ✓ | -- | -- | -- | Y | -- | -- | Y | Y | -- | Y | -- | ! | Y |
| Fernandez-San-Martin 2010 | ✓ | -- | -- | -- | -- | Y | ! | Y | -- | -- | Y | -- | -- | Y |
| Lopresti 2021 | † | Anxiety | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shinjyo 2020 | ✓ | -- | ! | ! | -- | ! | ! | ! | Y | ! | ! | ! | ! | ! |
| Tandon 2020 | † | ? | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hieu 2019 | ✓ | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shinjyo 2020 | ✓ | HRQoL | -- | ! | ! | -- | ! | ! | ! | ! | Y | ! | ! | ! | ! |

Abbreviations: HRQoL, health-related quality of life; RCT, randomised controlled trial

a. Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 [Framework for selecting the systematic review from which to extract data]).

b. Only critical or important outcome domains with available data included here (see Appendix D1.1.3)

# population described as with insomnia in some reviews, others suggest participants have menopause-related sleep problems.

## Participants are diagnosed with insomnia according to ICD-10 criteria or are described as having a nonorganic sleep disorder.

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Systematic review not assessed. A study result is available and reported in another systematic review nominated as the best available evidence.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review & meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, only the information presented in the systematic review is reported.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Hieu 2019 and Leach 2015 used the Cochrane Collaboration risk of bias assessment tool to assess bias in the included RCTs ([54](#_ENREF_54)), whereas Shinjyo 2020 and Fernandez-San-Martin 2010 used the Jaded Scale ([234](#_ENREF_234)).

The majority of RCTs were reported as having unclear methodology, therefore most were judged to be at overall unclear risk of bias. Almost all were judged to be at high risk of bias relating to sponsorship bias.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 11 RCTs (found by the included systematic reviews that compared WHM with placebo in people with insomnia. Of these, 5 RCTs (Taavoni 2011, Zick 2011, Oxman 2007, Taibi 2009, Jacobs 2005) contributed data to at least one critical or important outcome. Four RCTs (Langade 2019, Morin 2005, Coxeter 2003, Donath 2000) could have contributed data but the results were not adequately reported in the reviews.

The other 2 RCTs (Koetter 2007, Farag 2003) did not measure or report an outcome considered to be critical or important for this review.

| WHM compared to placebo for insomnia | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Insomnia  **Setting:** Community  **Intervention:** WHM (valerian or combination with hops or Withania, ginger, black pepper, liquorice)  **Comparison:** Placebo | | | | | | |
| Outcomes | Anticipated absolute effects\* (95% CI) | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| Risk with placebo | Risk with WHM |
| Sleep quality assessed with: PSQI, ISI (higher is worse), VAS (higher is better) Follow-up: range 4 to 24 weeks | -- | **SMD** **0.12 lower ^** (0.24 lower to 0.21 higher) | -- | 946  (5 RCTs) † | ⨁⨁⨁◯ Moderate a,b,c,d,e | WHM probably results in little to no difference in sleep quality in people with insomnia. |
| Patient reported improvement | -- | -- | -- | (0 studies) | -- | The effect of WHM on global improvement in people with insomnia is unknown. |
| Health related quality of life | -- | -- | -- | (0 studies) \* | -- | The effect of WHM on quality of life in people with insomnia is unknown. |
| Symptoms of depression | -- | -- | -- | (0 studies) \*\* | -- | The effect of WHM on symptoms of depression in people with insomnia is unknown. |
| Symptoms of anxiety assessed with: STAI  scale range: 20 to 80 (higher is worse) follow-up: 4 weeks | The mean STAI score was **40.8** | **MD 1.71 higher** (1.39 lower to 4.80 higher) ^^ | -- | 425 (2 RCTs) †† | ⨁⨁◯◯ LOW a,b,c,d,f | WHM may result in little to no difference in anxiety in people with insomnia. # |
| Physical functioning | -- | -- | -- | (0 studies) | -- | The effect of WHM on physical functioning in people with insomnia is unknown. |
| Fatigue | -- | -- | -- | (0 studies) \*\* | -- | The effect of WHM on fatigue in people with insomnia is unknown. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  ^^ Effect estimates were considered on three levels: small (MD <10% of the scale), moderate (MD between 10% to 20% of the scale) or large (MD more than 20% of the scale).  # A cut point of 39-40 and above indicates symptoms are clinically significant ([335](#_ENREF_335)).  † Data from 4 RCTs (total 284 participants) not included here because results were not adequately reported [missing information]. All 3 studies suggested no difference between groups.  †† Data from one RCT (total 606 participants) not included here because results were not adequately reported [missing information]. The study suggested an effect favouring WHM.  \* Data from one RCT (total 184 participants) not included here because results were not adequately reported [missing information].  \*\* Data from one RCT (total 34 participants) not included here because results were not adequately reported [missing information].  **CI:** confidence interval; **WHM:** Western Herbal Medicine | | | | | | |
| **GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ­ | | | | | | |

Explanations

a. No serious risk of bias. Certainty of evidence not downgraded.

b. Serious inconsistency. Point estimates do not overlap. High statistical heterogeneity (I2 = 78%) that is not able to be explained. Certainty of evidence downgraded.

c. No serious indirectness. The available evidence is in people with insomnia and is directly generalisable to the Australian population with few caveats. The herbs used in the identified studies are comparable to those commonly used in Australia and can be sensibly applied. Certainty of evidence not downgraded.

d. No serious imprecision. Certainty of evidence not downgraded.

e. Publication bias not suspected. Certainty of evidence not downgraded.

f. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no RCTs found by the included systematic reviews that compared WHM with control (no intervention, waitlist or usual care) in people with insomnia. In the absence of evidence, the effect of WHM compared with control on the prioritised outcomes in people with insomnia is unknown.

#### Tertiary Comparison (vs active control)

There were 3 RCTs found by the included systematic reviews that compared WHM with active comparators. Data from these studies are presented in Appendix F2.

### Forest plots

Outcome results related to people with insomnia are presented in Figure 24 (sleep quality) and Figure 25 (anxiety).

Figure 24 Forest plot of comparison: WHM vs placebo: Insomnia – sleep quality

P8144#yIS1

Figure 25 Forest plot of comparison: WHM vs placebo: Insomnia – anxiety

P8147#yIS1

## Diabetes and Impaired glucose tolerance

### Description of the condition

Diabetes and impaired glucose tolerance were initially prioritised as separate conditions. However, it was found that systematic reviews and studies within them were often unclear whether the studies enrolled people with diabetes or impaired glucose tolerance or both (or metabolic disorder). Diabetes and impaired glucose tolerance are therefore combined here and in Appendix D.

Impaired glucose tolerance occurs when blood glucose levels are higher than normal but not high enough to meet the diagnostic criteria for diabetes ([336](#_ENREF_336)). Impaired glucose tolerance is considered a high-risk factor for developing type 2 diabetes and cardiovascular disease ([337-341](#_ENREF_337)). In Australia, the prevalence of impaired glucose tolerance is estimated to be 8.8% ([342](#_ENREF_342)), with one in 6 Australians older than 25 years estimated to have pre-diabetes (impaired glucose intolerance and/or impaired fasting glucose) ([336](#_ENREF_336), [343](#_ENREF_343)).

Diabetes mellitus is a chronic metabolic disease characterised by elevated levels of blood glucose (hyperglycaemia) resulting from defects in insulin secretion, impaired insulin production, weakened response to insulin or absolute insulin deficiency ([344](#_ENREF_344)). Insulin deficiency leads to hyperglycaemia organ complication, primarily blood vessels, eyes, nerves and kidneys ([345](#_ENREF_345)). Classifying diabetes is critical for disease management. Common classifications of diabetes include type 1 diabetes, type 2 diabetes and gestational diabetes (occurs during pregnancy) ([346](#_ENREF_346)). Clinical presentation and disease pathogenesis various among individuals, and may be influenced by environmental, lifestyle and genetic factors ([345](#_ENREF_345), [346](#_ENREF_346)).

Type 1 diabetes, also known as juvenile diabetes constitutes about 5-10% of all diabetes cases ([347](#_ENREF_347)) and is caused by the auto-immune destruction of insulin-producing beta cells in the islets of Langerhans leading to little to no production of insulin ([348](#_ENREF_348), [349](#_ENREF_349)). The exact cause of Type 1 diabetes is unknown but risk factors include genetic predisposition and environmental triggers such as exposure to certain viruses ([350](#_ENREF_350), [351](#_ENREF_351)). Type 2 diabetes is the most common, making up 85-90% of all diabetes cases and usually occurs in adults over the age of 45 ([352](#_ENREF_352)). It is characterised by insulin resistance and/or the gradual loss to produce enough insulin in the pancreas and is associated with modifiable lifestyle risk factors such as diet and exercise ([352](#_ENREF_352)). Gestational diabetes is defined as an intolerance to glucose that is first diagnosed or has its onset during pregnancy. It is estimated to affect almost 5% of pregnancies in Australia and between 3% and 9% worldwide ([353](#_ENREF_353)). Although some women will continue to have elevated glucose levels, gestational diabetes usually disappears after giving birth ([354](#_ENREF_354)), however an estimated 40% are at risk of recurrence of gestational diabetes in a subsequent pregnancy and at increased risk of developing type 2 diabetes at later age ([355](#_ENREF_355)).

An estimated 1.2 million Australians (4.9% of the total population) had diabetes in 2017–18, based on self-reported data from the Australian Bureau of Statistics (ABS) 2017–18 National Health Survey ([356](#_ENREF_356)). However, this is likely to be an underestimate of the true prevalence given this does not include people with undiagnosed diabetes ([356](#_ENREF_356)). Prevalence of diabetes in 2017-18 was higher in males (5.0%) than females (3.8%) and increases with age ([356](#_ENREF_356)). High blood plasma glucose (including diabetes) was responsible for 4.3% of ill health and premature death in Australia and was the fifth leading risk factor contributing to ill health and premature death in 2018 ([357](#_ENREF_357))

Primary management of diabetes involves lifestyle modifications such as weight modifications, controlled diet and increased physical activity. Life-long treatment with insulin is needed for type 1 diabetes but may be required for managing type 2 diabetes ([358](#_ENREF_358), [359](#_ENREF_359)). The effects of complementary and alternative medicines on metabolic control are conflicting due to deficiencies in the robustness of evidence and issues with safety. However, few studies have shown positive effects of certain complementary therapies for diabetes management ([360](#_ENREF_360), [361](#_ENREF_361)).

### Description of reviews

There were 166 citations ([24](#_ENREF_24), [25](#_ENREF_25), [27](#_ENREF_27), [28](#_ENREF_28), [33-35](#_ENREF_33), [64](#_ENREF_64), [113](#_ENREF_113), [124](#_ENREF_124), [153](#_ENREF_153), [154](#_ENREF_154), [158](#_ENREF_158), [159](#_ENREF_159), [161](#_ENREF_161), [163-166](#_ENREF_163), [168](#_ENREF_168), [169](#_ENREF_169), [171](#_ENREF_171), [172](#_ENREF_172), [174](#_ENREF_174), [178](#_ENREF_178), [181](#_ENREF_181), [183](#_ENREF_183), [189](#_ENREF_189), [193](#_ENREF_193), [194](#_ENREF_194), [197](#_ENREF_197), [199](#_ENREF_199), [219](#_ENREF_219), [255](#_ENREF_255), [257](#_ENREF_257), [296](#_ENREF_296), [362-490](#_ENREF_362)) corresponding to 166 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with diabetes and/or impaired glucose tolerance. No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were 14 systematic reviews awaiting classification (see Appendix C4) and 4 ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the 166 eligible systematic reviews is provided in Appendix D4.1.1.

There were 23 reviews ([362-384](#_ENREF_362)) that were published in 2018 or after, that presented results in a meta-analysis and focused on people with diabetes or metabolic disorders, that were to be prioritised for critical appraisal and data extraction. Another 66 reviews ([24](#_ENREF_24), [25](#_ENREF_25), [27](#_ENREF_27), [28](#_ENREF_28), [33-35](#_ENREF_33), [124](#_ENREF_124), [153](#_ENREF_153), [154](#_ENREF_154), [158](#_ENREF_158), [159](#_ENREF_159), [161](#_ENREF_161), [163-166](#_ENREF_163), [168](#_ENREF_168), [169](#_ENREF_169), [171](#_ENREF_171), [172](#_ENREF_172), [174](#_ENREF_174), [178](#_ENREF_178), [385-427](#_ENREF_385)) were earmarked for assessment as they were umbrella reviews published in 2018 or after that presented results in a meta-analysis and included primary studies in people with diabetes or pre-diabetes. Many of these reviews were focused on one or 2 outcomes considered critical or important for this review (i.e. glycaemic control, body composition) but many were focused on outcomes not considered critical or important for this overview (such as lipid profiles, blood pressure, oxidative stress and inflammatory biomarkers; See appendix D).

The remaining 77 reviews ([64](#_ENREF_64), [113](#_ENREF_113), [181](#_ENREF_181), [183](#_ENREF_183), [189](#_ENREF_189), [193](#_ENREF_193), [194](#_ENREF_194), [197](#_ENREF_197), [199](#_ENREF_199), [219](#_ENREF_219), [255](#_ENREF_255), [257](#_ENREF_257), [296](#_ENREF_296), [428-490](#_ENREF_428)) were judged likely to no longer represent the best available evidence or likely to not adequately report data of included primary studies.

Given the time and resource constraints further assessment of these reviews was not able to be performed (see NHMRC process report for additional information).

## Metabolic syndrome

### Description of the condition

Metabolic syndrome is not a disease state, but a collective term used to describe risk factors frequently associated with cardiovascular diseases and type 2 diabetes ([491](#_ENREF_491)). The risk factors correlated with metabolic syndrome include excessive waist circumference, lipid abnormalities, hypertension and elevated glucose levels ([492](#_ENREF_492)). Precise definitions of metabolic syndrome vary but generally encompass its efficacy in identifying cardiovascular diseases and diabetes in people who may be suitable for preventive therapy but would otherwise not be treated ([491](#_ENREF_491)).

In Australia, metabolic syndrome is becoming increasingly common due to the rise in obesity and sedentary lifestyle behaviours. The clinical diagnosis of metabolic syndrome has been used to predict individuals at risk of cardiovascular disease, diabetes and chronic kidney disease ([491](#_ENREF_491), [492](#_ENREF_492)). An estimated 33.5% of Australians aged over 12 have metabolic syndrome, with the prevalence higher in women than men ([493](#_ENREF_493)).

Changes in lifestyle behaviour are essential preventative methods for managing chronic comorbidities and preventing metabolic conditions. Individuals who were obese are 6 times more likely to develop metabolic syndrome than individuals within a normal weight range ([492](#_ENREF_492)). The effects of complementary and alternative medicines on metabolic control are conflicting due to deficiencies in the robustness of evidence.

### Description of reviews

There were 70 citations ([24](#_ENREF_24), [25](#_ENREF_25), [33](#_ENREF_33), [113](#_ENREF_113), [124](#_ENREF_124), [159](#_ENREF_159), [161](#_ENREF_161), [164-166](#_ENREF_164), [168](#_ENREF_168), [170-172](#_ENREF_170), [174](#_ENREF_174), [183](#_ENREF_183), [189](#_ENREF_189), [190](#_ENREF_190), [193](#_ENREF_193), [219](#_ENREF_219), [227](#_ENREF_227), [242](#_ENREF_242), [256](#_ENREF_256), [374](#_ENREF_374), [381](#_ENREF_381), [383](#_ENREF_383), [384](#_ENREF_384), [386](#_ENREF_386), [388](#_ENREF_388), [390](#_ENREF_390), [391](#_ENREF_391), [397](#_ENREF_397), [398](#_ENREF_398), [400](#_ENREF_400), [402](#_ENREF_402), [404](#_ENREF_404), [405](#_ENREF_405), [409-414](#_ENREF_409), [416-418](#_ENREF_416), [420](#_ENREF_420), [422](#_ENREF_422), [424](#_ENREF_424), [426](#_ENREF_426), [431](#_ENREF_431), [433](#_ENREF_433), [437](#_ENREF_437), [447](#_ENREF_447), [463-465](#_ENREF_463), [470](#_ENREF_470), [475](#_ENREF_475), [494-503](#_ENREF_494)) corresponding to 70 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with metabolic syndrome. No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were 3 systematic reviews awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the 70 eligible systematic reviews is provided in Appendix D4.2.1.

There were 12 reviews ([165](#_ENREF_165), [374](#_ENREF_374), [381](#_ENREF_381), [383](#_ENREF_383), [384](#_ENREF_384), [390](#_ENREF_390), [416](#_ENREF_416), [417](#_ENREF_417), [494-497](#_ENREF_494)) that were published in 2018 or after that presented results in a meta-analysis and focused on people with metabolic syndrome or those at risk of cardiovascular disease, that were to be prioritised for critical appraisal and data extraction. Another 36 reviews ([24](#_ENREF_24), [25](#_ENREF_25), [33](#_ENREF_33), [124](#_ENREF_124), [159](#_ENREF_159), [161](#_ENREF_161), [164](#_ENREF_164), [166](#_ENREF_166), [168](#_ENREF_168), [170-172](#_ENREF_170), [174](#_ENREF_174), [242](#_ENREF_242), [386](#_ENREF_386), [388](#_ENREF_388), [391](#_ENREF_391), [397](#_ENREF_397), [398](#_ENREF_398), [400](#_ENREF_400), [402](#_ENREF_402), [404](#_ENREF_404), [405](#_ENREF_405), [409-414](#_ENREF_409), [418](#_ENREF_418), [420](#_ENREF_420), [422](#_ENREF_422), [424](#_ENREF_424), [426](#_ENREF_426), [498](#_ENREF_498), [499](#_ENREF_499)) were earmarked for assessment as they were umbrella reviews published in 2018 or after that presented results in a meta-analysis and included primary studies in people with metabolic syndrome. Many of these reviews were focused on one or 2 outcomes considered critical or important for this review (i.e. glycaemic control, body composition) but many were focused on outcomes not considered critical or important for this overview (such as lipid profiles, blood pressure, oxidative stress and inflammatory biomarkers).

The remaining 21 reviews ([113](#_ENREF_113), [183](#_ENREF_183), [189](#_ENREF_189), [190](#_ENREF_190), [193](#_ENREF_193), [219](#_ENREF_219), [227](#_ENREF_227), [256](#_ENREF_256), [431](#_ENREF_431), [433](#_ENREF_433), [437](#_ENREF_437), [447](#_ENREF_447), [463-465](#_ENREF_463), [470](#_ENREF_470), [475](#_ENREF_475), [500-503](#_ENREF_500)) were judged likely to no longer represent the best available evidence or likely to not adequately report data of included primary studies.

Given the time and resource constraints, further assessment of these reviews was not able to be performed.

## Fatigue conditions (postviral fatigue, ME/CFS etc.)

### Description of the condition

Fatigue is defined as a constant feeling of tiredness and prolonged weariness that is not relieved by rest ([504](#_ENREF_504)). The onset of fatigue may be acute or insidious, with chronic fatigue typically experienced with greater intensity and longer duration, impacting daily life, functional activity and quality of life ([505](#_ENREF_505)). There are a broad range of factors contributing to the onset of fatigue, including underlying diseases and psychological, social and behavioural factors ([504](#_ENREF_504)). Postviral fatigue, idiopathic fatigue and Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) are conditions with limited understanding but are typically characterised by substantial fatigue following exertion, unsatisfactory rest or sleep and cognitive difficulties ([506](#_ENREF_506)). Classified as a neurologic disorder, ME/CFS is a complex illness that can affect many parts of the body, including muscles, cardiac, immune, and digestive systems, and can be associated with a variety of additional symptoms such as orthostatic intolerance and fibromyalgia ([507](#_ENREF_507), [508](#_ENREF_508)). While the cause of ME/CFS is not known, many people with ME/CFS often develop symptoms after a viral infection, with postviral fatigue (including long COVID) presenting with a similar diverse range of symptoms ([507](#_ENREF_507)).

Globally, ME/CFS prevalence is estimated to be around 1%, affecting approximately twice as many women as men ([506](#_ENREF_506)). However, these estimates are dependent on the diagnostic methods and case definitions used. In Australia, an estimated 250,000 individuals are affected by ME/CFS, with 25% presenting with severe symptoms, ultimately becoming housebound or bedbound ([506](#_ENREF_506), [507](#_ENREF_507)).

Diagnosis for ME/CFS and other fatigue conditions is often overlooked and difficult to identify due to varied definitions and established clinical diagnostic criteria ([509](#_ENREF_509)). Treatment guidelines for chronic fatigue are based on symptomatic management, routine follow-up with a general practitioner, and investigation of co-occurring conditions such as fibromyalgia and postural orthostatic tachycardia syndrome ([510](#_ENREF_510)). Alternative medicines for fatigue are aimed towards symptomatic relief and improvement in quality of life, as traditional pharmaceutical treatments are not available ([511](#_ENREF_511), [512](#_ENREF_512)).

### Description of reviews

There were 8 citations ([256](#_ENREF_256), [265](#_ENREF_265), [513-518](#_ENREF_513)) corresponding to 8 systematic reviews (Alraek 2011, Arring 2018, Bach 2016, Jin 2020, Kim 2020, Lopresti 2021, Ogawa-Ochiai 2018, Provino 2010) identified in the literature search that evaluated the effectiveness of WHMs in people with fatigue conditions. There were no additional reviews identified in the Department’s public call for evidence (see Appendix C2), no systematic reviews awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the 8 eligible systematic reviews is provided in Appendix D5.1.1.

The populations eligible for inclusion in the reviews were participants with chronic fatigue syndrome (Alraek 2011, Kim 2020, Jin 2020) or participants with fatigue (Arring 2018). Four reviews had no population restrictions but presented results where fatigue was measured as an outcome (Bach 2016, Lopresti 2021, Ogawa-Ochiai 2018, Provino 2010).

Three (3) of the reviews (Bach 2016, Jin 2020, Kim 2020) presented results in a meta-analysis and were prioritised for critical appraisal and data extraction. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 7 RCTs that met our PICO criteria, all of which examined the effect of ginseng compared with placebo. The included RCTs were conducted in Korea (Kim 2013), Iran (Etemadifar 2013), the United States (Hartz 2004) or not specified (Kim 2016, Lee 2016, Hyeong-Geug 2013, Le Gal 1996) and examined the effects of panax ginseng (Kim 2016, Lee 2016, Etemadifar 2013, Hyeong-Geug 2013, Kim 2013, Le Gal 1996) or Siberian ginseng (Hartz 2004) among people with chronic fatigue (Kim 2013, Hartz 2004) or multiple sclerosis (Etemadifar 2013). Sample sizes ranged from 46 to 218 (total 724 participants). All 7 RCTs compared WHM with placebo, with treatment delivered over 4 weeks (Kim 2016, Lee 2016, Hyeong-Geug 2013, Kim 2013), 6 weeks (Le Gal 1996), 8 weeks (Hartz 2004) or 12 weeks (Etemadifar 2013).

An overlap table of the RCTs within the included systematic reviews is shown in Table 12.

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.13.5). There were no studies found for the Secondary Comparison: WHM versus inactive control (no intervention, usual care [if inactive]) or the Tertiary Comparison (WHM versus active comparators). Additional details are provided in Appendix F2.

Table 12 List of included systematic reviews and overlap with eligible RCTs (per outcome): Fatigue conditions

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available\* | Prioritised outcome domain | Study ID | | | | | | |
| Kim 2016 | Lee 2016 | Kim 2013 | Etemadifar 2013 | Hyeong-Geug 2013 | Hartz 2004 | Le Gal 1996 |
| Jin 2020\* | † | Fatigue | ? | ? | -- | -- | ? | ? | ! |
| Kim 2020 | ✓ | -- | -- | -- | -- | -- | Y | -- |
| Bach 2016 | ✓ | -- | -- | Y | Y | -- | -- | -- |
| Arring 2018 | X | -- | -- | ? | -- | -- | -- | ? |
| Alraek 2011 | X | -- | -- | -- | -- | -- | ? | -- |
| Provino 2010 | X | -- | -- | -- | -- | -- | -- | -- |
| Jin 2020\* | † | Quality of Life | ! | ? | -- | -- | ! | ! | ! |
| Jin 2020\* | † | Emotional functioning | ! | ! | -- | -- | ! | ? | ? |
| Lopresti 2021 | X | Nil | -- | -- | -- | -- | -- | -- | -- |
| Ogawa-Ochiai 2018 | X | Nil | -- | -- | -- | -- | -- | -- | -- |

\* Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B2 Framework for selecting the systematic review from which to extract data)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

\* Jin 2020: The authors did not present results (only p values provided) for listed outcomes. A meta-analysis for 'Clinical effect’ based on self-reported fatigue scales (fatigue score, fatigue severity or checklist of individual strength), but the threshold for ‘Clinical effect’ (dichotomous) was not specified. Due to time and resource constraints, retrieval of primary studies was not pursued.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review, meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, retrieval of primary studies was not pursued.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Risk of bias

None of the eligible RCTs were judged by the included systematic reviews to be at overall high risk of bias. Risk of bias assessments for the included RCTs as summarised by included systematic reviews are provided in Appendix F1.

Both Kim 2013 and Etemadifar 2013 were rated by Bach 2016 using the Jadad Scale ([234](#_ENREF_234)). Kim 2013 met 4 out of the 5 items on the Jadad scale, with concerns about not "using identical placebo". Etemadifar 2013 met all 5 items on the Jadad scale.

Hartz 2004 was assessed by Kim 2020 using the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)) and was judged to be at low risk of bias in the domains relating to selection, performance, detection and attrition bias. The study was judged to be at unclear risk of bias for selective outcome reporting.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

Seven (7) RCTs (Etemadifar 2013, Gal 1996, Hartz 2004, Hyeong-Geug 2013, Kim 2013, Kim 2016, Lee 2016) were found by the included systematic reviews that compared ginseng with placebo in people with fatigue conditions. Three (3) RCTs (Etemadifar 2013, Hartz 2004, Kim 2013) contributed data relevant to one outcome. Four (4) studies (Gal 1996, Hyeong-Geug 2013, Kim 2016, Lee 2016) could have contributed data but there was insufficient information in the reviews to make an assessment.

| WHM compared to placebo for fatigue conditions | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Fatigue conditions  **Setting:** Community  **Intervention:** WHM (ginseng)  **Comparison:** Placebo | | | | | | |
| Outcomes | **Anticipated absolute effects\* (95% CI)** | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| **Risk with Placebo** | **Risk with WHM** |
| Fatigue assessed with: various (higher is worse) follow-up: range 4 to 12 weeks | - | SMD **0.36 SD lower^**  (0.71 lower to 0.00 lower) | - | 185  (3 RCTs) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM may result in little to no difference in fatigue severity in people with fatigue conditions |
| Quality of life assessed with: SF-36 (higher is best)  scale range: 0 to 100  follow-up: 4 weeks | No results available for inclusion in the synthesis. | | - | (0 studies) †† | - | The effect of WHM on health-related quality of life in people with fatigue conditions is unknown. |
| Patient reported improvement | No measures assessed in eligible reviews. | | - | (0 studies) | - | The effect of WHM on patient reported improvement in people with fatigue conditions is unknown. |
| Emotional functioning assessed with: MASQ (higher is best)  scale range: unclear follow-up: 8 weeks | No results available for inclusion in the synthesis. | | - | (0 studies) ††† | - | The effect of WHM on emotional functioning in people with fatigue conditions is unknown. |
| Physical functioning | No measures assessed in eligible reviews. | | - | (0 studies) | - | The effect of WHM on physical functioning in people with fatigue conditions is unknown. |
| Sleep quality | No measures assessed in eligible reviews. | | - | (0 studies) | - | The effect of WHM on sleep quality in people with fatigue conditions is unknown. |
| Thinking/ concentration | No measures assessed in eligible reviews. | | - | (0 studies) | - | The effect of WHM on ability to concentration in people with fatigue conditions is unknown. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  † Data from 4 RCTs (539 participants) not included here because results were not adequately reported [missing information]. The studies reported conflicting results.  †† Data from one RCT (52 participants) not included here because results were not adequately reported [missing information]. The study was reported to show no difference between groups (p > 0.05).  ††† Data from one RCT (96 participants) not included here because results were not adequately reported [missing information]. The study was reported to show an effect (p < 0.05) favouring WHM.  **CI:** confidence interval; **MASQ:** Mood and anxiety symptom questionnaire; **RR:** risk ratio; **SF-36:** 36-item short form; **WHM:** Western Herbal Medicine | | | | | | |
| **GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Certainty of evidence not downgraded.

b. No serious inconsistency. Certainty of evidence not downgraded.

c. No serious indirectness. The available evidence is in people with chronic fatigue or multiple sclerosis taking ginseng and is directly generalisable to the Australian population with few caveats. It is possible that the herbs used in the studies are contrary to what is prescribed in Australia, but the evidence can be sensibly applied. Certainty of evidence not downgraded.

d. Serious imprecision. Wide confidence intervals (lower bound overlaps with no important difference). Certainty of evidence downgraded.

E Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Data were missing from 4 studies that reported conflicting results. Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There were no studies found by the included systematic reviews that compared WHM with control (no intervention, waitlist or usual care) in people with fatigue conditions. In the absence of evidence, the effect of WHM compared with control (no intervention, waitlist or usual care) on the prioritised outcomes in people with fatigue conditions is unknown.

#### Tertiary Comparison (vs active control)

No studies found. The effect of WHM compared with active controls on the prioritised outcomes in people with fatigue conditions is unknown.

### Forest plots

Outcomes results related to people with fatigue conditions is presented in Figure 26 (fatigue severity).

Figure 26 Forest plot of comparison: WHM vs placebo: Fatigue conditions – fatigue severity

P8433#yIS1

## Upper respiratory tract infection

### Description of the condition

Upper respiratory tract infections are an umbrella category of illnesses caused by various bacteria and viruses. URTIs generally affect the nose, sinuses, pharynx, larynx and large airways, involving swelling and self-limited irritation of the upper airways ([519](#_ENREF_519)). The most common URTIs seen by primary care physicians include common cold, sinusitis, pharyngitis, epiglottitis and laryngotracheitis ([520](#_ENREF_520)). Risk factors for acquiring URTIs include exposure to children and pets, individuals with a compromised autoimmune system, poor hand hygiene, being in crowded areas and seasonal influence ([519](#_ENREF_519), [521](#_ENREF_521)).

Globally, the burden of URTIs reached 17.2 billion people in 2019, with the incident number of cases increasing by 37 per cent between 1990 and 2019 ([522](#_ENREF_522)). In Australia, URTIs are the most commonly managed respiratory problem in general practices, with 6 out of 100 visits relating to URTIs ([523](#_ENREF_523)).

General treatment surrounds symptomatic relief, although antibiotics are given to treat infections of bacterial origin ([524](#_ENREF_524)). Alternative medicines for treating URTIs have been reported for use as symptomatic treatment ([525](#_ENREF_525)). However, further testing and review of high-quality evidence are needed to implement complementary and alternative medicines into routine clinical practice.

### Description of studies

There were 27 citations ([199](#_ENREF_199), [478](#_ENREF_478), [526-550](#_ENREF_526)) corresponding to 27 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with URTIs. No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were 3 systematic reviews awaiting classification (see Appendix C4) and one ongoing review (see Appendix C5).

A summary of the PICO criteria of the 27 eligible systematic reviews is provided in Appendix D5.2.1.

There were 7 reviews ([526-532](#_ENREF_526)) published in 2018 or after that presented results in a meta-analysis that were to be prioritised for critical appraisal and data extraction. The other 20 reviews were earmarked for assessment as they were judged likely to no longer represent the best available evidence ([199](#_ENREF_199), [533-541](#_ENREF_533)) or did not adequately report data of included primary studies ([478](#_ENREF_478), [542-550](#_ENREF_542)).

Given time and resource constraints, further assessment of these reviews was not able to be performed.

## Dermatitis and eczema

### Description of the condition

Dermatitis is characterised by red, itchy rashes as a nonspecific response to inflammation of the skin. Some types of dermatitis are chronic (e.g. contact dermatitis and atopic dermatitis) ([551](#_ENREF_551)). Contact dermatitis is caused by contact with external agents and can have an irritant or allergic cause. Around 70% of contact dermatitis cases are caused by an irritant ([552](#_ENREF_552)). Atopic dermatitis also known as eczema, is an inflammatory skin condition characterised by dry, itchy and irritated skin, occurring more frequently in children than adults ([553](#_ENREF_553)). It is not uncommon for patients to have both atopic dermatitis and contact dermatitis. Dermatitis and eczema can affect any area of the skin but often affects the face, behind the elbows and knees, wrists and ankles and are influenced by a combination of environmental and genetic factors ([554](#_ENREF_554), [555](#_ENREF_555)). Generally, there is usually no single trigger for an eczema flare ([551](#_ENREF_551)).

The global incidence rate of dermatitis between 2007 and 2017 was 13.0%, whereas 2.4% of the population worldwide were affected with eczema ([556](#_ENREF_556), [557](#_ENREF_557)). In Australia, the estimated lifetime prevalence of atopic dermatitis is 16.4% ([553](#_ENREF_553)). Overall, prevalence of eczema is higher in younger individuals than in older individuals, affecting approximately 30% of children and 10% of adults in Australia with infantile eczema affecting 1 in 5 children ([551](#_ENREF_551)).

The primary treatments for dermatitis and eczema are aimed at reduced exposure to allergens and irritant topical agents (e.g. topical corticosteroids) and application of topical nonsteroidal treatments (e.g. pimecrolimus, tar preparations, crisaborole). Medicated dressings and herbal preparations may also be considered for some patients ([558-560](#_ENREF_558)).

### Description of studies

There were 2 citations ([473](#_ENREF_473), [561](#_ENREF_561)) corresponding to 2 systematic reviews identified in the literature search that evaluated the effectiveness of WHMs in people with dermatitis or eczema. No additional reviews were identified in the Department’s public call for evidence (see Appendix C2). There were no systematic reviews awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

Both reviews provided a narrative summary of primary study results examining the effect of WHM on people with dermatitis or eczema (Thandar 2017, Vaughn 2016). The reviews failed to provide any meaningful data for inclusion in a meta-analysis (with both reviews simply noting the benefits or harms of the intervention). In the absence of data, no further assessment of these reviews was made and the effect of WHM on dermatitis or eczema is unknown.

## Acne

### Description of the condition

Acne vulgaris is a chronic, inflammatory skin condition caused by a blockage of the hair follicle, increased sebum production, bacterial colonisation and inflammation ([562](#_ENREF_562)). The condition generally develops during adolescence and may resolve during adulthood, predominately affecting more women than men ([562](#_ENREF_562), [563](#_ENREF_563)). Individuals begin to experience whiteheads, blackheads and inflamed pus-filled lesions in area of the body producing excess sebum, such as the face, chest or back. Other clinical variants of acne exist (e.g. acne conglobate and acne fulminans) but are rare in occurrence. These clinical variants are more severe and typically affect young males ([564](#_ENREF_564), [565](#_ENREF_565)).

The global prevalence of acne is estimated to be 9.4% of the population, predominantly affecting teenagers and young adults ([566](#_ENREF_566)). In Australia, acne is considered almost universal in teenagers with an estimated prevalence of 93.3% in individuals aged 16 to 18 years ([567](#_ENREF_567)). Acne can persist beyond adolescence with women typically more affected than men ([568](#_ENREF_568)). There are many factors contributing to the cause of acne including hormonal changes often seen during puberty, environment, genetics and stress. Certain foods (e.g. whey protein, diets high in sugar) are suggested to contribute to the development of acne however robust evidence associating diet with acne is lacking ([563](#_ENREF_563), [569](#_ENREF_569)).

Current treatments for managing acne include improved face hygiene with soap-free face wash, the use of oil-free products and avoidance of triggers (e.g. oily substances, friction with clothes or other objects). Pharmacotherapies are also prescribed to clear severe acne and reduce scarring, this includes topical retinoids, antibiotics and oral isotretinoin ([570](#_ENREF_570)). Individuals with acne also often use herbal medicines or other complementary medicines to avoid potential side effects associated with pharmacotherapies ([360](#_ENREF_360)), with the aim of reducing inflammation, balancing hormones, restoring the skin’s natural oils or reducing bacterial load.

### Description of reviews

There were 5 citations ([473](#_ENREF_473), [490](#_ENREF_490), [571-573](#_ENREF_571)) corresponding to 5 systematic reviews (Kim 2021, Vaughn 2016, Tuong 2015, Ernst 2002, Volger 1999) identified in the literature search that evaluated the effectiveness of WHM in people with acne. There were no additional reviews identified in the Department’s public call for evidence (see Appendix C2), no systematic reviews awaiting classification (see Appendix C4) and no ongoing reviews (see Appendix C5).

A summary of the PICO criteria of the 5 eligible systematic reviews is provided in Appendix D5.4.1.

The populations eligible for inclusion in the reviews were participants with acne vulgaris (Kim 2021) or subjects diagnosed with a skin condition (Vaughn 2016, Tuong 2015, Ernst 2002). One review had no population restrictions but included a study in people with acne (Vogler 1999).

There was one review (Kim 2021) that presented results in a meta-analysis that was prioritised for critical appraisal and data extraction. Review details, including outcome domains and measures, and the risk of bias of eligible RCTs are provided in Appendix F1.

### Description of studies

Within the eligible systematic reviews, there were 9 RCTs that met our PICO criteria. Five (5) RCTs examined the effect of WHM compared with placebo (Lu 2016, Yoon 2013, Sharquie 2006, Lalla 2001) or control (no intervention) (Jung 2012). The other 3 RCTs (Sahrquie 2008, Waranuch 2019, Basset 1990) compared WHM with an active intervention (e.g. 1% clindamycin gel, 5% benzoyl peroxide solution).

An overlap table of the RCTs within the included systematic reviews is shown in Table 2.

The RCTs were conducted in Taiwan, Iraq, South Korea or not specified and examined the effects of green tea extract15F[[16]](#footnote-17) (Lu 2016, Yoon 2013, Jung 2012, Sharquie 2008, Sharquie 2006), tea tree oil (Bassett 1990), aloe vera (Fulton 1990) or an herbal combination containing green tea extract (Waranuch 2019) or curcumin (Lu 2001). Sample sizes ranged from 17 to 124 (total 488 participants). The interventions were administered over 4 (Waranuch 2019, Lu 2016, Lalla 2001), 8 (Yoon 2013, Jung 2012, Sharquie 2008, Sharquie 2006) or 12 weeks (Basset 1990) (or unclear Fulton 1990). None of the identified herbs matched to the Tier 1 herbs included in the Western herbal medicine curriculum for immune conditions (i.e. most commonly taught in Australian curriculum for this condition; see Appendix A6.3).

Results for the Primary Comparison: WHM versus placebo are provided in the Summary of Findings tables (see Section 4.16.5). There was one study found for the Secondary Comparison: WHM versus inactive control (no intervention, usual care [if inactive]), however it failed to provide any meaningful data for inclusion. Results for the Tertiary Comparison (versus active comparators) are provided in Appendix F2.

Table 13 List of included systematic reviews and overlap with eligible RCTs (per outcome): Acne

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Review ID | Best available\* | Prioritised outcome domain | Study ID | | | | | | | | |
| Waranuch 2019 | Lu 2016 | Yoon 2013 | Jung 2012 | Sharquie 2008 | Sharquie 2006 | Lalla 2001 | Basset 1990 | Fulton 1990 |
| Kim 2021 | ✓ | Disease improvement  (acne lesion count) | Y | Y | Y | -- | Y | Y | -- | -- | -- |
| Patient subjective assessment (VAS) | ! | ! | Y | -- | ! | ! | -- | -- | -- |
| Vaughn 2016 | X | Disease improvement  (Leed’s score) | -- | -- | -- | -- | -- | -- | ? | -- | -- |
| Tuong 2015 | X | Disease improvement  (acne lesion count) | -- | -- | -- | ? | -- | -- | -- | -- | -- |
| Ernst 2002 | X | Disease improvement  (acne lesion count) | -- | -- | -- | -- | -- | -- | -- | ? | ! |
| Vogler 1999 | X | Disease improvement  (acne lesion count) | -- | -- | -- | -- | -- | -- | -- | -- | ! |

Abbreviations: VAS, visual analogue scale

\* Best available information means the systematic review meets AMSTAR-2 domains 4, 8, 9, & 11 (see Appendix B1 Framework for selecting the systematic review from which to extract data)

✓ Systematic review meets (or partially meets) prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

† Systematic review meets (or partially meets) some, but not all, prespecified critical AMSTAR-2 domains (4, 8, 9 & 11).

X Systematic review does not meet prespecified critical AMSTAR-2 domain 11 and was not further assessed.

Y RCT is included in the systematic review, meets our PICO criteria & a study result is available for inclusion in the synthesis.

? RCT is included in the systematic review, meets our PICO criteria, but the systematic review does not adequately report the results. Due to time and resource constraints, retrieval of primary studies was not pursued.

! RCT is included in the systematic review but does not measure the listed outcome.

-- RCT is not included in systematic review.

### Risk of bias

Risk of bias assessment for the eligible RCTs as summarised by included systematic reviews are provided in Appendix F1.

Five RCTs were assessed by Kim 2021 using the Cochrane Collaboration’s risk of bias assessment tool ([54](#_ENREF_54)). The other RCTs were assessed using a 5- or 7-point Jadad scale ([234](#_ENREF_234)).

Four RCTs (Lu 2019, Waranuch 2019, Yoon 2013, Lalla 2001) were at overall low risk of bias and in one RCT (Sharquie 2008) the risk of bias was unclear. The other 3 RCTs (Jung 2012, Fulton 19909, Sharquie 2008) were judged by the included systematic reviews to be at overall high risk of bias. An assessment of bias for one RCT (Bassett 1990) was not provided.

### Summary of findings and evidence statements

#### Primary Comparison (vs placebo)

There were 3 RCTs (Lu 2016, Sharquie 2006, Yoon 2013) found by the included systematic review that compared green tea with placebo in people with acne and contributed to data relevant to 2 of the 5 critical or important outcomes. One other RCT (Lalla 2001) did not contribute any data.

There were no studies awaiting classification or ongoing that compared WHM with placebo in people with acne.

| WHM compared to placebo for Acne | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient or population:** Acne  **Setting:** Community  **Intervention:** WHM (green tea)  **Comparison:** Placebo | | | | | | |
| Outcomes | **Anticipated absolute effects**\* **(95% CI)** | | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Evidence statement |
| **Risk with control** | **Risk with WHM** |
| Patient reported improvement assessed with: VAS scale range: 0 to 10 (higher is worse) follow-up: 8 weeks | The mean change in VAS score was **1.2 points** | **MD 4.61 lower** (3.23 lower to 5.98 lower) | - | 70 (1 RCT) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM may result in a large improvement in global symptoms in people with acne. # |
| Quality of Life | - | - | - | (0 studies) | - | The effect of WHM on quality of life in people with acne is unknown. |
| Emotional functioning | - | - | - | (0 studies) | - | The effect of WHM on emotional functioning in people with acne is unknown. |
| Physical functioning | - | - | - | (0 studies) | - | The effect of WHM on physical functioning in people with acne is unknown. |
| Disease severity assessed with: inflammatory acne lesion count scale range: 0 to >150 (higher is worse) follow-up: range 4 to 8 weeks | - | **SMD 3.59 SD lower ^** (5.97 lower to 1.20 lower) | - | 183 (3 RCTs) † | ⨁⨁◯◯ Low a,b,c,d,e | WHM may result in a large reduction in disease severity (inflammatory lesions) in people with acne. |
| Disease severity assessed with: noninflammatory acne lesion count  scale range: 0 to >150 (higher is worse) follow-up: range 4 to 8 weeks |  | **SMD 0.73 SD lower ^** (6.44 lower to 4.99 higher) | - | 134 (2 RCTs) † | ⨁◯◯◯ Very Low a,c,e,f,g | The evidence is very uncertain about the effect of WHM on disease severity (noninflammatory lesions) in people with acne. |
| \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  ^ As a rule of thumb, an SMD of 0.2 represents a small difference, 0.5 is moderate, and 0.8 is a large difference ([55](#_ENREF_55)).  # In the absence of an MCID, effect estimates were considered on three levels: small (MD <10% of the scale), moderate (MD between 10% to 20% of the scale) or large (MD more than 20% of the scale).  † One RCT was considered as 2 separate studies in this analysis as it examined different concentrations of green tea extract independently in a split-face trial design.  **CI:** confidence interval; **MD:** mean difference; **SD:** standard deviations; **SMD:** standardised mean difference; **VAS:** visual analogue scale; **WHM,** Western herbal medicine | | | | | | |
| **GRADE Working Group grades of evidence High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty**: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | | | | | | |

Explanations

a. No serious risk of bias. Certainty of evidence not downgraded.

b. Serious inconsistency. Substantial statistical heterogeneity (I2 = 90%) that cannot be explained. Certainty of evidence downgraded.

c. No serious indirectness. The evidence is in people with acne vulgaris and is directly applicable to the Australian healthcare context with few caveats. It is possible that the herbs used in the studies are contrary to what is prescribed in Australia, but the evidence can be sensibly applied. Certainty of evidence not downgraded.

d. No serious imprecision. Certainty of evidence not downgraded.

e. Publication bias suspected. There is a strong suspicion of non-reporting of results likely related to the p value, direction or magnitude of effect. Certainty of evidence downgraded.

f. Very serious inconsistency. Point estimates vary and confidence intervals do not overlap. Substantial statistical heterogeneity (I2 > 90%) that cannot be explained. Certainty of evidence downgraded 2 levels.

g. Serious imprecision. Wide confidence intervals (upper and lower bounds overlap with both large and no important differences). Certainty of evidence downgraded.

#### Secondary Comparison (vs inactive control)

There was one RCT found by the included systematic reviews that compared WHM with control (no intervention, waitlist, usual care [if inactive]) in people with acne. The review did not provide any usable data. In the absence of evidence, the effect of WHM compared with inactive control on the prioritised outcomes in people with acne is unknown.

#### Tertiary Comparison (vs active control)

There were 4 studies found by the included systematic reviews that compared WHM with active comparators (see Appendix F2).

### Forest plots

Outcomes results for people with acne is presented in Figure 27 (global improvement) and Figure 28 (disease severity).

Figure 27 Forest plot of comparison: WHM vs placebo: Acne vulgaris - Global improvement (patient reported)

P8681#yIS1

Abbreviation: EGCG, epigallocatechin-3-gallate solution (green tea extract); VAS, visual analogue scale

Figure 28 Forest plot of comparison: WHM vs placebo: Acne vulgaris - Disease severity (acne lesion count)

P8684#yIS1

Abbreviations: EGCG, epigallocatechin-3-gallate (green tea extract) solution

# Discussion

## Summary of main results

We conducted a systematic review of systematic reviews (an overview) to evaluate the effectiveness of WHM for 16 clinical or preclinical conditions prioritised (by NTWC) as most relevant to the practice of WHM in Australia. We identified 402 systematic reviews that reported on critical or important outcomes and were included in the qualitative synthesis. The 2 comparators of interest were placebo and ‘inactive’ control. Evidence from 270 RCTs covering 11 conditions are include in the final analysis for Primary Comparison: WHM versus placebo presented in the summary of findings tables. There were 5 RCTs found for Secondary Comparison: WHM versus ‘inactive’ control covering 2 conditions (inflammatory bowel disease, menstrual conditions).

For the Tertiary comparison: WHM versus ‘active’ control, studies of prioritised conditions are described in the results section and data presented in Appendix F2. For one population (depression), results are presented in a summary of findings table, as there were several studies evaluating the effects of the same (or similar) WHM compared with the same (or similar) evidence-based treatment (a pre-specified criterion for presenting results). No other priority populations are included in the synthesis or summary of findings tables, as the wide range of comparators and outcomes did not allow for synthesis as planned in the protocol.

Given time and resource constraints, critical appraisal and synthesis of the evidence for 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome, and upper respiratory tract infections) were not able to be performed. The Natural Therapies Working Committee (NTWC) was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information).

Our confidence in the result from the body of evidence for each outcome was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. GRADE combines information to assess overall how certain systematic review authors can be that the estimates of the effect (reported across a study/s for each critical or important outcome) are correct.

Certainty of evidence is interpreted as follows:

|  |  |
| --- | --- |
| Certainty | Definition |
| High certainty | The authors have a lot of confidence that the true effect is similar to the estimated effect. |
| Moderate certainty | The true effect is probably close to the estimated effect. |
| Low certainty | The true effect may be markedly different from the estimated effect. |
| Very low certainty | The true effect is probably markedly different from the estimated effect |

For 11 prioritised conditions there was moderate or low certainty evidence about the effect of WHM on at least one of the outcomes considered critical or important by NTWC. The overview found, that compared with placebo, the evidence provides:

* moderate certainty evidence that WHM probably results in:
  + a large improvement (>20%) in pain intensity in people with menstrual conditions (7 RCTs, 601 participants) [WHM included ginger, cinnamon, valerian root or fenugreek]
  + a large increase (>20%) in patient-reported improvement in people with premenstrual disturbances (6 RCTs, 839 participants) [WHM included chaste tree berry]
  + a moderate increase (10-20%) in the proportion with clinical remission in people with inflammatory bowel disease (14 RCTs, 974 participants) [WHM included green tea extract, curcumin, Boswellia, aloe vera gel, Wormwood, St Mary’s thistle or Andrographis]
  + a moderate increase (10-20%) in the proportion with clinical improvement in people with irritable bowel syndrome (19 RCTs, 1279 participants) [WHM included peppermint oil, curcumin + fennel, Carmint + Psyllium, anise oil, aloe vera juice, ginger or St Jonh’s wort]
  + a moderate improvement (10-20%) in symptoms severity in people with symptoms of menopause (16 RCTs, 1680 participants) [WHM included black cohosh extract, alone or in combination with St John’s wort or red clover]
  + a moderate reduction (10-20%) in depressive symptoms in people with depression (33 RCTs, 3910 participants) [WHM included curcumin, saffron or St John’s wort]
  + a slight reduction (<10%) in anxiety in people with anxiety (20 RCTs, 2087 participants) [WHM included valerian root, kava, Passiflora, saffron, chamomile, ginkgo biloba or lavender].
* low certainty evidence that WHM may result in:
  + a large reduction (>20%) in depressive symptoms (5 RCTs 613 participants) and anxiety (2 RCTs, 208 participants), and a large improvement (>20%) in overall symptoms (8 RCTs, 1133 participants) in people with premenstrual disturbances [WHM included chaste tree]
  + a large reduction (>20%) in anxiety (5 RCTs, 397 participants) and a slight improvement (<10%) in emotional functioning (2 RCTs, 3587 participants) in people with depression [WHM included curcumin or saffron]
  + a large reduction (>20%) in disease severity (3 RCTs, 183 participants) and a large increase (>20%) in patient-reported improvement (1 RCT, 70 participants) in people with acne [WHM included green tea-oral, green tea-topical]
  + a moderate increase (10-20%) in the proportion with a clinical response (8 RCTs, 403 participants) in people with inflammatory bowel disease [WHM included green tea extract or curcumin]
  + a moderate reduction (10-20%) in abdominal pain intensity (7 RCTs, 606 participants) and a slight (<10%) increase in clinical improvement (3 RCTs, 236 participants) in people with irritable bowel syndrome [WHM included peppermint oil or aloe vera juice]
  + a moderate reduction (10-20%) in depressive symptoms (2 RCTs, 129 participants), a moderate improvement (10-20%) in global improvement (3 RCTs, 670 participants) and emotional functioning (2 RCTs, 508 participants) in people with anxiety [WHM included lavender, saffron, or chamomile]
  + a slight improvement (<10%) in physical functioning (2 RCTs 508 participants) and sleep quality (2 RCTs, 382 participants) in people with anxiety [WHM included lavender]
  + a moderate reduction in symptoms of fatigue (3 RCTs, 185 participants) in people with chronic fatigue conditions [WHM included Siberian ginseng or panax ginseng]
  + a slight reduction (<10%) in hot flush frequency (14 RCTs, 1355 participants) in people with symptoms of menopause [WHM included black cohosh, red clover, valerian, valerian root, St John’s wort or St John’s wort + chaste tree].
* moderate certainty evidence that WHM probably results in little (to no) change in:
  + sexual functioning in people with symptoms of menopause (7 RCTs, 887 participants) [WHM included ginseng, withania (ashwagandha), red clover or ginseng]
  + sleep quality in people with insomnia (5 RCTs, 946 participants) [WHM included chamomile, valerian or kava].
* low certainty evidence that WHM may result in little (to no) change in:
  + clinical improvement in people with inflammatory bowel disease (2 RCTs, 151 participants) [WHM included curcumin]
  + symptoms of anxiety in people with insomnia (2 RCTs, 425 participants) [WHM included kava, valerian or chamomile].

The evidence provides very low certainty of the effect of WHM compared with placebo for 6 critical or important outcomes prioritised for analysis in this review (across 4 conditions: menstrual conditions, symptoms of menopause, depression and acne). For these outcomes, the true effect is probably markedly different from the estimated effect, with more studies needed to determine the true effect.

Of the 104 outcomes prioritised as critical or important in this review, there were no studies found reporting on 43 of those outcomes and therefore, the effect of WHM on these outcomes is unknown. There were 2 conditions assessed in this review where the effect of using WHMs is unknown (reflux and dermatitis/eczema). The effect of WHM for 27 outcomes across 4 conditions was not assessed due to the volume of evidence, time and resource constraints. There are numerous systematic reviews examining the effect of WHM on these conditions, but preliminary data suggest the results are limited to one or 2 outcomes per condition.

Results for WHM compared to inactive control (e.g. waitlist) were also examined, but for the majority of conditions there were no results found. For 2 populations (IBD, menstrual conditions) the evidence was very uncertain.

Compared to active control, results were examined for one condition. Here, the evidence provides moderate certainty that WHM (St John’s wort) is probably comparable to antidepressants for improving symptoms of depression in people with depression. Results for all other conditions were listed but not assessed because they did not meet criteria prespecified in the protocol.

An assessment of harms of WHM was not conducted for this review, as it was out of scope of this review to assess adverse effects of WHM.

Overall, the evidence suggests that WHM may provide people with some benefit for a range of outcomes considered critical or important by the NTWC, when compared with placebo. There remain many outcomes for which the benefits are unknown.

## Overall completeness and applicability of evidence

The practice of Western herbalism includes a holistic treatment framework that includes a wider social, emotional, economical, spiritual and cultural framework. In the absence of studies that focus on Western herbalism as a practice, the overview has focused on individual herbal medicines. Extrapolation of the effect of these interventions may or may not reflect Western herbalism as a practise, and given the broad nature of the overview, it is difficult to specify if the included primary studies examined the individual WHM delivered in a manner that would be considered applicable to the Australian context.

The identified systematic reviews could be categorised as being:

* a review that focused on the effect of a single herb (or herbal extract) on a single condition (e.g. a review of the effectiveness of St John’s Wort on depression)
* an umbrella review that focused on the properties of a particular herb and its effectiveness across multiple conditions (e.g. effect of Nigella sativa across circulatory, endocrine and mental health conditions)
* an umbrella review that focused on a particular condition and examined the effectiveness of various interventions for that condition (e.g. a review of pharmacological and non-pharmacological interventions for insomnia)

an umbrella review that focused on a particular outcome and searched for herbal medicines (or other intervention) shown to be effective for that outcome (e.g. herbal medicines that improve blood pressure).

This overview aimed to compile the evidence from systematic reviews of RCTs and quasi RCTs to assess the effectiveness of WHM in conditions prioritised by the NTWC. Only studies that assessed WHM versus placebo or WHM versus inactive control (no intervention, waitlist, usual care if considered inactive) were included in the synthesis. Studies of prioritised conditions with active comparators were not able to be included in the synthesis or summary of findings tables (except depression), as the wide range of comparators and outcomes did not allow for synthesis as planned in the protocol. There are 192 systematic reviews covering 4 conditions prioritised by the NTWC that have been earmarked for assessment, but given time and resources, critical appraisal and data synthesis were not completed.

There were 452 systematic reviews that met the eligibility criteria for the overview but were not included in the evidence evaluation. This is because they either examined the effects of WHMs in populations (or conditions) not prioritised by NTWC for analysis or synthesis (396 reviews) or they were conducted in populations that were of lower priority (56 reviews). These studies are listed in an inventory titled Citation details of systematic reviews of low and non-priority populations (Appendix C3).

Databases in languages other than English were not searched. Studies published in a language other than English (identified through English databases) were not translated and were not included in the synthesis but are listed in an inventory for completeness (Appendix C4.2). There were 124 reviews identified in a language other than English. There is no reason to suspect that the results of the reviews awaiting classification would differ substantially from those published in English or change the reviews overall conclusions.

The primary studies included within the eligible reviews were conducted in a range of countries including Australia, Brazil, Canada, China, Germany, Greece, India, Iran, Israel, New Zealand, South Korea, Spain, Sweden, the Netherlands, the United Kingdom and the United States. For some herbs, there tended to be a disproportionate number of studies from one region (e.g. many studies relating to effect of saffron were conducted in Iran, whereas studies in lavender extract were conducted in Germany). The primary studies identified by the reviews were often conducted over a 6 to 12-week time-period, with some studies examining the effect of the WHM for a slightly longer timeframe (24 weeks). Few, if any, provided any longer-term data (WHM administered for longer than 52 weeks).

The included primary studies were generally assumed to have provided a description of the condition and interventions examined in the study, however the reporting of this within the systematic reviews was often limited. This is because they often did not capture details about the participants comorbidities and did not provide complete details about the herbal product (such as mode of delivery, how often, how much etc.). The systematic reviews also often did not describe all the outcomes measured by the primary study (although it is possible this information was also missing from the primary study). There were also issues with determining if the data reported by the reviews were end of treatment scores, or differences in means from baseline. As per the protocol, we made no attempt to retrieve this information from the primary studies. For the outcomes with available evidence, it is considered unlikely this information would have impacted the overall conclusions of this review. However, it is possible that some of the outcomes with minimal or no information (i.e. the effect of WHM is uncertain or unknown) have been assessed by the primary studies, but the results have not been captured in the published systematic reviews. This may be because the results are not favourable to the intervention but, may also be because the reviews simply were not focused on that outcome. Among the 11 prioritised conditions for WHM versus placebo (not including the 5 conditions awaiting assessment), 45 (~58%) out of the 77 outcomes prioritised as critical or important for this overview were not reported by the included reviews.

Systematic reviews included in this overview are those published up until April 2021. At the time of the search, there were 199 reviews awaiting classification (67 in priority populations) and 39 ongoing reviews (11 in priority populations) that would meet the eligibility criteria for this overview. These reviews (awaiting classification and ongoing) appear comparable to those included in the evidence synthesis in terms of population, WHM and outcomes measured. There is no reason to suspect that the results of the reviews would differ substantially from those already included in this overview.

## Certainty of the evidence

The certainty of evidence across outcomes was generally downgraded for issues with imprecision (related to sample size and wide confidence intervals that were compatible with both important benefit and little or no difference). In rare instances, the certainty of evidence was downgraded for inconsistency, when the effect estimates differed importantly across studies, as indicated by minimal or no overlap in the confidence intervals, and no clear explanation for statistical heterogeneity. We did not downgrade for indirectness, although in some cases note that the studies may not be directly applicable to the Australian healthcare context, meaning the delivery of the intervention or the participants included within the trial may have unknown factors that do not directly match the WHM as delivered in Australia.

The certainty of evidence was downgraded due to serious risk of bias when sensitivity analysis showed clear interaction between the effect estimates and the studies judged to be at high risk of bias. It is noted that we did not independently assess the risk of bias of the primary studies and instead relied upon the published systematic reviews to provide this information. At times, we noted disagreement between reviews with regards to risk of bias assessments for the same study, but as per protocol, did not return to the primary studies to conduct our own assessment.

## Potential biases in the review process

To ensure transparency in the review process, we published the final NTWC-endorsed research protocol on PROSPERO. To capture the majority of reviews assessing the effectiveness of WHMs, we comprehensively searched multiple databases and did not apply date, language, population or outcome restrictions in our search. Screening was performed by 2 reviewers (independently). In addition, we provided detailed documentation of the inclusion criteria to avoid inconsistent application of study selection criteria and used standardised procedures for data collection and critical appraisal. Where possible, we have applied a methodological approach consistent with the Cochrane Handbook for Systematic Reviews of Interventions and other best practice methods.

Data collection was performed by two reviewers, the first collected data using data extraction forms and the second checked for completeness and accuracy in data extraction. Decisions regarding prioritisation of conditions and critical or important outcomes were made by the NTWC, with input from NTREAP, who were blinded to the number and details of the studies found.

While we have attempted to control for potential biases, some deviations from the protocol were necessary for pragmatic reasons. To ensure these deviations from protocol are clear, deviations and post-hoc decisions have been documented and explained in **Appendix G**.

## Limitations

### At review level

This overview was limited to the assessment of the evidence for certain conditions and groups of people to inform the Australian Government about health policy decisions for private health insurance rebates. This review was not designed to assess all the reasons that people seek out WHM, or the reasons practitioners prescribe WHM and was not intended to inform individual choices about Western herbalism, individual herbs, extracts of herb or combinations of herbs. Conditions were prioritised by NTWC, who were guided by relevant patient and/or practitioner reported Australian survey data (where available) and expert advice from NTREAP during the prioritisation process. The priority list was intended to represent the key conditions for which an individual would consult with a Western herbalist in Australia (not for which an individual would purchase over-the-counter herbal products). Given the large number of studies identified across a diverse range of conditions and as agreed a priori, the evidence synthesis was limited to 11 priority conditions. The breadth and diversity of conditions identified for inclusion in this overview means that it is possible that some interventions, conditions, outcome domains and outcome measures may have been misclassified or missed during the outcome prioritisation process.

In the absence of studies that focus on Western herbalism as a practice, the overview has focused on individual herbal medicines. This approach limits the ability to assess a key part of Western herbalism as a practice, being diagnosis and prescribing of the most appropriate individual herb (or herb combinations). Given the size of the overview, detailed descriptions and follow-up about the herbal preparation (e.g. liquid extracts, herbs, tablet or capsule) used within the primary studies was not pursued. The overview has therefore not considered whether the individual WHMs identified in the primary studies for a condition correlate with that typically prescribed by Western herbalists in Australia for that condition (in terms of herb(s), dose or preparation prescribed).

The 2 main comparators of interest were WHM compared to placebo or WHM compared to an inactive control (no intervention, waitlist or usual care) with the outcomes assessed limited to those deemed critical or important by NTWC for each condition. The available evidence was often limited to between one and 3 critical or important outcomes per condition. The effectiveness of WHM compared with other active comparators was not assessed for most conditions. Data from these studies are listed in Appendix F2. It is unknown whether the results of these studies would impact the overall conclusions of this review.

It was out of scope of the review to assess safety. Information regarding the sustainability of the effect is also unknown as the overview did not assess any follow‐up data (noting neither did any of the included reviews).

Systematic reviews included in this overview are those published up until April 2021. It is likely there are numerous reviews that have been published after this search date and would meet the eligibility criteria for this overview. There is no reason to suspect that the results of the reviews would differ substantially from those already identified in this overview; however, it is possible a search for primary studies targeted to a defined condition would increase the certainty of evidence across some outcomes.

# Authors' conclusions

## Implications for health policy

This report was commissioned by the Australian Government as part of the Natural Therapies Review, with findings intended to inform decisions relating to whether private health insurance cover should be reinstated to WHM. As such, specific recommendations are not provided.

While there remains an absence of high certainty evidence about the effectiveness of individual WHMs compared with placebo for the 11 priority conditions and outcomes that align with the reasons why consumers commonly use WHMs in Australia, there is moderate to low certainty for certain individual WHMs to improve outcomes in a variety of common health conditions.

There are 7 conditions for which the evidence provides moderate certainty of benefit for at least one outcome (inflammatory bowel disease, irritable bowel syndrome, menstrual conditions, premenstrual disturbances, symptoms of menopause, anxiety, depression) and 2 conditions for which the evidence provides low certainty of benefit for at least one outcome (chronic fatigue, acne). In contrast, there was one condition where the evidence provides moderate and low certainty that WHM provides little to no benefit for 2 outcomes (insomnia). The effect of WHM is unknown in two conditions (GORD and dermatitis/eczema) due to lack of usable data. The effect of WHM for 4 of the 16 prioritised conditions (diabetes, impaired glucose tolerance, metabolic syndrome and upper respiratory tract infections) was not assessed due to the volume of evidence, time and resource constraints. The Natural Therapies Working Committee (NTWC) was not involved in selection of which prioritised conditions were completed versus not completed (see NHMRC process report for additional information).

## Implications for research

Trials evaluating the effectiveness of individual WHMs compared with placebo are in abundance. However, the available evidence could be enhanced by measuring and reporting outcomes that are considered critical or important for decision-making in Australia. Many of the studies focused on the effect of WHM in participants who received treatment for 12 weeks or less, so it is possible the benefits of WHM may be more apparent in people who continue using the WHM for more than 12 weeks. Information about the sustainability of the effect would also be valuable. Most important, however, is the need for clinical trials that focus on the broader research question about the effectiveness of Western herbalism as a health service.

References

1. Department of Health. The 2015 Review of the Australian Government Rebate on Private Health Insurance for Natural Therapies Canberra ACT: Commonwealth of Australia; 2019.

2. Higgins JPT, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, et al., (editors). Methodological Expectations of Cochrane Intervention Reviews. London: Cochrane; 2019 [cited 2019]. Available from: https://community.cochrane.org/mecir-manual.

3. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

4. Churchill R, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, et al. Standards for the reporting of new Cochrane Intervention Reviews. 2019 [cited 4 June 2020]. In: Methodological Expectations of Cochrane Intervention Reviews [Internet]. London: Cochrane, [cited 4 June 2020]. Available from: https://community.cochrane.org/mecir-manual/standards-reporting-new-cochrane-intervention-reviews-r1-r109.

5. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet]. 2013. [Accessed; (Updated October 2013). Available from: https://gdt.gradepro.org/app/handbook/handbook.html.

6. The Australasian Cochrane Centre. Review of the Australian Government Rebate on Private Health Insurance for Natural Therapies. Part A - Overview report for herbalism as a health service Monash University 2014.

7. Wohlmuth H, Oliver C, Nathan PJ. A review of the status of Western herbal medicine in Australia. *J Herb Pharmacother*. 2002;2(2):33-46.

8. Lin V, McCabe P, Bensoussan A, Myers S, Cohen M, Hill S, et al. The practice and regulatory requirements of naturopathy and western herbal medicine in Australia. *Risk Manag Healthc Policy*. 2009;2:21-33. https://doi.org/10.2147/RMHP.S4652

9. National Herbalists Association of Australia. Review of the Australian Government rebate on private health insurance for Natural Therapies. 2013 [Available from: https://www.nhaa.org.au/docs/Submissions/NHAA\_Private\_Health\_Insurance\_Submission\_\_29\_01\_2013\_.pdf.

10. Casey MG, Adams J, Sibbritt D. An examination of the prescription and dispensing of medicines by Western herbal therapists: a national survey in Australia. *Complement Ther Med*. 2007;15(1):13-20. https://doi.org/10.1016/j.ctim.2005.10.008

11. Poisons Standard February 2020, editor. Schedule 2 - Standard for the uniform scheduling of medicines and poisons. No. 27. Regulatory Engagement and Planning Branch, Woden, ACT: Australian Government Department of Health; February 2020 [cited February 2020]. Available from: https://www.legislation.gov.au/Details/F2020L00017/Html/Text#\_Toc28084707.

12. Vickers A, Zollman C, Lee R. Herbal medicine. *West J Med*. 2001;175(2):125-8. https://doi.org/10.1136/ewjm.175.2.125

13. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). London: Cochrane; 2023 [cited 2023]. Available from: http://www.training.cochrane.org/handbook.

14. Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E, Munn Z, editors. *Joanna Briggs Institute Reviewer's Manual*: The Joanna Briggs Institute; 2017.

15. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2020.

16. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut*. 2011;60(5):571-607. https://doi.org/10.1136/gut.2010.224154

17. Ha F, Khalil H. Crohn's disease: a clinical update. *Therap Adv Gastroenterol*. 2015;8(6):352-9. https://doi.org/10.1177/1756283X15592585

18. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2019;114(3):384-413. https://doi.org/10.14309/ajg.0000000000000152

19. The Gastroenterological Society of Australia (GESA). Clinical Update for General Practitioners and Physicians – Inflammatory Bowel Disease 2018 [Available from: https://www.gesa.org.au/public/13/files/Education%20%26%20Resources/Clinical%20Practice%20Resources/IBD/2018\_IBD\_Clinical\_Update\_May\_update.pdf.

20. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390(10114):2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0

21. Department of Health. National Strategic Action Plan for Inflammatory Bowel Disease. Canberra ACT: Commonwealth of Australia; 2019.

22. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68(Suppl 3):s1-s106. https://doi.org/10.1136/gutjnl-2019-318484

23. Ng JY, Liu H, Wang MC. Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II. *BMC Complement Med Ther*. 2023;23(1):230. https://doi.org/10.1186/s12906-023-04062-0

24. Ghassab-Abdollahi N, Malekian S, Mirghafourvand M, Farshbaf-Khalili A. The effect of Nigella sativa on oxidative stress and inflammatory biomarkers: a systematic review and meta-analysis. *Journal of Complementary and Integrative Medicine*. 2021;18(2):235-59. https://doi.org/10.1515/jcim-2019-0198

25. Montazeri RS, Fatahi S, Sohouli MH, Abu-Zaid A, Santos HO, Gaman MA, et al. The effect of nigella sativa on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *Journal of Food Biochemistry*. 2021;45(4):e13625. https://doi.org/10.1111/jfbc.13625

26. Liu F, Li D, Wang X, Cui Y, Li X. Polyphenols intervention is an effective strategy to ameliorate inflammatory bowel disease: a systematic review and meta-analysis. *Int J Food Sci Nutr*. 2021;72(1):14-25. https://doi.org/10.1080/09637486.2020.1760220

27. Morvaridzadeh M, Sadeghi E, Agah S, Fazelian S, Rahimlou M, Kern FG, et al. Effect of ginger (Zingiber officinale) supplementation on oxidative stress parameters: A systematic review and meta-analysis. *Journal of Food Biochemistry*. 2021;45(2):e13612. https://doi.org/10.1111/jfbc.13612

28. Ardiana M, Pikir BS, Santoso A, Hermawan HO, Al-Farabi MJ. Effect of Supplementation on Oxidative Stress and Antioxidant Parameters: A Meta-Analysis of Randomized Controlled Trials. *Scientific World Journal*. 2020;2020:1-7. https://doi.org/10.1155/2020/2390706

29. Chandan S, Mohan BP, Chandan OC, Ahmad R, Challa A, Tummala H, et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. *Ann Gastroenterol*. 2020;33(1):53-8. https://doi.org/10.20524/aog.2019.0439

30. Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. *Nutrients*. 2020;12(8):2296. https://doi.org/10.3390/nu12082296

31. Goulart RDA, Barbalho SM, Rubira CJ, Araujo AC, Lima VM, Rogerio Leoni B, et al. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. *Expert Review of Gastroenterology and Hepatology*. 2020;14(12):1171-9. https://doi.org/10.1080/17474124.2020.1808460

32. Goulart RA, Barbalho SM, Lima VM, Souza GA, Matias JN, Araujo AC, et al. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review. *Journal of Medicinal Food*. 2020;05(7):05. https://doi.org/10.1089/jmf.2020.0129

33. Hallajzadeh J, Milajerdi A, Mobini M, Amirani E, Azizi S, Nikkhah E, et al. Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: A systematic review and meta-analysis of randomized controlled clinical trials. *Phytotherapy Research*. 2020;34(10):2586-608. https://doi.org/10.1002/ptr.6708

34. Jalali M, Mahmoodi M, Moosavian SP, Jalali R, Ferns G, Mosallanezhad A, et al. The effects of ginger supplementation on markers of inflammatory and oxidative stress: A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2020;34(8):1723-33. https://doi.org/10.1002/ptr.6638

35. Mohit M, Farrokhzad A, Faraji SN, Heidarzadeh-Esfahani N, Kafeshani M. Effect of Nigella sativa L. supplementation on inflammatory and oxidative stress indicators: A systematic review and meta-analysis of controlled clinical trials. *Complementary Therapies in Medicine*. 2020;54:102535. https://doi.org/10.1016/j.ctim.2020.102535

36. Zheng T, Wang X, Chen Z, He A, Zheng Z, Liu G. Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials. *Journal of Gastroenterology & Hepatology*. 2020;35(5):722-9. https://doi.org/10.1111/jgh.14911

37. Tavakoly R, Arab A, Vallianou N, Clark CCT, Hadi A, Ghaedi E, et al. The effect of Nigella sativa L. supplementation on serum C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2019;45:149-55. https://doi.org/10.1016/j.ctim.2019.06.008

38. Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients*. 2018;10(11):12. https://doi.org/10.3390/nu10111737

39. Iqbal U, Anwar H, Quadri AA. Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis. *American Journal of the Medical Sciences*. 2018;356(4):350-6. https://doi.org/10.1016/j.amjms.2018.06.023

40. Restellini S, Kherad O, Bessissow T, Menard C, Martel M, Taheri Tanjani M, et al. Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease. *World Journal of Gastroenterology*. 2017;23(32):5994-6002. https://doi.org/10.3748/wjg.v23.i32.5994

41. Kafil TS, Nguyen TM, Patton PH, MacDonald JK, Chande N, McDonald JWD. Interventions for treating collagenous colitis. *Cochrane Database of Systematic Reviews*. 2017;11(11):CD003575. https://doi.org/10.1002/14651858.CD003575.pub6

42. Kim S, Lee BH, Zhang X, Park JW, Lee S, Lee H. Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. *European Journal of Integrative Medicine*. 2017;12:12-22. https://doi.org/10.1016/j.eujim.2017.03.009

43. Schneider A, Hossain I, VanderMolen J, Nicol K. Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review. *Complementary Therapies in Medicine*. 2017;33:32-8. https://doi.org/10.1016/j.ctim.2017.06.002

44. Simadibrata M, Halimkesuma CC, Suwita BM. Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review. *Acta Medica Indonesiana*. 2017;49(4):363-8.

45. Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. *Journal of Crohn's & colitis*. 2015;9(1):86-106. https://doi.org/10.1093/ecco-jcc/jju007

46. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*. 2013;38(8):854-63. https://doi.org/10.1111/apt.12464

47. Rahimi R, Nikfar S, Abdollahi M. Comparison of the efficacy and tolerability of herbal medicines with 5-aminosalisylates in inflammatory bowel disease: A meta-analysis of placebo controlled clinical trials involving 812 patients. *International Journal of Pharmacology*. 2013;9(4):227-44. https://doi.org/10.3923/ijp.2013.227.244

48. Kumar S, Ahuja V, Kumar A, Sankar MJ, Alan CM. Efficacy of Curcumin (turmeric) in the treatment of InflammatoryBowel Disease: A systematic review. *Inflammatory Bowel Diseases*. 2011;17(SUPPL. 2):S16. https://doi.org/10.1002/ibd.21939

49. Ernst E. Christmas 2008: Seasonal Fayre: frankincense: systematic review. *BMJ*. 2008;337(7684):a2813. https://doi.org/10.1136/bmj.a2813

50. Moole H, Settypalli S, Ahmed Z, Dharmapuri S, Boddireddy R, Moole V, et al. Outcomes Research. *Am J Gastroenterol*. 2016;111(S1):S400-S51. https://doi.org/10.1038/ajg.2016.360

51. Moole H, Yerasi C, Moole V, Dharmapuri S, Uppu A. A systematic review and meta-analysis of randomized controlled trials: Improvement in endoscopic disease activity of ulcerative colitis with curcumin treatment. *Gastrointestinal Endoscopy*. 2016;83(5 SUPPL. 1):AB294.

52. Langhorst J. Complementary and alternative medicine treatments in inflammatory bowel diseases. *Journal fur Gastroenterologische und Hepatologische Erkrankungen*. 2016;14(1):9-16.

53. Lauche R, Cramer H, Klose P, Kraft K, Dobos GJ, Langhorst J. Herbal medicines for the treatment of inflammatory bowel disease. *Cochrane Database of Systematic Reviews*. 2014;2014(7):CD011223. https://doi.org/10.1002/14651858.Cd011223

54. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928

55. Faraone SV. Interpreting estimates of treatment effects: implications for managed care. *P T*. 2008;33(12):700-11.

56. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin Epidemiol*. 2014;6:71-80. https://doi.org/10.2147/CLEP.S40245

57. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015;313(9):949-58. https://doi.org/10.1001/jama.2015.0954

58. Barbara G, Cremon C, Stanghellini V. Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. *Curr Opin Gastroenterol*. 2014;30(4):352-8. https://doi.org/10.1097/MOG.0000000000000070

59. Dietiticians Australia. Irritable bowel syndrome (IBS) 2022 [cited 2022 21st April]. Available from: https://dietitiansaustralia.org.au/health-advice/irritable-bowel-syndrome-ibs.

60. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. 2021;116(1):17-44. https://doi.org/10.14309/ajg.0000000000001036

61. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes*. 2017;15(1):35. https://doi.org/10.1186/s12955-017-0611-2

62. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70(7):1214-40. https://doi.org/10.1136/gutjnl-2021-324598

63. Basnayake C. Treatment of irritable bowel syndrome. *Aust Prescr*. 2018;41(5):145-9. https://doi.org/10.18773/austprescr.2018.044

64. Anh NH, Kim SJ, Long NP, Min JE, Yoon YC, Lee EG, et al. Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials. *Nutrients*. 2020;12(1). https://doi.org/10.3390/nu12010157

65. Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. *Lancet Gastroenterol Hepatol*. 2020;5(2):117-31. https://doi.org/10.1016/S2468-1253(19)30324-3

66. Hawrelak JA, Wohlmuth H, Pattinson M, Myers SP, Goldenberg JZ, Harnett J, et al. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. *Complement Ther Med*. 2020;48:102233. https://doi.org/10.1016/j.ctim.2019.102233

67. Tan N, Gwee KA, Tack J, Zhang M, Li Y, Chen M, et al. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta-analysis. *J Gastroenterol Hepatol*. 2020;35(4):544-56. https://doi.org/10.1111/jgh.14905

68. Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. *BMC Complement Altern Med*. 2019;19(1):21. https://doi.org/10.1186/s12906-018-2409-0

69. Hong SW, Chun J, Park S, Lee HJ, Im JP, Kim JS. Aloe vera Is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. *J Neurogastroenterol Motil*. 2018;24(4):528-35. https://doi.org/10.5056/jnm18077

70. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS). *J Clin Med*. 2018;7(10):298. https://doi.org/10.3390/jcm7100298

71. Anheyer D, Frawley J, Koch AK, Lauche R, Langhorst J, Dobos G, et al. Herbal Medicines for Gastrointestinal Disorders in Children and Adolescents: A Systematic Review. *Pediatrics*. 2017;139(6). https://doi.org/10.1542/peds.2017-0062

72. Korterink JJ, Rutten JM, Venmans L, Benninga MA, Tabbers MM. Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review. *J Pediatr*. 2015;166(2):424-31 e6. https://doi.org/10.1016/j.jpeds.2014.09.067

73. Lakhan SE, Ford CT, Tepper D. Zingiberaceae extracts for pain: a systematic review and meta-analysis. *Nutr J*. 2015;14(1):50. https://doi.org/10.1186/s12937-015-0038-8

74. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clin Gastroenterol*. 2014;48(6):505-12. https://doi.org/10.1097/MCG.0b013e3182a88357

75. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. *Cochrane Database Syst Rev*. 2011;2011(8):CD003460. https://doi.org/10.1002/14651858.CD003460.pub3

76. Robertshawe P. Effect of fibre, antispasmodics and peppermint oil on irritable bowel syndrome. *Journal of the Australian Traditional-Medicine Society*. 2010;16:21.

77. Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. *Can Fam Physician*. 2009;55(2):143-8.

78. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. *BMJ*. 2008;337:a2313. https://doi.org/10.1136/bmj.a2313

79. Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. *Cochrane Database Syst Rev*. 2008(1):CD003017. https://doi.org/10.1002/14651858.CD003017.pub2

80. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. *Cochrane Database Syst Rev*. 2006(1):CD004116. https://doi.org/10.1002/14651858.CD004116.pub2

81. Grigoleit HG, Grigoleit P. Peppermint oil in irritable bowel syndrome. *Phytomedicine*. 2005;12(8):601-6. https://doi.org/10.1016/j.phymed.2004.10.005

82. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. *Ann Intern Med*. 2000;133(2):136-47. https://doi.org/10.7326/0003-4819-133-2-200007180-00013

83. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. *Am J Gastroenterol*. 1998;93(7):1131-5. https://doi.org/10.1111/j.1572-0241.1998.00343.x

84. Nehme F, Al Momani L, Alomari M, Zafar Y. Peppermint Oil Decreases Colonic Spasm Without Significantly Affecting Cecal Intubation Time and Adenoma Detection Rate: A Systematic Review and Meta-Analysis. *American Journal of Gastroenterology*. 2019;114(1):S309-S. https://doi.org/10.14309/01.ajg.0000591672.06829.6a

85. Tan N-D, Zhang M-Y, Li Y-W, Chen M-H, Xiao Y-L, Gwee KA, et al. Posters. *Journal of Digestive Diseases*. 2019;20(S1):4-67. https://doi.org/10.1111/1751-2980.12808

86. Koch AK, Trifunovic-Koenig M, Klose P, Cramer H, Dobos G, Langhorst J. P95 Herbal medicine in the treatment of irritable bowel syndrome – a systematic review. *BMC Complementary and Alternative Medicine*. 2017;17(S1). https://doi.org/10.1186/s12906-017-1783-3

87. Gomes JC, Silva F. Análise da eficácia do óleo de hortelã pimenta (Mentha piperita L) na síndrome do intestino irritável: revisão baseada em evidência. *Rev bras med fam comunidade*. 2013;8(27):121-6.

88. Fallah Huseini H, Mohtashami R, Sadeqi Z, Saidi Y, Fallah Huseini A. A review on pharmacological effects of Nigella sativa L. seeds. *Journal of Medicinal Plants*. 2011;10(38):1-18.

89. Buitrago F. Fiber, antispasmodics, and peppermint oil are effective treatments in irritable bowel syndrome. *FMC Formacion Medica Continuada en Atencion Primaria*. 2009;16(7):455. https://doi.org/10.1016/S1134-2072%2809%2971976-0

90. Zhang Y, Liu R, Wang J, Yan S, Guo Z. To assess the effective and safety of compound glutamine entersoluble capsules in irritable bowel syndrome: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2021;100(10):e25098. https://doi.org/10.1097/MD.0000000000025098

91. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. *Gut*. 2014;63(7):1185-93. https://doi.org/10.1136/gutjnl-2013-306393

92. Keung C, Hebbard G. The management of gastro-oesophageal reflux disease. *Aust Prescr*. 2016;39(1):6-10. https://doi.org/10.18773/austprescr.2016.003

93. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. *Gut*. 2018;67(3):430-40. https://doi.org/10.1136/gutjnl-2016-313589

94. Tack J, Pandolfino JE. Pathophysiology of Gastroesophageal Reflux Disease. *Gastroenterology*. 2018;154(2):277-88. https://doi.org/10.1053/j.gastro.2017.09.047

95. Graeme C Miller CW, Allan J Pollack. Gastro-oesophageal reflux disease (GORD) in Australian general practice patients. *Australian Journal for General Practitioners*. 2015;44:701-4.

96. Sadeghi F, Mohammad S, Sepehri B, Khodaie L, Monirifar H, Mirghafourvand M. Effects of herbal medicine in gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. *Tradit Med Res*. 2020;5(6):425–506. https://doi.org/10.53388/tmr20200929200

97. Mahboubi M. Aloe Vera (Aloe barbadensis) Gel for the Management of Gastroesophageal Reflux Disease (GERD). *The Natural Products Journal*. 2021;11(1):13-20. https://doi.org/10.2174/2210315509666191114141533

98. Kho KA, Shields JK. Diagnosis and Management of Primary Dysmenorrhea. *JAMA*. 2020;323(3):268-9. https://doi.org/10.1001/jama.2019.16921

99. Practice Committee of American Society for Reproductive M. Current evaluation of amenorrhea. *Fertil Steril*. 2008;90(5 Suppl):S219-25. https://doi.org/10.1016/j.fertnstert.2008.08.038

100. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. *Hum Reprod*. 2014;29(3):400-12. https://doi.org/10.1093/humrep/det457

101. Fooladi E, Bell RJ, Robinson PJ, Skiba M, Davis SR. Dysmenorrhea, Workability, and Absenteeism in Australian Women. J Womens Health (Larchmt). 2023 Nov;32(11):1249-1256. doi: 10.1089/jwh.2023.0199.

102. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. *Curr Obstet Gynecol Rep*. 2017;6(1):34-41. https://doi.org/10.1007/s13669-017-0187-1

103. Endometriosis Australia. Management and Treatment. 2023. [Accessed: July 2023]. Available from: https://endometriosisaustralia.org/management-and-treatment/.

104. Pelvic Pain Foundation of Australia. Management of Chronic Pelvic Pain. 2022. [Accessed: July 2023]. Available from: https://www.pelvicpain.org.au/learn/for-health-professionals/for-health-professionals-management-of-chronic-pelvic-pain/.

105. Negi R, Sharma SK, Gaur R, Bahadur A, Jelly P. Efficacy of Ginger in the Treatment of Primary Dysmenorrhea: A Systematic Review and Meta-analysis. *Cureus*. 2021;13(3):e13743. https://doi.org/10.7759/cureus.13743

106. Mollazadeh S, Mirghafourvand M, Abdollahi NG. The effects of Vitex agnus-castus on menstrual bleeding: A systematic review and meta-analysis. *Journal of Complementary and Integrative Medicine*. 2020;17(1).

107. Shinjyo N, Waddell G, Green J. Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis. *J Evid Based Integr Med*. 2020;25:2515690X20967323. https://doi.org/10.1177/2515690X20967323

108. Xu Y, Yang Q, Wang X. Efficacy of herbal medicine (cinnamon/fennel/ginger) for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *Journal of International Medical Research*. 2020;48(6):300060520936179. https://doi.org/10.1177/0300060520936179

109. Pellow J, Nienhuis C. Medicinal plants for primary dysmenorrhoea: A systematic review. *Complementary Therapies in Medicine*. 2018;37:13-26. https://doi.org/10.1016/j.ctim.2018.01.001

110. Chen CX BB, Kwekkeboom KL. Efficacy of oral ginger (Zingiber officinale) for dysmenorrhea: A systematic review and meta-analysis. *Evidence-Based Complementary andAlternative Medicine*. 2016;2016:6295737. https://doi.org/10.1155/2016/6295737

111. Javan R, Yousefi M, Nazari SM, Amiri P, Mosavi ‐ Jarrahi A, Modiramani P, et al. Herbal Medicines in Idiopathic Heavy Menstrual Bleeding: A Systematic Review. *Phytotherapy Research*. 2016;30(10):1584-91. https://doi.org/10.1002/ptr.5675

112. Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, et al. Dietary supplements for dysmenorrhoea. *Cochrane Database of Systematic Reviews*. 2016;3(3):CD002124. https://doi.org/10.1002/14651858.CD002124.pub2

113. Ursoniu S, Sahebkar A, Andrica F, Serban C, Banach M. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. *Clinical Nutrition*. 2016;35(3):615-25. https://doi.org/10.1016/j.clnu.2015.05.012

114. Daily JW, Xin Z, Da Sol K, Park S. Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *Pain Medicine*. 2015;16(12):2243-55. https://doi.org/10.1111/pme.12853

115. Terry R, Posadzki P, Watson LK, Ernst E. The Use of Ginger ( Zingiber officinale) for the Treatment of Pain: A Systematic Review of Clinical Trials. *Pain Medicine*. 2011;12(12):1808-18. https://doi.org/10.1111/j.1526-4637.2011.01261.x

116. Ulbricht C, Conquer J, Costa D, Hollands W, Iannuzzi C, Isaac R, et al. An evidence-based systematic review of saffron (Crocus sativus) by the Natural Standard Research Collaboration. *Journal of Dietary Supplements*. 2011;8(1):58-114. https://doi.org/10.3109/19390211.2011.547666

117. Peng J, Xu W, Li X, Wu Q. [Efficacy of black cohosh extracts for improving low estrogen status induced by postoperative GnRHa treatment in patients with endometriosis: a systematic review]. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2020;49(3):397-405. https://doi.org/10.3785/j.issn.1008-9292.2020.06.06

118. Mozafari S, Naz MSG, Ozgoli G. Effect of ginger on primary dysmenorrhea: A systematic review of clinical trials and quasi-experimental studies in the world. *Iranian Journal of Obstetrics, Gynecology and Infertility*. 2018;21:86-93. https://doi.org/10.22038/ijogi.2018.11624

119. Gao M, Gao D, Sun H, Cheng X, An L, Qiao M. Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis. *Front Public Health*. 2021;9:596128. https://doi.org/10.3389/fpubh.2021.596128

120. Hantsoo L, Epperson CN. Premenstrual Dysphoric Disorder: Epidemiology and Treatment. *Curr Psychiatry Rep*. 2015;17(11):87. https://doi.org/10.1007/s11920-015-0628-3

121. Green L, O’Brien P, Panay N, Craig M, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2017;124(3):e73-e105. https://doi.org/https://doi.org/10.1111/1471-0528.14260

122. Hofmeister S, Bodden S. Premenstrual Syndrome and Premenstrual Dysphoric Disorder. *Am Fam Physician*. 2016;94(3):236-40.

123. Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. *Am Fam Physician*. 2011;84(8):918-24.

124. Ghaderi A, Asbaghi O, Reiner Z, Kolahdooz F, Amirani E, Mirzaei H, et al. The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. *Complementary Therapies in Medicine*. 2020;48:102250. https://doi.org/10.1016/j.ctim.2019.102250

125. Shinjyo N, Waddell G, Green J, Abdellah AABBBBBBMBBBBBBBBBBBCCCCCCCCdA. Valerian root in treating sleep problems and associated disorders-A systematic review and meta-analysis. *Journal of Evidence-Based Integrative Medicine*. 2020;25:2515690X20967323. https://doi.org/10.1177/2515690X20967323

126. Csupor D, Lantos T, Hegyi P, Benko R, Viola R, Gyongyi Z, et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. *Complementary Therapies in Medicine*. 2019;47:102190. https://doi.org/10.1016/j.ctim.2019.08.024

127. Khalesi ZB, Beiranvand SP, Bokaie M. Efficacy of Chamomile in the Treatment of Premenstrual Syndrome: A Systematic Review. *Journal of Pharmacopuncture*. 2019;22(4):204-9. https://doi.org/10.3831/KPI.2019.22.028

128. Cerqueira R, Frey B, Leclerc E, Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. *Archives of Women's Mental Health*. 2017;20(6):713-9. https://doi.org/10.1007/s00737-017-0791-0

129. Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. *American Journal of Obstetrics & Gynecology*. 2017;217(2):150-66. https://doi.org/10.1016/j.ajog.2017.02.028

130. Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. *Journal of Integrative Medicine*. 2015;13(4):231-40. https://doi.org/10.1016/S2095-4964%2815%2960176-5

131. Su Hee J, Dong Il K, Min-Sun C. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. *BMC Complementary & Alternative Medicine*. 2014;14(1):11-32. https://doi.org/10.1186/1472-6882-14-11

132. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus Extracts for Female Reproductive Disorders: A Systematic Review of Clinical Trials. *Planta Medica*. 2013;79(7):562-75. https://doi.org/10.1055/s-0032-1327831

133. Dante G, Facchinetti F, Agha-Hosseini AABBBCCCCCCCCEFGGGHHHHHHHJJJK. Herbal treatments for alleviating premenstrual symptoms: A systematic review. *Journal of Psychosomatic Obstetrics & Gynecology*. 2011;32(1):42-51. https://doi.org/10.3109/0167482X.2010.538102

134. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. *Canadian Journal of Clinical Pharmacology/Journal Canadien de Pharmacologie Clinique*. 2009;16(3):e407-29.

135. Alsadat EP, Abdolmajid P, Maryam A. Traditional Medicine in Treatment of Women with Premenstrual Syndrome, A Systematic Review. *Indian Journal of Forensic Medicine & Toxicology*. 2018;12(3):161-5. https://doi.org/10.5958/0973-9130.2018.00152.4

136. Peacock K, Ketvertis K. Menopause. 2021 Jan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Updated 2021 Jun 29. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507826/.

137. Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. *Semin Reprod Med*. 2020;38(4-05):237-46. https://doi.org/10.1055/s-0040-1722317

138. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. *NIH Consens State Sci Statements*. 2005;22(1):1-38.

139. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. *Maturitas*. 1992;14(2):103-15. https://doi.org/10.1016/0378-5122(92)90003-m

140. Caruso D, Masci I, Cipollone G, Palagini L. Insomnia and depressive symptoms during the menopausal transition: theoretical and therapeutic implications of a self-reinforcing feedback loop. *Maturitas*. 2019;123:78-81. https://doi.org/10.1016/j.maturitas.2019.02.007

141. Mishra GD, Pandeya N, Dobson AJ, Chung HF, Anderson D, Kuh D, et al. Early menarche, nulliparity and the risk for premature and early natural menopause. *Hum Reprod*. 2017;32(3):679-86. https://doi.org/10.1093/humrep/dew350

142. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. *Int J Epidemiol*. 2014;43(5):1542-62. https://doi.org/10.1093/ije/dyu094

143. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. *Climacteric*. 2019;22(4):403-11. https://doi.org/10.1080/13697137.2019.1574738

144. Australasian Menopause Society. Menopause Treatment Options [updated September 2018. Available from: https://www.menopause.org.au/hp/management/treatment-options.

145. The NHTPSAP. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2017;24(7):728-53. https://doi.org/10.1097/GME.0000000000000921

146. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A, Perez-Lopez FR, et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). *Maturitas*. 2016;89:63-72. https://doi.org/10.1016/j.maturitas.2016.04.013

147. Management of Osteoporosis in Postmenopausal Women: The Position Statement of The North American Menopause Society'' Editorial P. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. *Menopause*. 2021;28(9):973-97. https://doi.org/10.1097/GME.0000000000001831

148. The NGSMPSEP. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause*. 2020;27(9):976-92. https://doi.org/10.1097/GME.0000000000001609

149. Dodin S, Blanchet C, Marc I, Ernst E, Wu T, Vaillancourt C, et al. Acupuncture for menopausal hot flushes. *Cochrane Database Syst Rev*. 2013;2013(7):CD007410. https://doi.org/10.1002/14651858.CD007410.pub2

150. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. *Cochrane Database Syst Rev*. 2012;2012(9):CD007244. https://doi.org/10.1002/14651858.CD007244.pub2

151. Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. *Cochrane Database Syst Rev*. 2014(7):CD008582. https://doi.org/10.1002/14651858.CD008582.pub2

152. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. *Cochrane Database Syst Rev*. 2014;2014(11):CD006108. https://doi.org/10.1002/14651858.CD006108.pub4

153. Askari M, Mozaffari H, Darooghegi Mofrad M, Jafari A, Surkan PJ, Amini MR, et al. Effects of garlic supplementation on oxidative stress and antioxidative capacity biomarkers: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2021;23(6):23. https://doi.org/10.1002/ptr.7021

154. Azizi N, Amini MR, Djafarian K, Shab-Bidar S. The Effects of Nigella sativa Supplementation on Liver Enzymes Levels: a Systematic Review and Meta-analysis of Randomized Controlled Trials. *Clin Nutr Res*. 2021;10(1):72-82. https://doi.org/10.7762/cnr.2021.10.1.72

155. Castelo-Branco C, Gambacciani M, Cano A, Minkin MJ, Rachoń D, Ruan X, et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. *Climacteric*. 2021;24(2):109-19. https://doi.org/10.1080/13697137.2020.1820477

156. Firoozeei TS, Feizi A, Rezaeizadeh H, Zargaran A, Roohafza HR, Karimi M. The Antidepressant Effects of Lavender (Lavandula angustifolia Mill.): A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. *Complementary Therapies in Medicine*. 2021;59:102679. https://doi.org/10.1016/j.ctim.2021.102679

157. Kanadys W, Baranska A, Drop B, Malm M, Blaszczuk A, Polz-Dacewicz M, et al. Evaluation of clinical meaningfulness of red clover (Trifolium pratense l.) extract to relieve hot flushes and menopausal symptoms in peri-and post-menopausal women: A systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2021;13(4):1258. https://doi.org/10.3390/nu13041258

158. Koushki M, Amiri-Dashatan N, Pourfarjam Y, Doustimotlagh AH. Effect of garlic intake on inflammatory mediators: a systematic review and meta-analysis of randomised controlled trials. *Postgraduate Medical Journal*. 2021;97(1145):156-63. https://doi.org/10.1136/postgradmedj-2019-137267

159. Ghavami A, Ziaei R, Foshati S, Hojati Kermani MA, Zare M, Amani R. Benefits and harms of ginseng supplementation on liver function? A systematic review and meta-analysis. *Complementary Therapies in Clinical Practice*. 2020;39:N.PAG-N.PAG. https://doi.org/10.1016/j.ctcp.2020.101173

160. Kanadys W, Baranska A, Jedrych M, Religioni U, Janiszewska M. Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of perimenopausal and postmenopausal women-A systematic review and meta-analysis. *Maturitas*. 2020;132:7-16. https://doi.org/10.1016/j.maturitas.2019.11.001

161. Mirzavandi F, Mollahosseini M, Salehi-Abargouei A, Makiabadi E, Mozaffari-Khosravi H. Effects of garlic supplementation on serum inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. *Diabetes & Metabolic Syndrome*. 2020;14(5):1153-61. https://doi.org/10.1016/j.dsx.2020.06.031

162. Moosavian SP, Arab A, Paknahad Z, Moradi S. The effects of garlic supplementation on oxidative stress markers: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2020;50:102385. https://doi.org/10.1016/j.ctim.2020.102385

163. Razmpoosh E, Safi S, Abdollahi N, Nadjarzadeh A, Nazari M, Fallahzadeh H, et al. The effect of Nigella sativa on the measures of liver and kidney parameters: A systematic review and meta-analysis of randomized-controlled trials. *Pharmacological Research*. 2020;156:104767. https://doi.org/10.1016/j.phrs.2020.104767

164. Xu R, Yang K, Li S, Dai M, Chen G. Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. *Nutrition Journal*. 2020;19(1):N.PAG-N.PAG. https://doi.org/10.1186/s12937-020-00557-5

165. Ziaei R, Ghavami A, Ghaedi E, Hadi A, Javadian P, Clark CCT. The efficacy of ginseng supplementation on plasma lipid concentration in adults: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2020;48:102239. https://doi.org/10.1016/j.ctim.2019.102239

166. Askari G, Rouhani MH, Ghaedi E, Ghavami A, Nouri M, Mohammadi H. Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2019;33(5):1341-52. https://doi.org/10.1002/ptr.6337

167. Ghorbani Z, Mirghafourvand M. A meta-analysis of the efficacy of panax ginseng on menopausal women's sexual function. *International Journal of Women's Health and Reproduction Sciences*. 2019;7(1):124-33. https://doi.org/10.15296/ijwhr.2019.20

168. Hadi A, Pourmasoumi M, Ghaedi E, Sahebkar A. The effect of Curcumin/Turmeric on blood pressure modulation: A systematic review and meta-analysis. *Pharmacological Research*. 2019;150:104505. https://doi.org/10.1016/j.phrs.2019.104505

169. Hallajzadeh J, Milajerdi A, Kolahdooz F, Amirani E, Mirzaei H, Asemi Z. The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2019;33(11):2989-95. https://doi.org/10.1002/ptr.6477

170. Hernandez-Garcia D, Granado-Serrano AB, Martin-Gari M, Naudi A, Serrano JCE. Efficacy of Panax ginseng supplementation on blood lipid profile. A meta-analysis and systematic review of clinical randomized trials. *Journal of Ethnopharmacology*. 2019;243:112090. https://doi.org/10.1016/j.jep.2019.112090

171. Mohammadi H, Hadi A, Kord‐Varkaneh H, Arab A, Afshari M, Ferguson AJR, et al. Effects of ginseng supplementation on selected markers of inflammation: A systematic review and meta-analysis. *Phytotherapy Research*. 2019;33(8):1991-2001. https://doi.org/10.1002/ptr.6399

172. Saboori S, Falahi E, Yousefi Rad E, Asbaghi O, Khosroshahi MZ. Effects of ginseng on C-reactive protein level: A systematic review and meta-analysis of clinical trials. *Complementary Therapies in Medicine*. 2019;45:98-103. https://doi.org/10.1016/j.ctim.2019.05.021

173. Shahmohammadi A, Ramezanpour N, Mahdavi Siuki M, Dizavandi F, Ghazanfarpour M, Rahmani Y, et al. The efficacy of herbal medicines on anxiety and depression in peri- and postmenopausal women: A systematic review and meta-analysis. *Post Reproductive Health*. 2019;25(3):131-41. https://doi.org/10.1177/2053369119841166

174. Jovanovski E, Yashpal S, Komishon A, Zurbau A, Mejia SB, Ho HVT, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. *American Journal of Clinical Nutrition*. 2018;108(5):922-32. https://doi.org/10.1093/ajcn/nqy115

175. Khadivzadeh T, Abdolahian S, Ghazanfarpour M, Kargarfard L, Dizavandi FR, Khorsand I. A Systematic Review and Meta-analysis on the Effect of Herbal Medicine to Manage Sleep Dysfunction in Peri- and Postmenopause. *J Menopausal Med*. 2018;24(2):92-9. https://doi.org/10.6118/jmm.2018.24.2.92

176. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. *Oral Diseases*. 2018;24(3):325-34. https://doi.org/10.1111/odi.12660

177. Luís Â, Domingues F, Pereira L. Effects of red clover on perimenopausal and postmenopausal women's blood lipid profile: A meta-analysis. *Climacteric*. 2018;21(5):446-53. https://doi.org/10.1080/13697137.2018.1501673

178. Mousavi SM, Sheikhi A, Varkaneh HK, Zarezadeh M, Rahmani J, Milajerdi A. Effect of Nigella sativa supplementation on obesity indices: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2018;38:48-57. https://doi.org/10.1016/j.ctim.2018.04.003

179. Najaf Najafi M, Ghazanfarpour M. Effect of phytoestrogens on sexual function in menopausal women: a systematic review and meta-analysis. *Climacteric*. 2018;21(5):437-45. https://doi.org/10.1080/13697137.2018.1472566

180. Rahmani Y, Chaleh KC, Shahmohammadi A, Safari S. Effect of Herbal Medicine on Vaginal Epithelial Cells: A Systematic Review and Meta-analysis. *J Menopausal Med*. 2018;24(1):11-6. https://doi.org/10.6118/jmm.2018.24.1.11

181. Haghighatdoost F, Nobakht M. Gh BF, Hariri M. Effect of Green Tea on Plasma Adiponectin Levels: A Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials. *Journal of the American College of Nutrition*. 2017;36(7):541-8. https://doi.org/10.1080/07315724.2017.1333470

182. Kapoor MP, Sugita M, Fukuzawa Y, Okubo T. Physiological effects of epigallocatechin-3-gallate (EGCG) on energy expenditure for prospective fat oxidation in humans: A systematic review and meta-analysis. *Journal of Nutritional Biochemistry*. 2017;43:1-10. https://doi.org/10.1016/j.jnutbio.2016.10.013

183. Mohammadi-Sartang M, Mazloom Z, Raeisi-Dehkordi H, Barati-Boldaji R, Bellissimo N, Totosy de Zepetnek JO. The effect of flaxseed supplementation on body weight and body composition: a systematic review and meta-analysis of 45 randomized placebo-controlled trials. *Obesity Reviews*. 2017;18(9):1096-107. https://doi.org/10.1111/obr.12550

184. Myers SP, Vigar V, Myers SP. Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: A systematic review and meta-analysis. *Phytomedicine*. 2017;24:141-7. https://doi.org/10.1016/j.phymed.2016.12.003

185. Sarri G, Pedder H, Dias S, Guo Y, Lumsden MA, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2017;124(10):1514-23. https://doi.org/10.1111/1471-0528.14619

186. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. *JAMA*. 2016;315(23):2554-63. https://doi.org/10.1001/jama.2016.8012

187. Ghazanfarpour M, Sadeghi R, Roudsari RL, Khorsand I, Khadivzadeh T, Muoio B. Red clover for treatment of hot flashes and menopausal symptoms: A systematic review and meta-analysis. *Journal of Obstetrics & Gynaecology*. 2016;36(3):301-11. https://doi.org/10.3109/01443615.2015.1049249

188. Li Y, Zhu X, Bensussan A, Li P, Moylan E, Delaney G, et al. Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis. *Evidence-based Complementary & Alternative Medicine (eCAM)*. 2016;2016:1-11. https://doi.org/10.1155/2016/1327251

189. Sahebkar A, Beccuti G, Simental-Mendia LE, Nobili V, Bo S. Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. *Pharmacological Research*. 2016;106:37-50. https://doi.org/10.1016/j.phrs.2016.02.008

190. Sahebkar A, Soranna D, Xiaoqiu L, Thomopoulos C, Simental-Mendia LE, Derosa G, et al. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. *Journal of Hypertension*. 2016;34(11):2127-35. https://doi.org/10.1097/HJH.0000000000001049

191. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. *Climacteric*. 2015;18(2):260-9. https://doi.org/10.3109/13697137.2014.966241

192. Ghazanfarpour M, Sadeghi R, Latifnejad Roudsari R, Mirzaii Najmabadi K, Mousavi Bazaz M, Abdolahian S, et al. Effects of red clover on hot flash and circulating hormone concentrations in menopausal women: a systematic review and meta-analysis. *Avicenna J Phytomed*. 2015;5(6):498-511.

193. Khalesi S, Irwin C, Schubert M. Flaxseed consumption may reduce blood pressure: a systematic review and meta-analysis of controlled trials. *Journal of Nutrition*. 2015;145(4):758-65. https://doi.org/10.3945/jn.114.205302

194. Yarmolinsky J, Gon G, Edwards P. Effect of tea on blood pressure for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. *Nutrition Reviews*. 2015;73(4):236-46. https://doi.org/10.1093/nutrit/nuv001

195. Gartoulla P, Han MM. Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis. *Maturitas*. 2014;79(1):58-64. https://doi.org/10.1016/j.maturitas.2014.06.018

196. Liu YR, Jiang YL, Huang RQ, Yang JY, Xiao BK, Dong JX. Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety. *Climacteric*. 2014;17(4):325-35. https://doi.org/10.3109/13697137.2013.861814

197. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials. *Nutrition, Metabolism & Cardiovascular Diseases*. 2014;24(8):823-36. https://doi.org/10.1016/j.numecd.2014.01.016

198. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. *Cochrane Database of Systematic Reviews*. 2013;2013(12):N.PAG-N.PAG. https://doi.org/10.1002/14651858.CD001395.pub4

199. Shergis JL, Zhang AL, Zhou W, Xue CC. Panax ginseng in randomised controlled trials: a systematic review. *Phytotherapy Research*. 2013;27(7):949-65. https://doi.org/10.1002/ptr.4832

200. Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast density in pre-and post-menopausal women: A systematic review and meta-analysis of randomized controlled trials. *Human Reproduction Update*. 2010;16(6):745-60. https://doi.org/10.1093/humupd/dmq011

201. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh containing preparations on menopausal symptoms: A meta-analysis. *Alternative Therapies in Health and Medicine*. 2010;16(1):36-44.

202. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. *Molecular Nutrition & Food Research*. 2009;53(9):1084-97. https://doi.org/10.1002/mnfr.200800552

203. Coon JT, Pittler MH, Ernst E. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. *Phytomedicine*. 2007;14(2/3):153-9. https://doi.org/10.1016/j.phymed.2006.12.009

204. Tempfer CB, Bentz EK, Leodolter S, Tscherne G, Reuss F, Cross HS, et al. Phytoestrogens in clinical practice: a review of the literature. *Fertility & Sterility*. 2007;87(6):1243-9. https://doi.org/10.1016/j.fertnstert.2007.01.120

205. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA: Journal of the American Medical Association*. 2006;295(17):2057-85. https://doi.org/10.1001/jama.295.17.2057

206. Koliji T, Keshavarz Z, Zare E, Mojab F, Nasiri M. A systematic review of herbal medicines to improve the sexual function of menopausal women. *Journal of HerbMed Pharmacology*. 2021;10(1):51-60. https://doi.org/10.34172/jhp.2021.04

207. Lopresti AL, Smith SJ, Drummond PD. Modulation of the hypothalamic-pituitary-adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials. *Nutritional Neuroscience*. 2021;25(8):1-27. https://doi.org/10.1080/1028415X.2021.1892253

208. Ebrahimi A, Tayebi N, Fatemeh A, Akbarzadeh M. Investigation of the role of herbal medicine, acupressure, and acupuncture in the menopausal symptoms: An evidence-based systematic review study. *J Family Med Prim Care*. 2020;9(6):2638-49. https://doi.org/10.4103/jfmpc.jfmpc\_1094\_19

209. Rashidi Fakari F, Simbar M, Nasab MB, Ghazanfarpour M, Rashidi Fakari F. A Review of Pharmacological Treatments for Vaginal Atrophy in Postmenopausal Women in Iran. *J Menopausal Med*. 2020;26(2):104-11. https://doi.org/10.6118/jmm.19021

210. Darand M, Hajizadeh M, Mirmiran P, Mokari-Yamchi A. The effect of Nigella sativa on infertility in men and women: A systematic review. *Progress in Nutrition*. 2019;21:33-41. https://doi.org/10.23751/pn.v21i2-S.7088

211. Dizavandi FR, Ghazanfarpour M, Roozbeh N, Kargarfard L, Khadivzadeh T, Dashti S. An overview of the phytoestrogen effect on vaginal health and dyspareunia in peri- and post-menopausal women. *Post Reproductive Health*. 2019;25(1):11-20. https://doi.org/10.1177/2053369118823365

212. Niazi A, Moradi M. Sexual Satisfaction and Function in Postmenopausal Women Treated with Herbal Medicines: A Review of Clinical Trials. *Journal of Evidence-based Care*. 2019;9(2):6-16. https://doi.org/10.22038/ebcj.2019.38679.2016

213. Roozbeh N, Ghazanfarpour M, Khadivzadeh T, Kargarfard L, Dizavandi FR, Shariati K. Effect of Lavender on Sleep, Sexual Desire, Vasomotor, Psychological and Physical Symptom among Menopausal and Elderly Women: A Systematic Review. *J Menopausal Med*. 2019;25(2):88-93. https://doi.org/10.6118/jmm.18158

214. Kim J, Lee SL, Kang I, Song YA, Ma J, Hong YS, et al. Natural Products from Single Plants as Sleep Aids: A Systematic Review. *J Med Food*. 2018;21(5):433-44. https://doi.org/10.1089/jmf.2017.4064

215. Fattah A. Effect of Phytoestrogen on Depression and Anxiety in Menopausal Women: A Systematic Review. *J Menopausal Med*. 2017;23(3):160-5. https://doi.org/10.6118/jmm.2017.23.3.160

216. Thaung Zaw JJ, Howe PRC, Wong RHX. Does phytoestrogen supplementation improve cognition in humans? A systematic review. *Annals of the New York Academy of Sciences*. 2017;1403(1):150-63. https://doi.org/10.1111/nyas.13459

217. Abdi F, Alimoradi Z, Haqi P, Mahdizad F. Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials. *Climacteric*. 2016;19(6):535-45. https://doi.org/10.1080/13697137.2016.1238451

218. Ghazanfarpour M, Sadeghi R, Abdolahian S, Latifnejad Roudsari R. The efficacy of Iranian herbal medicines in alleviating hot flashes: A systematic review. *Int J Reprod Biomed*. 2016;14(3):155-66.

219. Mohtashami A, Entezari MH. Effects of Nigella sativa supplementation on blood parameters and anthropometric indices in adults: A systematic review on clinical trials. *Journal of Research in Medical Sciences*. 2016;21:1-9. https://doi.org/10.4103/1735-1995.175154

220. Ismail R, Taylor-Swanson L, Thomas A, Schnall JG, Cray L, Mitchell ES, et al. Effects of herbal preparations on symptom clusters during the menopausal transition. *Climacteric*. 2015;18(1):11-28. https://doi.org/10.3109/13697137.2014.900746

221. Ulbricht C, Windsor RC. An Evidence-Based Systematic Review of Black cohosh (Cimicifuga racemosa, Actaea racemosa) by the Natural Standard Research Collaboration. *Journal of Dietary Supplements*. 2015;12(3):265-358. https://doi.org/10.3109/19390211.2014.946731

222. Thomas AJ, Ismail R, Taylor-Swanson L, Cray L, Schnall JG, Mitchell ES, et al. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review. *Maturitas*. 2014;78(4):263-76. https://doi.org/10.1016/j.maturitas.2014.05.007

223. Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. *Menopause (10723714)*. 2013;20(11):1207-15. https://doi.org/10.1097/GME.0b013e3182896ae5

224. Kim MS, Lim HJ, Yang HJ, Lee MS, Shin BC, Ernst E. Ginseng for managing menopause symptoms: a systematic review of randomized clinical trials. *J Ginseng Res*. 2013;37(1):30-6. https://doi.org/10.5142/jgr.2013.37.30

225. Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: Ethnopharmacology, clinical application, safety and evaluation of clinical trials. *Journal of Ethnopharmacology*. 2013;150(3):791-804. https://doi.org/10.1016/j.jep.2013.09.047

226. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. *Gynecological Endocrinology*. 2012;28(9):703-9. https://doi.org/10.3109/09513590.2011.650772

227. Ulbricht C, Basch E, Basch S, Chao W, Conquer J, Costa D, et al. Hops (Humulus lupulus): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. *Alternative and Complementary Therapies*. 2012;18(2):98-108. https://doi.org/10.1089/act.2012.18204

228. Clement YN, Onakpoya I, Hung SK, Ernst E. Effects of herbal and dietary supplements on cognition in menopause: A systematic review. *Maturitas*. 2011;68(3):256-63. https://doi.org/10.1016/j.maturitas.2010.12.005

229. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. *Pharmacological Research*. 2008;58(1):8-14. https://doi.org/10.1016/j.phrs.2008.05.008

230. Booth NL, Piersen CE, Banuvar S, Geller SE, Shulman LP, Farnsworth NR. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review. *Menopause (10723714)*. 2006;13(2):251-64. https://doi.org/10.1097/01.gme.0000198297.40269.f7

231. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: A systematic review. *Obstetrics and Gynecology*. 2004;104(4):824-36. https://doi.org/10.1097/01.AOG.0000140688.71638.d3

232. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. *Menopause (10723714)*. 2003;10(5):465-76. https://doi.org/10.1097/01.gme.0000058147.24036.b0

233. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. *European Journal of Clinical Pharmacology*. 2002;58(4):235-41. https://doi.org/10.1007/s00228-002-0457-2

234. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996;17(1):1-12. https://doi.org/10.1016/0197-2456(95)00134-4

235. Beyond Blue. Anxiety n.d. [30 July 2021]. Available from: https://www.beyondblue.org.au/the-facts/anxiety.

236. Australian Institute of Health and Welfare. Australian Burden of Disease Study: impact and causes of illness and death in Australia 2015. 2019. [Accessed: 16 Dec 2020]. Available from: https://www.aihw.gov.au/reports/burden-of-disease/burden-disease-study-illness-death-2015.

237. Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. *Australian & New Zealand Journal of Psychiatry*. 2018;52(12):1109-72. https://doi.org/10.1177/0004867418799453

238. Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K. Passiflora incarnata in Neuropsychiatric Disorders—A Systematic Review. *Nutrients*. 2020;12(12):3894. https://doi.org/10.3390/nu12123894

239. Sayed AM, Morsy S, Tawfik GM, Naveed S, Minh-Duc NT, Hieu TH, et al. The best route of administration of lavender for anxiety: a systematic review and network meta-analysis. *General Hospital Psychiatry*. 2020;64:33-40. https://doi.org/10.1016/j.genhosppsych.2020.02.001

240. Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: A systematic review and meta-analysis. *Phytomedicine*. 2019;65:N.PAG-N.PAG. https://doi.org/10.1016/j.phymed.2019.153099

241. Hieu TH, Dibas M, Surya Dila KA, Sherif NA, Hashmi MU, Mahmoud M, et al. Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta-analysis of randomized trials and quasi-randomized trials. *Phytother Res*. 2019;33(6):1604-15. https://doi.org/10.1002/ptr.6349

242. Marx W, Lane M, Rocks T, Ruusunen A, Loughman A, Lopresti A, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. *Nutrition Reviews*. 2019;77(8):557-71. https://doi.org/10.1093/nutrit/nuz023

243. Moller HJ, Volz HP, Dienel A, Schlafke S, Kasper S. Efficacy of Silexan in subthreshold anxiety: Meta-analysis of randomised, placebo-controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*. 2019;269(2):183-93. https://doi.org/10.1007/s00406-017-0852-4

244. Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis. *Scientific Reports*. 2019;9(1):18042. https://doi.org/10.1038/s41598-019-54529-9

245. Barić H, Đorđević V, Cerovečki I, Trkulja V. Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials. *Advances in Therapy*. 2018;35(3):261-88. https://doi.org/10.1007/s12325-018-0680-6

246. Ooi SL, Henderson P, Pak SC. Kava for Generalized Anxiety Disorder: A Review of Current Evidence. *Journal of Alternative & Complementary Medicine*. 2018;24(8):770-80. https://doi.org/10.1089/acm.2018.0001

247. Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. *Complementary Therapies in Clinical Practice*. 2018;33:107-17. https://doi.org/10.1016/j.ctcp.2018.09.003

248. Brondino N, De Silvestri A, Re S, Lanati N, Thiemann P, Verna A, et al. A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. *Evidence-based Complementary & Alternative Medicine (eCAM)*. 2013;2013:1-11. https://doi.org/10.1155/2013/915691

249. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. *Journal of Psychopharmacology*. 2007;21(8):864-72. https://doi.org/10.1177/0269881107076996

250. Miyasaka LS, Atallah Á, Soares B. Passiflora for anxiety disorder. *Cochrane Database of Systematic Reviews*. 2007(1):CD004518. https://doi.org/10.1002/14651858.CD004518.pub2

251. Miyasaka LS, Atallah Á, Soares B. Valerian for anxiety disorders. *Cochrane Database of Systematic Reviews*. 2006(4):CD004515. https://doi.org/10.1002/14651858.CD004515.pub2

252. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. *Phytotherapy Research*. 2005;19(3):183-8. https://doi.org/10.1002/ptr.1609

253. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. *Cochrane Database of Systematic Reviews*. 2003(1). https://doi.org/10.1002/14651858.CD003383

254. Pittler MH, Ernst E, Astin BBBBBBCCDDEEGHHHHHHJJJKKLLLLLL. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. *Journal of Clinical Psychopharmacology*. 2000;20(1):84-9. https://doi.org/10.1097/00004714-200002000-00014

255. Lopresti AL, Smith SJ. Ashwagandha (Withania somnifera) for the treatment and enhancement of mental and physical conditions: A systematic review of human trials. *Journal of Herbal Medicine*. 2021;28:100434. https://doi.org/10.1016/j.hermed.2021.100434

256. Lopresti AL, Smith SJ, Drummond PD. Modulation of the hypothalamic-pituitary-adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials. *Nutr Neurosci*. 2022;25(8):1704-30. https://doi.org/10.1080/1028415X.2021.1892253

257. Tandon N, Yadav SS. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. *J Ethnopharmacol*. 2020;255:112768. https://doi.org/10.1016/j.jep.2020.112768

258. Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. *Phytotherapy Research*. 2018;32(7):1147-62. https://doi.org/10.1002/ptr.6055

259. Pratte MA, Nanavati KB, Young V, Morley CP. An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha ( Withania somnifera). *Journal of Alternative & Complementary Medicine*. 2014;20(12):901-8. https://doi.org/10.1089/acm.2014.0177

260. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. *CNS Drugs*. 2013;27(4):301-19. https://doi.org/10.1007/s40263-013-0059-9

261. Perry R, Terry R, Watson LK, Ernst E. Is lavender an anxiolytic drug? A systematic review of randomised clinical trials. *Phytomedicine*. 2012;19(8/9):825-35. https://doi.org/10.1016/j.phymed.2012.02.013

262. Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, et al. Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: A review of current evidence. *Evidence-based Complementary and Alternative Medicine*. 2012;2012:809653. https://doi.org/10.1155/2012/809653

263. Sarris J, Laporte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. *Australian and New Zealand Journal of Psychiatry*. 2011;45(1):27-35. https://doi.org/10.3109/00048674.2010.522554

264. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. *Nutrition Journal*. 2010;9:42-. https://doi.org/10.1186/1475-2891-9-42

265. Provino R. The role of adaptogens in stress management. *Australian Journal of Medical Herbalism*. 2010;22:41+.

266. Sarris J, Kavanagh DJ, Alonso AAABBBBBBBBBBBBBCCCCCCDDDFFFGG. Kava and St. John's wort: Current evidence for use in mood and anxiety disorders. *The Journal of Alternative and Complementary Medicine*. 2009;15(8):827-36. https://doi.org/10.1089/acm.2009.0066

267. Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. *Phytotherapy Research*. 2007;21(8):703-16. https://doi.org/10.1002/ptr.2187

268. Ernst E. Herbal remedies for anxiety -- a systematic review of controlled clinical trials. *Phytomedicine*. 2006;13(3):205-8. https://doi.org/10.1016/j.phymed.2004.11.006

269. Jorm AF, Christensen H, Griffiths KM, Parslow RA, Rodgers B, Blewitt KA. Effectiveness of complementary and self-help treatments for anxiety disorders. *Medical Journal of Australia*. 2004;181(7 Supp):S29-46. https://doi.org/10.5694/j.1326-5377.2004.tb06352.x

270. Nunes A, Sousa M. [Use of valerian in anxiety and sleep disorders: what is the best evidence?]. *Acta Med Port*. 2011;24 Suppl 4:961-6.

271. Faustino TT, Almeida RB, Andreatini R. [Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies]. *Braz J Psychiatry*. 2010;32(4):429-36. https://doi.org/10.1590/s1516-44462010005000026

272. Welfare AIoHa. Australia’s Health 2014. *AIHW: Canberra*. 2014.

273. Australian Bureau of Statistics A. National Survey of Mental Health and Wellbeing: Summary of Results, 2007. 2008. p. 27-8.

274. WHO. Depression: World Health Organization; 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/depression.

275. American Psychiatric Association A. DSMIV‐TR: Diagnostic and Statistical Manual of Mental Disorders. Arlington, Virginia: American Psychiatric Association; 2000.

276. WHO. Depression a global public health concern. 2012. [Accessed: 21 September 2021]. Available from: http://www.who.int/mental\_health/management/depression/who\_paper\_depression\_wfmh\_2012.pdf.

277. Beyond Blue. Types of depression. 2024. [Accessed: September 2024]. Available from: https://www.beyondblue.org.au/mental-health/depression/types-of-depression.

278. Bressington D, Mui J, Yu C, Leung SF, Cheung K, Wu CST, et al. Feasibility of a group-based laughter yoga intervention as an adjunctive treatment for residual symptoms of depression, anxiety and stress in people with depression. *J Affect Disord*. 2019;248:42-51. https://doi.org/10.1016/j.jad.2019.01.030

279. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry*. 2021;55(1):7-117. https://doi.org/10.1177/0004867420979353

280. Wang Z, Zhang Q, Huang H, Liu Z. The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis. *Journal of Affective Disorders*. 2021;282:242-51. https://doi.org/10.1016/j.jad.2020.12.158

281. Dai L, Chen L, Wang W. Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis. *Journal of Nervous & Mental Disease*. 2020;208(4):269-76. https://doi.org/10.1097/NMD.0000000000001118

282. Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, et al. Curcumin for depression: a meta-analysis. *Critical Reviews in Food Science & Nutrition*. 2020;60(15):2643-53. https://doi.org/10.1080/10408398.2019.1653260

283. Khaksarian M, Behzadifar M, Behzadifar M, Alipour M, Jahanpanah F, Re TS, et al. The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: A systematic review and meta-analysis. *Psychology Research and Behavior Management*. 2019;12:297-305. https://doi.org/10.2147/PRBM.S199343

284. Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, et al. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. *Planta Medica*. 2019;85(1):24-31. https://doi.org/10.1055/a-0660-9565

285. Yang X, Chen X, Fu Y, Luo Q, Du L, Qiu H, et al. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. *Neuropsychiatr Dis Treat*. 2018;14:1297-305. https://doi.org/10.2147/ndt.S157550

286. Ng QX, Venkatanarayanan N, Ho CYX. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. *Journal of Affective Disorders*. 2017;210:211-21. https://doi.org/10.1016/j.jad.2016.12.048

287. Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical Use of Curcumin in Depression: A Meta-Analysis. *Journal of the American Medical Directors Association*. 2017;18(6):503-8. https://doi.org/10.1016/j.jamda.2016.12.071

288. Asher GN, Gartlehner G, Gaynes BN, Amick HR, Forneris C, Morgan LC, et al. Comparative Benefits and Harms of Complementary and Alternative Medicine Therapies for Initial Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. *Journal of Alternative & Complementary Medicine*. 2017;23(12):907-19. https://doi.org/10.1089/acm.2016.0261

289. Al‐Karawi D, Al Mamoori DA, Tayyar Y. The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials. *Phytotherapy Research*. 2016;30(2):175-83. https://doi.org/10.1002/ptr.5524

290. Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JNV, Sorbero ME, et al. A systematic review of St. John's wort for major depressive disorder. *Systematic Reviews*. 2016;5(1):148. https://doi.org/10.1186/s13643-016-0325-2

291. Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. *Neuropsychiatr Dis Treat*. 2016;12:1715-23. https://doi.org/10.2147/NDT.S106752

292. Linde K, Berner MM, Kriston L. St John's wort for major depression. *Cochrane Database of Systematic Reviews*. 2009(4):CD000448.

293. Whiskey E, Werneke U, Taylor D, Bergmann BBBBCCCDDEEGGGHHHHHHHJKKLLLLLM. A systematic review and meta-analyis of Hypericum perforatum in depression: A comprehensive clinical review. *International Clinical Psychopharmacology*. 2001;16(5):239-52. https://doi.org/10.1097/00004850-200109000-00001

294. Williams JW, Jr., Mulrow CD, Chiquette E, Noël PH, Aguilar C, Cornell J, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. *Annals of Internal Medicine*. 2000;132(9):743-56. https://doi.org/10.7326/0003-4819-132-9-200005020-00011

295. Kim HL, Streltzer J, Goebert D, Bergmann CDDEGHHHHHJJKKLMMMMNNORSSVVWW. St. John's Wort for depression: A meta-analysis of well-defined clinical trials. *Journal of Nervous and Mental Disease*. 1999;187(9):532-8. https://doi.org/10.1097/00005053-199909000-00002

296. Matias JN, Achete G, Campanari G, Guiguer EL, Araujo AC, Buglio DS, et al. A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory. *Australian & New Zealand Journal of Psychiatry*. 2021;55(5):4867421998795. https://doi.org/10.1177/0004867421998795

297. McCloskey RJ, Reno R. Complementary health approaches for postpartum depression: A systematic review. *Social Work in Mental Health*. 2018;17(1):106-28. https://doi.org/10.1080/15332985.2018.1509412

298. Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. *Phytotherapy Research*. 2018;32(5):865-91. https://doi.org/10.1002/ptr.6033

299. Maher AR, Hempel S, Apaydin E, Shanman RM, Booth M, Miles JN, et al. St. John's Wort for Major Depressive Disorder: A Systematic Review. *Rand Health Quarterly*. 2016;5(4):12.

300. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: A meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*. 2013;11(6):377-83. https://doi.org/10.3736/jintegrmed2013056

301. Dhingra S, Parle M, Andrews ABCCCDCDEFFFFFFGHJKK-ELLMMPPPPS. Herbal remedies and nutritional supplements in the treatment of depression: A review. *Klinik Psikofarmakoloji Bulteni / Bulletin of Clinical Psychopharmacology*. 2012;22(3):286-92. https://doi.org/10.5455/bcp.20120729090446

302. Dwyer AV, Whitten DL, Hawrelak JA. Herbal Medicines, other than St. John's Wort, in the Treatment of Depression: A Systematic Review. *Alternative Medicine Review*. 2011;16(1):40-9.

303. Hung SK, Perry R, Ernst E. The effectiveness and efficacy of Rhodiola rosea L.: A systematic review of randomized clinical trials. *Phytomedicine*. 2011;18(4):235-44. https://doi.org/10.1016/j.phymed.2010.08.014

304. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *Eur Neuropsychopharmacol*. 2011;21(12):841-60. https://doi.org/10.1016/j.euroneuro.2011.04.002

305. Ulbricht C, Chao W, Tanguay-Colucci S, Costa D, Culwell S, Giese N, et al. Rhodiola ( Rhodiola spp.): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. *Alternative & Complementary Therapies*. 2011;17(2):110-9. https://doi.org/10.1089/act.2011.17208

306. Morgan AJ, Jorm AF, Akhondzadeh AAAAABBBBBBBBBBBBBBBBBBBBCCCCC. Self-help interventions for depressive disorders and depressive symptoms: A systematic review. *Annals of General Psychiatry*. 2008;7:13. https://doi.org/10.1186/1744-859X-7-13

307. Gahlsdorf T, Krause R, Beal MW. Efficacy of St. John's wort for treating mild to moderate depression. *Complementary Health Practice Review*. 2007;12(3):184-95. https://doi.org/10.1177/1533210107306294

308. Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. *Holist Nurs Pract*. 2006;20(4):197-203. https://doi.org/10.1097/00004650-200607000-00008

309. Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. Effectiveness of complementary and self-help treatments for depression in children and adolescents. *Medical Journal of Australia*. 2006;185(7):368-72.

310. Frazer CJ, Christensen H, Griffiths KM. Effectiveness of treatments for depression in older people. *Medical Journal of Australia*. 2005;182(12):627-32. https://doi.org/10.5694/j.1326-5377.2005.tb06849.x

311. Jorm AF, Christensen H, Griffiths KM, Rodgers B. Effectiveness of complementary and self-help treatments for depression. *Medical Journal of Australia*. 2002;176 Supp(10):S84-96. https://doi.org/10.5694/j.1326-5377.2002.tb04508.x

312. Gaster B, Holroyd J. St John's Wort for depression: a systematic review. *Archives of Internal Medicine*. 2000;160(2):152-8. https://doi.org/10.1001/archinte.160.2.152

313. Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence. *European Neuropsychopharmacology*. 1999;9(6):501-5. https://doi.org/10.1016/s0924-977x(99)00032-2

314. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - An overview. *Pharmacopsychiatry*. 1997;30(SUPPL.):72-6. https://doi.org/10.1055/s-2007-979522

315. Ernst E. St. John's Wort, an anti-depressant? A systematic, criteria-based review. *Phytomedicine*. 1995;2(1):67-71. https://doi.org/10.1016/S0944-7113(11)80051-6

316. Jou HJ, Hsu IP, Ling PY, Huang HT, Lin CT, Wu SC. Extracts of St. John's wort for mild to moderate depression - A meta-analysis of randomized, double-blinded and placebo-controlled trials. *Nutritional Sciences Journal*. 2005;30(4):166-73.

317. Roder C, Schaefer M, Leucht S. [Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort]. *Fortschr Neurol Psychiatr*. 2004;72(6):330-43. https://doi.org/10.1055/s-2003-812513

318. Werneke U, Horn O, Taylor DM. How Effective Is St. John’s Wort? The Evidence Revisited. *The Journal of Clinical Psychiatry*. 2004;65(5):471-7. https://doi.org/10.4088/JCP.v65n0504

319. Schulz V. [New therapeutic studies and meta-analysis. St. John's wort extract vs. synthetics]. *Pharm Unserer Zeit*. 2003;32(3):228-34; discussion 34-5. https://doi.org/10.1002/pauz.200390069

320. Laakmann G, Jahn G, Schule C. [Hypericum perforatum extract in treatment of mild to moderate depression. Clinical and pharmacological aspects]. *Nervenarzt*. 2002;73(7):600-12. https://doi.org/10.1007/s00115-002-1300-9

321. Laux P, Volz H-P. Antidepressive pharmacotherapy in mild to moderate depression - A comparison of extracts of St. John's wort and fluoxetine. *Psychopharmakotherapie*. 1999;6(4):138-42.

322. Reynolds A, Appleton, S., Gill, T. and Adams, R. . Chronic Insomnia Disorder in Australia. A Report to the Sleep Health Foundation. 2019. [Accessed: July 2019]. Available from: https://www.sleephealthfoundation.org.au/pdfs/Special\_Reports/SHF\_Insomnia\_Report\_2019\_Final\_SHFlogo.pdf

323. Santos-Longhurst A. What Are the Different Types of Insomnia? 2019. [Accessed. Available from: https://www.healthline.com/health/types-of-insomnia#types.

324. Grima N, Bei B, Mansfield D. Insomnia theory and assessment. Australian Journal for General Practitioners [Internet]. 2019. [Accessed: 03/19]; 48:[193-7 pp.]. Available from: https://www1.racgp.org.au/ajgp/2019/april/insomnia-theory-and-assessment.

325. Grima N, Bei B, Mansfield D. Insomnia management. Australian Journal for General Practitioners [Internet]. 2019. [Accessed: 03/20]; 48:[198-202 pp.]. Available from: https://www1.racgp.org.au/ajgp/2019/april/insomnia-management.

326. Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. *Eur J Clin Pharmacol*. 2020;76(3):363-81. https://doi.org/10.1007/s00228-019-02812-z

327. Feizi F, Namazi N, Rahimi R, Ayati MH. Medicinal Plants for Management of Insomnia: A Systematic Review of Animal and Human Studies. *Galen Med J*. 2019;8:e1085. https://doi.org/10.31661/gmj.v8i0.1085

328. Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. *Sleep Med Rev*. 2015;24:1-12. https://doi.org/10.1016/j.smrv.2014.12.003

329. Taslaman M. The efficacy and safety of herbal medicine for insomnia in adults: An overview of recent research. *Australian Journal of Herbal Medicine*. 2014;26(3):86-93.

330. Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. *Sleep Med Rev*. 2011;15(2):99-106. https://doi.org/10.1016/j.smrv.2010.04.001

331. Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. *Sleep Med*. 2010;11(6):505-11. https://doi.org/10.1016/j.sleep.2009.12.009

332. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. *Sleep Med Rev*. 2007;11(3):209-30. https://doi.org/10.1016/j.smrv.2007.03.002

333. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. *Sleep Med*. 2000;1(2):91-9. https://doi.org/10.1016/s1389-9457(99)00015-5

334. Bostanova Z, Riemann D, Feige B, Baglioni C, Hertenstein E, Rucker G. Abstracts of the 24th Congress of the European Sleep Research Society, 25-28 September 2018, Basel, Switzerland. *J Sleep Res*. 2018;27 Suppl 1(Supplement 1):e12751. https://doi.org/10.1111/jsr.12751

335. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). *Arthritis Care Res (Hoboken)*. 2011;63 Suppl 11(0 11):S467-72. https://doi.org/10.1002/acr.20561

336. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: The Royal Australian College of General Practitioners; 2020 [cited 2020]. Available from: https://www.racgp.org.au/getattachment/41fee8dc-7f97-4f87-9d90-b7af337af778/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx.

337. Rao SS, Disraeli P, McGregor T. Impaired glucose tolerance and impaired fasting glucose. *Am Fam Physician*. 2004;69(8):1961-8.

338. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. *Diabetes*. 1997;46(4):701-10. https://doi.org/10.2337/diab.46.4.701

339. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care*. 2002;25(5):829-34. https://doi.org/10.2337/diacare.25.5.829

340. Ligthart S, van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. *Lancet Diabetes Endocrinol*. 2016;4(1):44-51. https://doi.org/10.1016/s2213-8587(15)00362-9

341. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. *Lancet*. 2012;379(9833):2279-90. https://doi.org/10.1016/s0140-6736(12)60283-9

342. Boyko EJ, Magliano DJ, Karuranga S, Piemonte L, Riley P, Saeedi P, et al., (editors). IDF Diabetes Atlas 10th edition: International Diabetes Federation; 2021 [cited 2021]. Available from: https://diabetesatlas.org/.

343. Tijs L, Hunter J, Molodysky E. Annual trends in diabetes screening and management in Australia: A secondary analysis of Medicare Benefits Schedule data. *Aust J Gen Pract*. 2021;50(10):766-72. https://doi.org/10.31128/AJGP-11-20-5718

344. Petersmann A, Muller-Wieland D, Muller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2019;127(S 01):S1-S7. https://doi.org/10.1055/a-1018-9078

345. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatr Diabetes*. 2018;19 Suppl 27(Suppl 27):7-19. https://doi.org/10.1111/pedi.12773

346. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S13-S27. https://doi.org/10.2337/dc18-S002

347. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. *Health Promot Perspect*. 2020;10(2):98-115. https://doi.org/10.34172/hpp.2020.18

348. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. *N Engl J Med*. 2019;381(7):603-13. https://doi.org/10.1056/NEJMoa1902226

349. World Health Organization. Diabetes 2020 [Available from: https://www.who.int/health-topics/diabetes#tab=tab\_1.

350. Centers for Disease Control and Prevention. Type 1 Diabetes 2020 [Available from: https://www.cdc.gov/diabetes/basics/type1.html.

351. Diabetes Australia. Type 1 Diabetes 2020 [Available from: https://www.diabetesaustralia.com.au/about-diabetes/type-1-diabetes/.

352. Diabetes Australia. Type 2 Diabetes 2020 [Available from: https://www.diabetesaustralia.com.au/about-diabetes/type-2-diabetes/.

353. Donovan P, David McIntyre H. Drugs for gestational diabetes. *Australian Prescriber*. 2010;33(5):141-4.

354. Diabetes Australia. Gestational diabetes 2020 [Available from: https://www.diabetesaustralia.com.au/about-diabetes/gestational-diabetes/.

355. Poola-Kella S, Steinman RA, Mesmar B, Malek R. Gestational Diabetes Mellitus: Post-partum Risk and Follow Up. *Rev Recent Clin Trials*. 2018;13(1):5-14. https://doi.org/10.2174/1574887112666170911124806

356. Australian Institute of Health and Welfare. Diabetes 2020 [Available from: https://www.aihw.gov.au/reports/diabetes/diabetes/contents/how-many-australians-have-diabetes.

357. Australian Institute of Health and Welfare. Australian Burden of Disease Study 2018: Interactive data on risk factor burden. 2021. [Accessed: Sept 2024]. Available from: https://www.aihw.gov.au/reports/burden-of-disease/abds-2018-interactive-data-risk-factors/contents/high-blood-plasma-glucose.

358. Australian Diabetes Educators Association. Clinical Guiding Principles for Sick Day Management of Adults with Type 1 and Type 2 Diabetes 2016 [Available from: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.001~2014-15~Main%20Features~Diabetes%20mellitus~12.

359. American Diabetes A. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S126-S36. https://doi.org/10.2337/dc18-S012

360. Cao H, Yang G, Wang Y, Liu JP, Smith CA, Luo H, et al. Complementary therapies for acne vulgaris. *Cochrane Database Syst Rev*. 2015;1(1):CD009436. https://doi.org/10.1002/14651858.CD009436.pub2

361. Medagama AB, Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? *Nutr J*. 2014;13(1):102. https://doi.org/10.1186/1475-2891-13-102

362. Asbaghi O, Fouladvand F, Moradi S, Ashtary-Larky D, Choghakhori R, Abbasnezhad A. Effect of green tea extract on lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes & Metabolic Syndrome*. 2020;14(4):293-301. https://doi.org/10.1016/j.dsx.2020.03.018

363. Asbaghi O, Fouladvand F, Ashtary-Larky D, Bagheri R, Choghakhori R, Wong A, et al. Effects of green tea supplementation on serum concentrations of adiponectin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Archives of Physiology & Biochemistry*. 2020;129(2):1-8. https://doi.org/10.1080/13813455.2020.1846202

364. Durg S, Bavage S, Shivaram SB. Withania somnifera (Indian ginseng) in diabetes mellitus: A systematic review and meta-analysis of scientific evidence from experimental research to clinical application. *Phytotherapy Research*. 2020;34(5):1041-59. https://doi.org/10.1002/ptr.6589

365. Barzkar F, Baradaran HR, Khamseh ME, Vesal Azad R, Koohpayehzadeh J, Moradi Y. Medicinal plants in the adjunctive treatment of patients with type-1 diabetes: a systematic review of randomized clinical trials. *J Diabetes Metab Disord*. 2020;19(2):1917-29. https://doi.org/10.1007/s40200-020-00633-x

366. Hajizadeh-Sharafabad F, Varshosaz P, Jafari-Vayghan H, Alizadeh M, Maleki V. Chamomile (Matricaria recutita L.) and diabetes mellitus, current knowledge and the way forward: A systematic review. *Complementary Therapies in Medicine*. 2020;48:102284. https://doi.org/10.1016/j.ctim.2019.102284

367. Heshmati J, Morvaridzadeh M, Sepidarkish M, Fazelian S, Rahimlou M, Omidi A, et al. Effects of Melissa officinalis (Lemon Balm) on cardio‐metabolic outcomes: A systematic review and meta‐analysis. *Phytotherapy Research*. 2020;34(12):3113-23. https://doi.org/10.1002/ptr.6744

368. Jalali R, Mahmoodi M, Moosavian SP, Ferns GA, Sohrabi Z. Cinnamon supplementation improves blood pressure in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials. *Clinical Diabetology*. 2020;9(4):259-66. https://doi.org/10.5603/DK.2020.0021

369. Jamali N, Jalali M, Saffari-Chaleshtori J, Samare-Najaf M, Samareh A. Effect of cinnamon supplementation on blood pressure and anthropometric parameters in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials. *Diabetes & Metabolic Syndrome*. 2020;14(2):119-25. https://doi.org/10.1016/j.dsx.2020.01.009

370. Jamali N, Kazemi A, Saffari-Chaleshtori J, Samare-Najaf M, Mohammadi V, Clark CCT. The effect of cinnamon supplementation on lipid profiles in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials. *Complementary Therapies in Medicine*. 2020;55:102571. https://doi.org/10.1016/j.ctim.2020.102571

371. Tabrizi R, Nowrouzi-Sohrabi P, Hessami K, Rezaei S, Jalali M, Savardashtaki A, et al. Effects of Ginkgo biloba intake on cardiometabolic parameters in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2020;08:08. https://doi.org/10.1002/ptr.6822

372. Xiao Z, Chen H, Zhang Y, Deng H, Wang K, Bhagavathula AS, et al. The effect of psyllium consumption on weight, body mass index, lipid profile, and glucose metabolism in diabetic patients: A systematic review and dose-response meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2020;34(6):1237-47. https://doi.org/10.1002/ptr.6609

373. Ziaei R, Foshati S, Hadi A, Kermani MAH, Ghavami A, Clark CCT, et al. The effect of nettle (Urtica dioica) supplementation on the glycemic control of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Phytotherapy Research*. 2020;34(2):282-94. https://doi.org/10.1002/ptr.6535

374. Akbari M, Lankarani KB, Tabrizi R, Ghayour-Mobarhan M, Peymani P, Ferns G, et al. The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Front Pharmacol*. 2019;10:649. https://doi.org/10.3389/fphar.2019.00649

375. Huang F-Y, Deng T, Meng L-X, Ma X-L. Dietary ginger as a traditional therapy for blood sugar control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Medicine*. 2019;98(9):e15054-e. https://doi.org/10.1097/MD.0000000000015054

376. Namazi N, Khodamoradi K, Khamechi SP, Heshmati J, Ayati MH, Larijani B. The impact of cinnamon on anthropometric indices and glycemic status in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials. *Complementary Therapies in Medicine*. 2019;43:92-101. https://doi.org/10.1016/j.ctim.2019.01.002

377. Asbaghi O, Fouladvand F, Gonzalez MJ, Aghamohammadi V, Choghakhori R, Abbasnezhad A. The effect of green tea on C-reactive protein and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2019;46:210-6. https://doi.org/10.1016/j.ctim.2019.08.019

378. Deyno S, Eneyew K, Seyfe S, Tuyiringire N, Peter EL, Muluye RA, et al. Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression. *Diabetes Research and Clinical Practice*. 2019;156:107815. https://doi.org/10.1016/j.diabres.2019.107815

379. Rocha DMUP, Caldas APS, da Silva BP, Hermsdorff HHM, Alfenas RdCG. Effects of blueberry and cranberry consumption on type 2 diabetes glycemic control: A systematic review. *Critical Reviews in Food Science & Nutrition*. 2019;59(11):1816-28. https://doi.org/10.1080/10408398.2018.1430019

380. Shabani E, Sayemiri K, Mohammadpour M. The effect of garlic on lipid profile and glucose parameters in diabetic patients: A systematic review and meta-analysis. *Primary Care Diabetes*. 2019;13(1):28-42. https://doi.org/10.1016/j.pcd.2018.07.007

381. Yuan F, Dong H, Gong J, Wang D, Hu M, Huang W, et al. A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases. *Advances in Nutrition*. 2019;10(5):791-802. https://doi.org/10.1093/advances/nmz021

382. Zhang L, Shergis JL, Yang L, Zhang AL, Guo X, Zhou S, et al. Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis. *Journal of Ethnopharmacology*. 2019;239:111921.

383. Tabrizi R, Akbari M, Vakili S, Lankarani KB, Mirhosseini N, Ghayour-Mobarhan M, et al. The effects of curcumin on glycemic control and lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. *Current Pharmaceutical Design*. 2018;24(27):3184-99. https://doi.org/10.2174/1381612824666180828162053

384. Zhu J, Chen H, Song Z, Wang X, Sun Z. Effects of ginger (Zingiber officinale Roscoe) on type 2 diabetes mellitus and components of the metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *Evidence-Based Complementary andAlternative Medicine*. 2018;2018:5692962. https://doi.org/10.1155/2018/5692962

385. Altobelli E, Angeletti PM, Marziliano C, Mastrodomenico M, Giuliani AR, Petrocelli R. Potential therapeutic effects of curcumin on glycemic and lipid profile in uncomplicated type 2 diabetes-a meta-analysis of randomized controlled trial. *Nutrients*. 2021;13(2):1-13. https://doi.org/10.3390/nu13020404

386. Asbaghi O, Sadeghian M, Sadeghi O, Rigi S, Tan SC, Shokri A, et al. Effects of saffron (Crocus sativus L.) supplementation on inflammatory biomarkers: A systematic review and meta-analysis. *Phytotherapy Research*. 2021;35(1):20-32. https://doi.org/10.1002/ptr.6748

387. Asbaghi O, Fouladvand F, Gonzalez MJ, Ashtary-Larky D, Choghakhori R, Abbasnezhad A. Effect of green tea on glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes & Metabolic Syndrome*. 2021;15(1):23-31. https://doi.org/10.1016/j.dsx.2020.11.004

388. Atefi M, Ghavami A, Hadi A, Askari G. The effect of barberry (Berberis vulgaris L.) supplementation on blood pressure: A systematic review and meta-analysis of the randomized controlled trials. *Complementary Therapies in Medicine*. 2021;56:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102608

389. Karimi E, Farrokhzad A, Darand M, Arab A. The Effect of Saffron Consumption on Liver Function: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. *Complementary Medical Research*. 2021;28(5):1-10. https://doi.org/10.1159/000515003

390. Kutbi EH, Sohouli MH, Fatahi S, Lari A, Shidfar F, Aljhdali MM, et al. The beneficial effects of cinnamon among patients with metabolic diseases: A systematic review and dose-response meta-analysis of randomized-controlled trials. *Critical Reviews in Food Science and Nutrition*. 2021;62(22):6113-31. https://doi.org/10.1080/10408398.2021.1896473

391. Moradi M, Sohrabi G, Golbidi M, Yarmohammadi S, Hemati N, Campbell MS, et al. Effects of artichoke on blood pressure: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2021;57:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2021.102668

392. Mousavi SM, Mokhtari P, Asbaghi O, Rigi S, Persad E, Jayedi A, et al. Does saffron supplementation have favorable effects on liver function indicators? A systematic review and meta-analysis of randomized controlled trials. *Critical Reviews in Food Science and Nutrition*. 2021;62(23):6315-27. https://doi.org/10.1080/10408398.2021.1900059

393. Shekarchizadeh-Esfahani P, Heydarpour F, Izadi F, Jalili C. The effect of cinnamon supplementation on liver enzymes in adults: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2021;58:102699. https://doi.org/10.1016/j.ctim.2021.102699

394. Askari G, Aghajani M, Salehi M, Najafgholizadeh A, Keshavarzpour Z, Fadel A, et al. The effects of ginger supplementation on biomarkers of inflammation and oxidative stress in adults: A systematic review and meta-analysis of randomized controlled trials. *Journal of Herbal Medicine*. 2020;22:100364. https://doi.org/10.1016/j.hermed.2020.100364

395. Askarpour M, Alami F, Campbell MS, Venkatakrishnan K, Hadi A, Ghaedi E. Effect of fenugreek supplementation on blood lipids and body weight: A systematic review and meta-analysis of randomized controlled trials. *Journal of Ethnopharmacology*. 2020;253:112538. https://doi.org/10.1016/j.jep.2019.112538

396. Clark CCT, Salek M, Aghabagheri E, Jafarnejad S. The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. *Korean Journal of Internal Medicine*. 2020;35(6):1385-99. https://doi.org/10.3904/kjim.2019.049

397. Hadi A, Campbell MS, Hassani B, Pourmasoumi M, Salehi-Sahlabadi A, Hosseini SA. The effect of cinnamon supplementation on blood pressure in adults: A systematic review and meta-analysis of randomized controlled trials. *Clinical Nutrition ESPEN*. 2020;36:10-6. https://doi.org/10.1016/j.clnesp.2020.01.002

398. Jalili C, Moradi S, Babaei A, Boozari B, Asbaghi O, Lazaridi A-V, et al. Effects of Cynara scolymus L. on glycemic indices:A systematic review and meta-analysis of randomized clinical trials. *Complementary Therapies in Medicine*. 2020;52:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102496

399. Khodamoradi K, Khosropanah MH, Ayati Z, Chang D, Nasli-Esfahani E, Ayati MH, et al. The Effects of Fenugreek on Cardiometabolic Risk Factors in Adults: A Systematic Review and Meta-analysis. *Complementary Therapies in Medicine*. 2020;52:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102416

400. Miraghajani M, Hadi A, Hajishafiee M, Arab A, Ghaedi E, Moody V. The effects of ginseng supplementation on anthropometric indices and body composition: A systematic review and meta-analysis. *Journal of Herbal Medicine*. 2020;23:100379. https://doi.org/10.1016/j.hermed.2020.100379

401. Morvaridzadeh M, Fazelian S, Agah S, Khazdouz M, Rahimlou M, Agh F, et al. Effect of ginger (Zingiber officinale) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. *Cytokine*. 2020;135:155224. https://doi.org/10.1016/j.cyto.2020.155224

402. Mousavi SM, Karimi E, Hajishafiee M, Milajerdi A, Amini MR, Esmaillzadeh A. Anti-hypertensive effects of cinnamon supplementation in adults: A systematic review and dose-response Meta-analysis of randomized controlled trials. *Critical Reviews in Food Science & Nutrition*. 2020;60(18):3144-54. https://doi.org/10.1080/10408398.2019.1678012

403. Mousavi SM, Rahmani J, Kord-Varkaneh H, Sheikhi A, Larijani B, Esmaillzadeh A. Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. *Clinical Nutrition*. 2020;39(1):123-33. https://doi.org/10.1016/j.clnu.2019.02.017

404. Mousavi SM, Milajerdi A, Varkaneh HK, Gorjipour MM, Esmaillzadeh A. The effects of curcumin supplementation on body weight, body mass index and waist circumference: a systematic review and dose-response meta-analysis of randomized controlled trials. *Critical Reviews in Food Science and Nutrition*. 2020;60(1):171-80. https://doi.org/10.1080/10408398.2018.1517724

405. Pourmasoumi M, Hadi A, Najafgholizadeh A, Joukar F, Mansour-Ghanaei F. The effects of cranberry on cardiovascular metabolic risk factors: A systematic review and meta-analysis. *Clinical Nutrition*. 2020;39(3):774-88. https://doi.org/10.1016/j.clnu.2019.04.003

406. Rahmani J, Bazmi E, Clark C, Hashemi Nazari SS. The effect of Saffron supplementation on waist circumference, HA1C, and glucose metabolism: A systematic review and meta-analysis of randomized clinical trials. *Complementary Therapies in Medicine*. 2020;49:102298. https://doi.org/10.1016/j.ctim.2020.102298

407. Renfan X, Ke Y, Jie D, Guangzhi C. Effect of green tea supplementation on blood pressure A systematic review and meta-analysis of randomized controlled trials. *Medicine*. 2020;99(6):1-8.

408. Roshanravan B, Samarghandian S, Ashrafizadeh M, Amirabadizadeh A, Saeedi F, Farkhondeh T. Metabolic impact of saffron and crocin: an updated systematic and meta-analysis of randomised clinical trials. *Archives of Physiology & Biochemistry*. 2020;128(3):1-13. https://doi.org/10.1080/13813455.2020.1716020

409. Safari Z, Farrokhzad A, Ghavami A, Fadel A, Hadi A, Rafiee S, et al. The effect of barberry (Berberis vulgaris L.) on glycemic indices: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2020;51:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102414

410. Yazdanpanah Z, Azadi-Yazdi M, Hooshmandi H, Ramezani-Jolfaie N, Salehi-Abargouei A. Effects of cinnamon supplementation on body weight and composition in adults: A systematic review and meta-analysis of controlled clinical trials. *Phytotherapy Research*. 2020;34(3):448-63. https://doi.org/10.1002/ptr.6539

411. Alizadeh M, Kheirouri S. Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: a comprehensive meta-analysis of randomized controlled trials. *Biomedicine (Taipei)*. 2019;9(4):23. https://doi.org/10.1051/bmdcn/2019090423

412. Asbaghi O, Soltani S, Norouzi N, Milajerdi A, Choobkar S, Asemi Z. The effect of saffron supplementation on blood glucose and lipid profile: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2019;47:102158. https://doi.org/10.1016/j.ctim.2019.07.017

413. Clark CCT, Ghaedi E, Arab A, Pourmasoumi M, Hadi A. The effect of curcumin supplementation on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials. *Diabetes & Metabolic Syndrome*. 2019;13(5):2819-25. https://doi.org/10.1016/j.dsx.2019.07.045

414. Hadi A, Arab A, Ghaedi E, Rafie N, Miraghajani M, Kafeshani M. Barberry (Berberis vulgaris L.) is a safe approach for management of lipid parameters: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*. 2019;43:117-24.

415. Hasani H, Arab A, Hadi A, Pourmasoumi M, Ghavami A, Miraghajani M. Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2019;33(6):1639-47. https://doi.org/10.1002/ptr.6362

416. Huang J, Qin S, Huang L, Tang Y, Ren H, Hu H. Efficacy and safety of Rhizoma curcumea longae with respect to improving the glucose metabolism of patients at risk for cardiovascular disease: a meta‐analysis of randomised controlled trials. *Journal of Human Nutrition & Dietetics*. 2019;32(5):591-606. https://doi.org/10.1111/jhn.12648

417. Pourmasoumi M, Hadi A, Najafgholizadeh A, Kafeshani M, Sahebkar A. Clinical evidence on the effects of saffron (Crocus sativus L.) on cardiovascular risk factors: A systematic review meta-analysis. *Pharmacological Research*. 2019;139:348-59. https://doi.org/10.1016/j.phrs.2018.11.038

418. Tabrizi R, Vakili S, Akbari M, Mirhosseini N, Lankarani KB, Rahimi M, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2019;33(2):253-62. https://doi.org/10.1002/ptr.6226

419. Taghizadeh M, Hamedifard Z, Jafarnejad S. Effect of garlic supplementation on serum C-reactive protein level: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2019;33(2):243-52. https://doi.org/10.1002/ptr.6225

420. White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*. 2019;146:104280. https://doi.org/10.1016/j.phrs.2019.104280

421. de Melo ISV, Dos Santos AF, Bueno NB. Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*. 2018;128:137-44. https://doi.org/10.1016/j.phrs.2017.09.010

422. Golzarand M, Toolabi K, Aghasi M. Effect of green tea, caffeine and capsaicin supplements on the anthropometric indices: A meta-analysis of randomized clinical trials. *Journal of Functional Foods*. 2018;46:320-8. https://doi.org/10.1016/j.jff.2018.04.002

423. Khan K, Jovanovski E, Ho HVT, Marques ACR, Zurbau A, Mejia SB, et al. The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Nutrition, Metabolism & Cardiovascular Diseases*. 2018;28(1):3-13. https://doi.org/10.1016/j.numecd.2017.09.007

424. Namazi N, Larijani B, Ayati MH, Abdollahi M. The effects of Nigella sativa L. on obesity: A systematic review and meta-analysis. *Journal of Ethnopharmacology*. 2018;219:173-81. https://doi.org/10.1016/j.jep.2018.03.001

425. Pourmasoumi M, Hadi A, Rafie N, Najafgholizadeh A, Mohammadi H, Rouhani MH. The effect of ginger supplementation on lipid profile: A systematic review and meta-analysis of clinical trials. *Phytomedicine*. 2018;43:28-36. https://doi.org/10.1016/j.phymed.2018.03.043

426. Qin S, Huang L, Gong J, Shen S, Huang J, Tang Y, et al. Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress. *Nutrition Research*. 2018;60:1-12. https://doi.org/10.1016/j.nutres.2018.08.003

427. Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, Cicero AFG. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. *Critical Reviews in Food Science & Nutrition*. 2018;58(15):2549-56. https://doi.org/10.1080/10408398.2017.1332572

428. Daryabeygi-Khotbehsara R, Golzarand M, Ghaffari MP, Djafarian K. Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2017;35:6-13. https://doi.org/10.1016/j.ctim.2017.08.016

429. Demmers A, Korthout H, van Etten-Jamaludin FS, Kortekaas F, Maaskant JM. Effects of medicinal food plants on impaired glucose tolerance: A systematic review of randomized controlled trials. *Diabetes Research & Clinical Practice*. 2017;131:91-106. https://doi.org/10.1016/j.diabres.2017.05.024

430. Emami S, Rouhani MH, Azadbakht L. The effect of garlic intake on glycemic control in humans: A systematic review and meta-analysis. *Progress in Nutrition*. 2017;19:10-8. https://doi.org/10.23751/pn.v19i1-S.5274

431. Si Q, Lifan H, Jiaojiao G, Shasha S, Juan H, Hong R, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Nutrition Journal*. 2017;16(1):1-10. https://doi.org/10.1186/s12937-017-0293-y

432. Wang J, Zhang X, Lan H, Wang W. Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): A meta-analysis of randomized controlled trials. *Food and Nutrition Research*. 2017;61(1):1377571. https://doi.org/10.1080/16546628.2017.1377571

433. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*. 2016;111:394-404. https://doi.org/10.1016/j.phrs.2016.07.004

434. Dick WR, Fletcher EA, Shah SA. Reduction of Fasting Blood Glucose and Hemoglobin A1c Using Oral Aloe Vera: A Meta-Analysis. *Journal of Alternative & Complementary Medicine*. 2016;22(6):450-7. https://doi.org/10.1089/acm.2015.0122

435. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis. *Journal of Ethnopharmacology*. 2016;194:260-8. https://doi.org/10.1016/j.jep.2016.08.003

436. Gui Q-F, Xu Z-R, Xu K-Y, Yang Y-M. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus. *Medicine (United States)*. 2016;95(6):e2584. https://doi.org/10.1097/MD.0000000000002584

437. Guo-Chong C, Chen-Wei P, Yong-Hong Z, Li-Qiang Q, Li-Hua C, Guan-Yu R, et al. Effect of Flaxseed Intervention on Inflammatory Marker C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients*. 2016;8(3):136. https://doi.org/10.3390/nu8030136

438. He LX, Zhao J, Huang YS, Li Y. The difference between oats and beta-glucan extract intake in the management of HbA1c, fasting glucose and insulin sensitivity: a meta-analysis of randomized controlled trials. *Food & Function*. 2016;7(3):1413-28. https://doi.org/10.1039/c5fo01364j

439. Komishon AM, Shishtar E, Ha V, Sievenpiper JL, de Souza RJ, Jovanovski E, et al. The effect of ginseng (genus Panax) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. *Journal of Human Hypertension*. 2016;30(10):619-26. https://doi.org/10.1038/jhh.2016.18

440. Mazidi M, Gao H-K, Rezaie P, Ferns GA. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. *Food & Nutrition Research*. 2016;60:1-N.PAG. https://doi.org/10.3402/fnr.v60.32613

441. Qi-feng G, Zhe-rong X, Ke-ying X, Yun-mei Y, Gui Q-F, Xu Z-R, et al. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. *Medicine*. 2016;95(6):1-10. https://doi.org/10.1097/MD.0000000000002584

442. Sahebkar A, Cicero AFG, Simental-Mendia LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-alpha levels: A systematic review and meta-analysis ofrandomized controlled trials. *Pharmacological Research*. 2016;107:234-42. https://doi.org/10.1016/j.phrs.2016.03.026

443. Suksomboon N, Poolsup N, Punthanitisarn S. Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis. *Journal of Clinical Pharmacy & Therapeutics*. 2016;41(2):180-8. https://doi.org/10.1111/jcpt.12382

444. Yiyi Z, Wen L, Dan L, Tieyun Z, Haoming T. Efficacy of Aloe Vera Supplementation on Prediabetes and Early Non-Treated Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients*. 2016;8(7):388. https://doi.org/10.3390/nu8070388

445. Hou LQ, Liu YH, Zhang YY. Garlic intake lowers fasting blood glucose: Meta-analysis of randomized controlled trials. *Asia Pacific Journal of Clinical Nutrition*. 2015;24(4):575-82. https://doi.org/10.6133/apjcn.2015.24.4.15

446. Zhu Y, Miao Y, Meng Z, Zhong Y, Piacente S. Effects of vaccinium berries on serum lipids: a meta-analysis of randomized controlled trials. *Evidence-Based Complementary andAlternative Medicine*. 2015;2015:790329. https://doi.org/10.1155/2015/790329

447. Khalesi S, Sun J, Buys N, Jamshidi A, Nikbakht-Nasrabadi E, Khosravi-Boroujeni H. Green tea catechins and blood pressure: a systematic review and meta-analysis of randomised controlled trials. *European Journal of Nutrition*. 2014;53(6):1299-311. https://doi.org/10.1007/s00394-014-0720-1

448. Kwak JS, Kim JY, Paek JE, Lee YJ, Kim HR, Park DS, et al. Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials. *Nutr Res Pract*. 2014;8(6):644-54. https://doi.org/10.4162/nrp.2014.8.6.644

449. Liu G, Mi XN, Zheng XX, Xu YL, Lu J, Huang XH. Effects of tea intake on blood pressure: A meta-analysis of randomised controlled trials. *British Journal of Nutrition*. 2014;112(7):1043-54. https://doi.org/10.1017/S0007114514001731

450. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. *Nutrition Journal*. 2014;13:7-. https://doi.org/10.1186/1475-2891-13-7

451. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. *Clinical Nutrition*. 2014;33(3):406-14. https://doi.org/10.1016/j.clnu.2013.09.012

452. Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, et al. The effect of ginseng (The Genus Panax) on glycemic control: A systematic review and meta-analysis of randomized controlled clinical trials. *PLoS ONE*. 2014;9(9):e107391. https://doi.org/10.1371/journal.pone.0107391

453. Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. *Annals of Family Medicine*. 2013;11(5):452-9. https://doi.org/10.1370/afm.1517

454. Akilen R, Tsiami A, Devendra D, Robinson N. Cinnamon in glycaemic control: Systematic review and meta analysis. *Clinical Nutrition*. 2012;31(5):609-15. https://doi.org/10.1016/j.clnu.2012.04.003

455. Gibb RD, Hasselblad V, Surwit RS, McRorie JW, Feinglos MN. Psyllium husk lowers fasting glucose and hba1c in populations with elevated fasting blood glucose: A meta-analysis of randomized, controlled clinical studies. *Diabetes*. 2012;61(SUPPL. 1):A258. https://doi.org/10.2337/db12-836-1328

456. Leach MJ, Kumar S. Cinnamon for diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2012;2012(9):CD007170. https://doi.org/10.1002/14651858.CD007170.pub2

457. Paul AD, Wallace Y. Cinnamon Intake Lowers Fasting Blood Glucose: Meta-Analysis. *Journal of Medicinal Food*. 2011;14(9):884-9. https://doi.org/10.1089/jmf.2010.0180

458. Shojaii A, Dabaghian FH, Goushegir A, Fard MA. Antidiabetic plants of Iran. *Acta Medica Iranica*. 2011;49(10):637-42.

459. Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. *Journal of Ethnopharmacology*. 2011;137(3):1328-33. https://doi.org/10.1016/j.jep.2011.07.059

460. Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI. Effect of cinnamon on glucose control and lipid parameters. *Diabetes Care*. 2008;31(1):41-3. https://doi.org/10.2337/dc07-1711

461. Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. *Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy*. 2007;27(4):595-9. https://doi.org/10.1592/phco.27.4.595

462. Ashkar F, Salahshoornezhad S, Rezaei S, Vahid F, Gholamalizadeh M, Dahka SM, et al. The Role of medicinal herbs in treatment of insulin resistance in patients with Polycystic Ovary Syndrome: A literature review. *Biomolecular concepts*. 2020;11(1):57-75. https://doi.org/10.1515/bmc-2020-0005

463. Chan W-JJ, McLachlan AJ, Luca EJ, Harnett JE. Garlic (Allium sativum L.) in the management of hypertension and dyslipidemia - A systematic review. *Journal of Herbal Medicine*. 2020;19:100292. https://doi.org/10.1016/j.hermed.2019.100292

464. Emamat H, Tangestani H, Totmaj AS, Ghalandari H, Nasrollahzadeh J. The effect of garlic on vascular function: A systematic review of randomized clinical trials. *Clinical Nutrition*. 2020;39(12):3563-70. https://doi.org/10.1016/j.clnu.2020.02.016

465. Giannoulaki P, Kotzakioulafi E, Chourdakis M, Hatzitolios A, Didangelos T. Impact of Crocus sativus L. on Metabolic Profile in Patients with Diabetes Mellitus or Metabolic Syndrome: A Systematic Review. *Nutrients*. 2020;12(5):1424-. https://doi.org/10.3390/nu12051424

466. Mahmoodi MR, Mohammadizadeh M. Therapeutic potentials of Nigella sativa preparations and its constituents in the management of diabetes and its complications in experimental animals and patients with diabetes mellitus: A systematic review. *Complementary Therapies in Medicine*. 2020;50:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102391

467. Wal A, Wal P, Roohi TF. A review on role of berries andits bioactive compounds in treating hypertension. *Asian Journal of Pharmaceutical and Clinical Research*. 2020;13(8):3-12. https://doi.org/10.22159/ajpcr.2020.v13i8.37932

468. Hamdan A, Haji Idrus R, Mokhtar MH. Effects of Nigella Sativa on Type-2 Diabetes Mellitus: A Systematic Review. *International Journal of Environmental Research & Public Health [Electronic Resource]*. 2019;16(24):05. https://doi.org/10.3390/ijerph16244911

469. Hekmatpou D, Mehrabi F, Rahzani K, Aminiyan A. The Effect of Aloe Vera Clinical Trials on Prevention and Healing of Skin Wound: A Systematic Review. *Iranian Journal of Medical Sciences*. 2019;44(1):1-9.

470. Hariri M, Haghighatdoost F. Effect of Curcumin on Anthropometric Measures: A Systematic Review on Randomized Clinical Trials. *Journal of the American College of Nutrition*. 2018;37(3):215-22. https://doi.org/10.1080/07315724.2017.1392263

471. Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E. Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review. *Journal of the Academy of Nutrition & Dietetics*. 2016;116(11):1794-802. https://doi.org/10.1016/j.jand.2016.07.015

472. Lee NH, Jung HC, Lee S. Red Ginseng as an Ergogenic Aid: A Systematic Review of Clinical Trials. *J Exerc Nutrition Biochem*. 2016;20(4):13-9. https://doi.org/10.20463/jenb.2016.0034

473. Vaughn AR, Branum A, Sivamani RK. Effects of Turmeric (Curcuma longa) on Skin Health: A Systematic Review of the Clinical Evidence. *Phytother Res*. 2016;30(8):1243-64. https://doi.org/10.1002/ptr.5640

474. Heshmati J, Namazi N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: A systematic review. *Complementary Therapies in Medicine*. 2015;23(2):275-82. https://doi.org/10.1016/j.ctim.2015.01.013

475. Choi J, Kim TH, Choi TY, Lee MS. Ginseng for Health Care: A Systematic Review of Randomized Controlled Trials in Korean Literature. *PLoS ONE*. 2013;8(4):e59978. https://doi.org/10.1371/journal.pone.0059978

476. Rashidi AA, Mirhashemi SM, Taghizadeh M, Sarkhail P. Iranian medicinal plants for diabetes mellitus: a systematic review. *Pakistan Journal of Biological Sciences*. 2013;16(9):401-11. https://doi.org/10.3923/pjbs.2013.401.411

477. Kim S, Shin B-C, Lee MS, Lee H, Ernst E. Red ginseng for type 2 diabetes mellitus: A systematic review of randomized controlled trials. *Chinese Journal of Integrative Medicine*. 2011;17(12):937-44. https://doi.org/10.1007/s11655-011-0937-2

478. Lee NH, Son CG. Systematic review of randomized controlled trials evaluating the efficacy and safety of ginseng. *Journal of Acupuncture and Meridian Studies*. 2011;4(2):85-97. https://doi.org/10.1016/S2005-2901(11)60013-7

479. Mehri A, Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of efficacy and safety of urtica dioica in the treatment of diabetes. *International Journal of Pharmacology*. 2011;7(2):161-70. https://doi.org/10.3923/ijp.2011.161.170

480. Ulbricht C, Abrams TR, Basch E, Davies-Heerema T, Foppa I, Hammerness P, et al. An evidence-based systematic review of Gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. *Journal of Dietary Supplements*. 2011;8(3):311-30. https://doi.org/10.3109/19390211.2011.597977

481. Kirkham S, Akilen R, Sharma S, Tsiami A. The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. *Diabetes, Obesity and Metabolism*. 2009;11(12):1100-13. https://doi.org/10.1111/j.1463-1326.2009.01094.x

482. Nahas R, Moher M. Complementary and alternative medicine for the treatment of type 2 diabetes. *Canadian Family Physician*. 2009;55(6):591-6.

483. Hasani-Ranjbar S, Larijani B, Abdollah M. A systematic review of iranian medicinal plants useful in diabetes mellitus. *Archives of Medical Science*. 2008;4(3):285-92.

484. Dugoua JJ, Seely D, Perri D, Cooley K, Forelli T, Mills E, et al. From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. *Canadian Journal of Physiology & Pharmacology*. 2007;85(9):837-47. https://doi.org/10.1139/Y07-080

485. Leach MJ. Gymnema sylvestre for diabetes mellitus: A systematic review. *J Altern Complement Med*. 2007;13(9):977-83. https://doi.org/10.1089/acm.2006.6387

486. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ. Systematic review of the of ginseng on cardiovascular risk factors. *Annals of Pharmacotherapy*. 2006;40(1):83-95. https://doi.org/10.1345/aph.1G216

487. Shekelle PG, Hardy M, Morton SC, Coulter I, Venuturupalli S, Favreau J, et al. Are Ayurvedic herbs for diabetes effective? *Journal of Family Practice*. 2005;54(10):876-86.

488. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS, Yeh GY, Eisenberg DM, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care*. 2003;26(4):1277-94. https://doi.org/10.2337/diacare.26.4.1277

489. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. *European Journal of Clinical Pharmacology*. 1999;55(8):567-75. https://doi.org/10.1007/s002280050674

490. Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical effectiveness. *Br J Gen Pract*. 1999;49(447):823-8.

491. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome in Australia: prevalence using four definitions. *Diabetes Res Clin Pract*. 2007;77(3):471-8. https://doi.org/10.1016/j.diabres.2007.02.002

492. Harris MF. The metabolic syndrome. *Aust Fam Physician*. 2013;42(8):524-7.

493. SK Tanamas DM, B Lynch, P Sethi, L Willenberg, KR Polkinghorne, S Chadban, D Dunstan, JE Shaw. The Australian Diabetes, Obesity and Lifestyle Study. Melbourne: Baker IDI Heart and Diabetes Institute 2013: AusDiab; 2012.

494. Jang HH, Lee J, Lee SH, Lee YM. Effects of Capsicum annuum supplementation on the components of metabolic syndrome: a systematic review and meta-analysis. *Scientific Reports*. 2020;10(1):20912. https://doi.org/10.1038/s41598-020-77983-2

495. Li X, Wang W, Hou L, Wu H, Wu Y, Xu R, et al. Does tea extract supplementation benefit metabolic syndrome and obesity? A systematic review and meta-analysis. *Clinical Nutrition*. 2020;39(4):1049-58. https://doi.org/10.1016/j.clnu.2019.05.019

496. Roshanravan B, Yousefizadeh S, Apaydin Yildirim B, Farkhondeh T, Amirabadizadeh A, Ashrafizadeh M, et al. The effects of Berberis vulgaris L. and Berberis aristata L. in metabolic syndrome patients: a systematic and meta-analysis study. *Archives of Physiology & Biochemistry*. 2020;129(2):1-12. https://doi.org/10.1080/13813455.2020.1828482

497. Azhdari M, Karandish M, Mansoori A. Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*. 2019;33(5):1289-301. https://doi.org/10.1002/ptr.6323

498. Shekarchizadeh-Esfahani P, Hassani B, Roshanravan N, Soraya N. Systematic review and meta-analysis of randomized, controlled trials on the effects of garlic supplementation on serum adiponectin and leptin levels. *International Journal of Clinical Practice*. 2021;75(10):e14200. https://doi.org/10.1111/ijcp.14200

499. Payab M, Hasani‐Ranjbar S, Shahbal N, Qorbani M, Aletaha A, Haghi‐Aminjan H, et al. Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2020;34(3):526-45. https://doi.org/10.1002/ptr.6547

500. Ponticelli M, Russo D, Faraone I, Sinisgalli C, Labanca F, Lela L, et al. The Promising Ability of Humulus lupulus L. Iso-alpha-acids vs. Diabetes, Inflammation, and Metabolic Syndrome: A Systematic Review. *Molecules*. 2021;26(4):11. https://doi.org/10.3390/molecules26040954

501. Eisvand F, Razavi BM, Hosseinzadeh H. The effects of Ginkgo biloba on metabolic syndrome: A review. *Phytotherapy Research*. 2020;34(8):1798-811. https://doi.org/10.1002/ptr.6646

502. Smith SJ, Lopresti AL, Teo SYM, Fairchild TJ. Examining the Effects of Herbs on Testosterone Concentrations in Men: A Systematic Review. *Advances in Nutrition*. 2020;05(3):05. https://doi.org/10.1093/advances/nmaa134

503. Jane M, McKay J, Pal S. Effects of daily consumption of psyllium, oat bran and polyGlycopleX on obesity-related disease risk factors: A critical review. *Nutrition*. 2019;57:84-91. https://doi.org/10.1016/j.nut.2018.05.036

504. Australian Family Physician. Fatigue – a rational approach to investigation. *Australian Journal for General Practitioners*. 2014;43:457-61.

505. Fowler-Davis S, Platts K, Thelwell M, Woodward A, Harrop D. A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid? *PLoS One*. 2021;16(11):e0259533. https://doi.org/10.1371/journal.pone.0259533

506. Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Transl Med*. 2020;18(1):100. https://doi.org/10.1186/s12967-020-02269-0

507. Emerge Australia. ME/CFS information [cited 2022. Available from: https://www.emerge.org.au/.

508. ME Association. NICE Guideline on ME/CFS: An ME Association Summary 2021. [Accessed. Available from: https://meassociation.org.uk/wp-content/uploads/NICE-Clinical-Guideline-on-MECFS-An-MEA-Summary-December-2021.pdf.

509. Noor N, Urits I, Degueure A, Rando L, Kata V, Cornett EM, et al. A Comprehensive Update of the Current Understanding of Chronic Fatigue Syndrome. *Anesth Pain Med*. 2021;11(3):e113629. https://doi.org/10.5812/aapm.113629

510. Sandler CX, Lloyd AR. Chronic fatigue syndrome: progress and possibilities. *Med J Aust*. 2020;212(9):428-33. https://doi.org/10.5694/mja2.50553

511. Castro-Marrero J, Saez-Francas N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. *Br J Pharmacol*. 2017;174(5):345-69. https://doi.org/10.1111/bph.13702

512. Chronic fatigue syndrome (Myalgic Encephalomyelitis) 2022 [Available from: https://www.healthdirect.gov.au/chronic-fatigue-syndrome-cfs-me#treatment.

513. Jin TY, Rong PQ, Liang HY, Zhang PP, Zheng GQ, Lin Y. Clinical and Preclinical Systematic Review of Panax ginseng C. A. Mey and Its Compounds for Fatigue. *Front Pharmacol*. 2020;11:1031. https://doi.org/10.3389/fphar.2020.01031

514. Kim T-H, Kim D-H, Kang JW. Medicinal herbs for managing fatigue symptoms in patients with idiopathic chronic fatigue: A PRISMA compliant updated systematic review and meta-analysis of randomized controlled trials based on the GRADE approach. *European Journal of Integrative Medicine*. 2020;35:101069. https://doi.org/10.1016/j.eujim.2020.101069

515. Arring NM, Millstine D, Marks LA, Nail LM. Ginseng as a Treatment for Fatigue: A Systematic Review. *Journal of Alternative & Complementary Medicine*. 2018;24(7):624-33. https://doi.org/10.1089/acm.2017.0361

516. Ogawa-Ochiai K, Kawasaki K. Panax ginseng for Frailty-Related Disorders: A Review. *Frontiers in Nutrition*. 2018;5:140. https://doi.org/10.3389/fnut.2018.00140

517. Bach HV, Kim J, Cho YA, Myung SK. Efficacy of Ginseng Supplements on Fatigue and Physical Performance: a Meta-analysis. *Journal of Korean medical science*. 2016;31(12):1879-86. http://dx.doi.org/10.3346/jkms.2016.31.12.1879

518. Alraek T, Lee MS, Choi TY, Cao H, Liu J. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review. *BMC Complement Altern Med*. 2011;11(1):87. https://doi.org/10.1186/1472-6882-11-87

519. Heikkinen T, Ruuskanen O. Upper Respiratory Tract Infection. In: Laurent GJ, Shapiro SD, editors. *Encyclopedia of Respiratory Medicine*. Oxford: Academic Press; 2006. p. 385-8.

520. Guibas GV, Papadopoulos NG. Viral Upper Respiratory Tract Infections. In: Green RJ, editor. *Viral Infections in Children, Volume II*. Cham: Springer International Publishing; 2017. p. 1-25.

521. Leung NHL. Transmissibility and transmission of respiratory viruses. *Nat Rev Microbiol*. 2021;19(8):528-45. https://doi.org/10.1038/s41579-021-00535-6

522. Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. *EClinicalMedicine*. 2021;37:100986. https://doi.org/10.1016/j.eclinm.2021.100986

523. Chen Y, Kirk MD. Incidence of acute respiratory infections in Australia. *Epidemiol Infect*. 2014;142(7):1355-61. https://doi.org/10.1017/S0950268813002471

524. Aplin-Snider C, Cooper D, Dieleman P, Smith A. Development and Implementation of an Upper Respiratory Infection Treatment Protocol in a Primary Care Health Clinic. *J Prim Care Community Health*. 2020;11:2150132720966811. https://doi.org/10.1177/2150132720966811

525. Barrett B. Viral Upper Respiratory Infection. *Integrative Medicine*. 2018:170-9.e7. https://doi.org/10.1016/B978-0-323-35868-2.00018-9

526. Snidvongs K, Hoang MP, Chitsuthipakorn W. Herbal Medicines for Allergic Rhinitis: a Systematic Review and Meta-analysis. *Current Allergy and Asthma Reports*. 2021;21(4):25. https://doi.org/10.1007/s11882-021-00999-9

527. Wieland LS, Piechotta V, Feinberg T, Ludeman E, Hutton B, Kanji S, et al. Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review. *BMC Complementary Medicine and Therapies*. 2021;21(1):112. https://doi.org/10.1186/s12906-021-03283-5

528. Ang L, Lee MS, Song E, Lee HW. Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials. *J Clin Med*. 2020;9(5):1583. https://doi.org/10.3390/jcm9051583

529. Antonelli M, Donelli D, Firenzuoli F. Ginseng integrative supplementation for seasonal acute upper respiratory infections: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2020;52:N.PAG-N.PAG. https://doi.org/10.1016/j.ctim.2020.102457

530. David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections: A systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2019;44:18-26. https://doi.org/10.1016/j.ctim.2019.03.011

531. Hawkins J, Baker C, Cherry L, Dunne E. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. *Complementary Therapies in Medicine*. 2019;42:361-5. https://doi.org/10.1016/j.ctim.2018.12.004

532. Anheyer D, Cramer H, Lauche R, Joyonto Saha F, Dobos G. Herbal Medicine in Children With Respiratory Tract Infection: Systematic Review and Meta-Analysis. *Academic Pediatrics*. 2018;18(1):8-19. https://doi.org/10.1016/j.acap.2017.06.006

533. Hu XY, Wu RH, Logue M, Blondel C, Lai LYW, Stuart B, et al. Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis. *PLoS ONE*. 2017;12(8):e0181780. https://doi.org/10.1371/journal.pone.0181780

534. Schapowal A, Klein P, Johnston SL. Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials. *Advances in Therapy*. 2015;32(3):187-200. https://doi.org/10.1007/s12325-015-0194-4

535. Wagner L, Cramer H, Klose P, Lauche R, Gass F, Dobos G, et al. Herbal medicine for cough: A systematic review and meta-analysis. *Forschende Komplementarmedizin*. 2015;22(6):359-68. https://doi.org/10.1159/000442111

536. Linde K, Barrett B, Bauer R, Melchart D, Woelkart K. Echinacea for preventing and treating the common cold. *Cochrane Database of Systematic Reviews*. 2014(2):N.PAG-N.PAG.

537. Seida JK, Durec T, Kuhle S. North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review. *Evidence-based Complementary & Alternative Medicine (eCAM)*. 2011;8(1):1-7. ecam/nep068

538. Pittler MH, Ernst E. Clinical effectiveness of garlic (Allium sativum). *Molecular Nutrition & Food Research*. 2007;51(11):1382-5. https://doi.org/10.1002/mnfr.200700073

539. Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. *The Lancet Infectious Diseases*. 2007;7(7):473-80. https://doi.org/10.1016/S1473-3099(07)70160-3

540. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: a meta-analysis. *Clinical Therapeutics*. 2006;28(2):174-83. https://doi.org/10.1016/j.clinthera.2006.02.001

541. Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A, Chanchareon U. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. *Journal of Clinical Pharmacy & Therapeutics*. 2004;29(1):37-45. https://doi.org/10.1046/j.1365-2710.2003.00534.x

542. Sierocinski E, Holzinger F, Chenot JF. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. *European Journal of Clinical Pharmacology*. 2021;01(8):01. https://doi.org/10.1007/s00228-021-03090-4

543. Harnett J, Oakes K, Carè J, Leach M, Brown D, Cramer H, et al. The effects of Sambucus nigra berry on acute respiratory viral infections: A rapid review of clinical studies. *Advances in Integrative Medicine*. 2020;7(4):240-6. https://doi.org/10.1016/j.aimed.2020.08.001

544. Jin AJ, Chin CJ. Complementary and Alternative Medicine in Chronic Rhinosinusitis: A Systematic Review and Qualitative Analysis. *American Journal of Rhinology & Allergy*. 2019;33(2):194-202. https://doi.org/10.1177/1945892418813079

545. Anushiravani M, Bakhshaee M, Taghipour A, Naghedi‐Baghdar H, Farshchi MK, Hoseini SS, et al. A systematic review of randomized controlled trials with herbal medicine on chronic rhinosinusitis. *Phytotherapy Research*. 2018;32(3):395-401. https://doi.org/10.1002/ptr.5968

546. Reckhenrich AK, Klüting A, Veit M. Ivy Leaf Extracts for the Treatment of Respiratory Tract Diseases Accompanied by Cough: A Systematic Review of Clinical Trials. *HerbalGram*. 2018(117):58-71.

547. Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. *Cochrane Database of Systematic Reviews*. 2014;2014(11):CD006206. https://doi.org/10.1002/14651858.CD006206.pub4

548. Zou C, Su G, Wu Y, Lu F, Mao W, Liu X. <i>Astragalus</i> in the Prevention of Upper Respiratory Tract Infection in Children with Nephrotic Syndrome: Evidence-Based Clinical Practice. *Evidence-Based Complementary and Alternative Medicine*. 2013;2013:352130. https://doi.org/10.1155/2013/352130

549. Guo R, Canter PH, Ernst E. A systematic review of randomised clinical trials of individualised herbal medicine in any indication. *Postgraduate Medical Journal*. 2007;83(984):633-7. https://doi.org/10.1136/pgmj.2007.060202

550. Coon JT, Ernst E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. *Planta Medica*. 2004;70(4):293-8. https://doi.org/10.1055/s-2004-818938

551. Australasian society of clinical immunology and allergy (ASCIA). Eczema (Atopic Dermatitis) 2019 [Available from: https://www.allergy.org.au/patients/fast-facts/eczema-atopic-dermatitis.

552. Australasian society of clinical immunology and allergy (ASCIA). Contact dermatitis 2019 [Available from: https://www.allergy.org.au/patients/skin-allergy/contact-dermatitis.

553. Chidwick K, Busingye D, Pollack A, Osman R, Yoo J, Blogg S, et al. Prevalence, incidence and management of atopic dermatitis in Australian general practice using routinely collected data from MedicineInsight. *Australas J Dermatol*. 2020;61(3):e319-e27. https://doi.org/10.1111/ajd.13268

554. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. *Expert Rev Clin Immunol*. 2017;13(1):15-26. https://doi.org/10.1080/1744666X.2016.1212660

555. Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. *Cochrane Database Syst Rev*. 2020;9(9):CD013206. https://doi.org/10.1002/14651858.CD013206.pub2

556. Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Nedley N, et al. The global, regional, and national burden of atopic dermatitis in 195 countries and territories: An ecological study from the Global Burden of Disease Study 2017. *JAAD Int*. 2021;2:12-8. https://doi.org/10.1016/j.jdin.2020.10.002

557. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789-858. https://doi.org/10.1016/S0140-6736(18)32279-7

558. Assarian Z, O'Brien TJ, Nixon R. Soak and smear: an effective treatment for eczematous dermatoses. *Australas J Dermatol*. 2015;56(3):215-7. https://doi.org/10.1111/ajd.12300

559. van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. *Br J Dermatol*. 2017;177(5):1256-71. https://doi.org/10.1111/bjd.15602

560. National Eczema Society. Complementary therapies and eczema factsheet 2019 [Available from: https://eczema.org/information-and-advice/treatments-for-eczema/complementary-therapies-and-eczema/.

561. Thandar Y, Gray A, Botha J, Mosam A. Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials. *British Journal of Dermatology*. 2017;176(2):330-43. https://doi.org/10.1111/bjd.14840

562. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: how to manage acne vulgaris. *Drugs Context*. 2021;10:2021-8-6. https://doi.org/10.7573/dic.2021-8-6

563. The Australasian College of Dermatologists. Acne Vulgaris 2015 [Available from: https://www.dermcoll.edu.au/atoz/acne-vulgaris/.

564. Amanda Oakley. Nodulocystic acne 2021 [Available from: https://dermnetnz.org/topics/nodulocystic-acne.

565. Bhatia J, Sarin A, Bhatia K. Acne Fulminans: A Case Report and Review of Literature. *Indian Journal of Paediatric Dermatology*. 2021;22(1).

566. Tan JK, Bhate K. A global perspective on the epidemiology of acne. *Br J Dermatol*. 2015;172 Suppl 1(S1):3-12. https://doi.org/10.1111/bjd.13462

567. Brown H, Tapley A, van Driel ML, Davey AR, Holliday E, Ball J, et al. Acne in primary care: A cross-sectional analysis. *Aust J Gen Pract*. 2019;48(11):781-8. https://doi.org/10.31128/AJGP-02-19-4864

568. Cooper AJ, Harris VR. Modern management of acne. *Med J Aust*. 2017;206(1):41-5. https://doi.org/10.5694/mja16.00516

569. Dall'Oglio F, Nasca MR, Fiorentini F, Micali G. Diet and acne: review of the evidence from 2009 to 2020. *Int J Dermatol*. 2021;60(6):672-85. https://doi.org/10.1111/ijd.15390

570. Huang Tom KG, Cook David. Acne Best practice management. *Australian Journal for General Practitioners*. 2012;39:656-60.

571. Kim S, Park TH, Kim WI, Park S, Kim JH, Cho MK. The effects of green tea on acne vulgaris: A systematic review and meta-analysis of randomized clinical trials. *Phytother Res*. 2021;35(1):374-83. https://doi.org/10.1002/ptr.6809

572. Tuong W, Walker L, Sivamani RK. Polyphenols as novel treatment options for dermatological diseases: A systematic review of clinical trials. *J Dermatolog Treat*. 2015;26(4):381-8. https://doi.org/10.3109/09546634.2014.991675

573. Ernst E, Pittler MH, Stevinson C. Complementary/alternative medicine in dermatology: evidence-assessed efficacy of two diseases and two treatments. *Am J Clin Dermatol*. 2002;3(5):341-8. https://doi.org/10.2165/00128071-200203050-00006

1. e.g. absence of rectal bleeding and return to normal bowel habit in UC or a reduction in inflammatory markers such as C-reactive protein in Crohn’s disease [↑](#footnote-ref-2)
2. Including curcumin, boswellia, green tea extract, St Mary’s thistle [↑](#footnote-ref-3)
3. delivered as an adjunct to corticosteroids [↑](#footnote-ref-4)
4. delivered alone or as an adjunct to mesalazine [↑](#footnote-ref-5)
5. Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols. [↑](#footnote-ref-6)
6. The RCT had a second intervention group (curcumin and fennel oil combination). [↑](#footnote-ref-7)
7. Including aloe vera, turmeric, psyllium, St John’s wort, capsicum, ginger, anise oil, senna or fixed dose herbal combinations [↑](#footnote-ref-8)
8. The overlap tables were separated for ease of presentation. As per protocol, to investigate potential sources of heterogeneity, primary studies could be stratified (if needed) based on the type of herb. [↑](#footnote-ref-9)
9. Chaste tree is the only herb studied in the included RCTs that is on the core list of herbs included in the WHM curriculum for menstrual conditions (see Appendix A6.3). [↑](#footnote-ref-10)
10. mefenamic acid, Ibuprofen or a fixed-combination NSAID (containing paracetamol, ibuprofen and caffeine). [↑](#footnote-ref-11)
11. Study included three treatment groups: WHM, placebo and active control. [↑](#footnote-ref-12)
12. Study included three treatment groups: WHM and 2 active controls. [↑](#footnote-ref-13)
13. Study included three treatment groups: WHM, placebo and active control. [↑](#footnote-ref-14)
14. We use the Australian language of hot flushes throughout instead of the American hot flashes. [↑](#footnote-ref-15)
15. One RCT (Kamalifard 2017) also included an ‘active’ intervention group (bitter orange). [↑](#footnote-ref-16)
16. epigallocatechin-3-gallate (EGCG) [↑](#footnote-ref-17)